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Chapter 1
General introduction
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 Currently, the presence of metastases at diagnosis is the only consistent clinical 
prognostic factor for risk stratification [2]. Nevertheless, the treatment regimen is still 
similar for all patients regardless of metastatic status at diagnosis. The histologic 
response (HR) after preoperative chemotherapy has been studied as an approach to 
distinguish poor responders from good responders at surgery. However, there are no 
options for substantial changes to the treatment other than extra salvage treatment for 
patients with a poor response. The recent European and American Osteosarcoma Study 
Group (EURAMOS)-1 trial, in which the addition of the chemotherapeutics ifosfamide 
and etoposide (IE) to the adjuvant MAP treatment (resulting in MAPIE) for poor histologic 
responders was studied, could not provide evidence of an advantage of MAPIE over 
MAP in event-free survival (EFS) and overall survival (OS), and MAPIE treatment was 
associated with greater toxicity [6]. Moreover, the histologic response is not a consistent 
and reliable predictor of outcome in past trials, and is not available at diagnosis but 
only after the first cycles of standard neoadjuvant chemotherapy [7]. Other than clinical 
factors, biological biomarkers could also be possible candidates for stratification and 
development of targeted therapy or treatment intensification, for example ATP-binding 
cassette sub-family B member 1 (ABCB1) overexpression [8], which is investigated 
as the basis for intensified treatment using the immunomodulator mifamurtide in the 
ongoing Italian Sarcoma Group (ISG)/OS-2 trial. However, in routine clinical practice, 
there are currently no treatment options other than chemotherapy available. Alternative 
treatment strategies, specifically targeting for example apoptosis resistance, proliferation, 
angiogenesis and immune evasion, are in development or clinical testing phase [9-12]. 
This includes agents in combination with chemotherapy such as monoclonal antibodies 
and interferon alpha 2b. The latter was tested in the EURAMOS-1 trial as maintenance 
therapy for patients with a good response to chemotherapy; however, the first report does 
not show an improvement in EFS when compared to chemotherapy alone [13]. Efforts 
to influence the bone microenvironment using bisphosphonates such as zoledronic acid 
are still in the early phase of clinical testing [14]. Furthermore, angiogenesis inhibitor 
sorafenib in combination with mTor inhibitor everolimus appeared to be favorable in a 
recent Phase II trial [15]. However, further development and testing of these strategies 
will still take considerable time.
 Despite advances in the field of tumor genomics in general, the complex karyotype 
and inter- and intra-tumor genetic heterogeneity of osteosarcoma is a complicating factor 
to design treatment regimens directed to the tumor genome. To date, tumor genomics 
approaches have not resulted in an established (somatic) genetic tumor profile that could 
already be clinically used as predictor of treatment efficacy [16]. Nevertheless, interesting 
results have been provided for example by genomic copy number variant studies, pointing 
towards chromosomal alterations as predictors of clinical outcome, which warrants 
further validation [17]. However, not only the tumor but also the germline genome is 
Introduction
Cancer is one of the major causes of death worldwide. Treatment of cancer varies among 
the different types of tumors, but classically involves either chemotherapy, radiotherapy, 
surgery, or a combination thereof. The increasing understanding of tumor biology and 
advances in the field of genomics have enabled the development of more precise 
treatment modalities such as immunotherapy and targeted therapy using monoclonal 
antibodies for specific subsets of tumors, based on predictive biomarkers. In addition, 
fine-tuning of chemotherapeutic treatment on the basis of insights in the pharmacokinetics 
and underlying genetics has become possible. All of these efforts, which are forms of 
personalized medicine, are aimed not only at increasing the patient’s chance to survive, 
but also at reducing the risk of side effects that can lead to morbidity and mortality in 
itself, and that have impact on the quality of life of surviving patients. This is especially 
important for cancers occurring during childhood, such as osteosarcoma, which is 
focused on in the current thesis.
Osteosarcoma
Osteosarcoma is a primary bone malignancy predominantly affecting children, adolescents 
and young adults. Although rare with a worldwide incidence of 3-4 per million, it is the 
most common type of primary bone cancer [1]. The primary site is most frequently the 
distal femur or proximal tibia and at diagnosis already 20% of patients present with 
clinically detectable metastases, mostly in the lungs [2,3]. The outcome for patients with 
high-grade osteosarcoma was poor before the introduction of effective chemotherapy in 
the late 1970s. Since the addition of multiagent chemotherapy to the treatment regimen, 
5-year survival increased from below 20% with surgery alone to 60-65% with combined 
surgery and chemotherapy [4]. However, the increase in survival has stagnated and 
still patients relapse, despite intensive treatment. Moreover, survivors often experience 
long-term chemotherapy-induced toxicities. Hence, there is a significant unmet need to 
improve survival of patients with osteosarcoma.
 The three-drug backbone of the treatment consists of cisplatin, doxorubicin and 
methotrexate (MTX) (MAP). Although these chemotherapeutics have been found to be 
the most effective treatment for osteosarcoma in clinical trials during the past decades 
[5], the sensitivity of patients to these agents, with regard to the antitumor effect and to 
the toxic side effects, varies highly among patients with osteosarcoma. As is the case for 
all chemotherapeutics, these agents have a narrow therapeutic window, which poses a 
challenge to treatment optimization. Further treatment intensification is generally limited 
due to treatment-related toxicity and mortality.
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were only a minority of the total cohort; no pharmacogenetic GWAS has been carried out 
with only osteosarcoma patients. The findings of pharmacogenetic studies of PK- and 
PD-related genes in osteosarcoma with regard to drug efficacy and toxicity are described 
hereafter. All discussed research involved germline pharmacogenetics, unless indicated 
otherwise.
Pharmacogenetics of drug efficacy
Pharmacogenetic studies in osteosarcoma have focused mainly on candidate genes 
related to drug transport, DNA repair and detoxification mechanisms, investigating the 
treatment response by analyzing the HR and survival. An overview of the published 
studies is shown in Table 1.
Transporters
Multiple studies have investigated the role of genetic variation in drug transporters 
in the efficacy of chemotherapeutic drugs used to treat osteosarcoma patients. All 
studies have selected candidate genes encoding transporters with a known function in 
the pharmacology of one or more of the core agents in the treatment regimen, which 
could impact efficacy of these agents through differences in PK. The first study that has 
assessed transporters of drugs in the MAP regimen was published by Caronia et al. 
[18]. The authors have retrospectively analyzed 91 osteosarcoma patients regarding 346 
single nucleotide polymorphisms (SNPs) in 24 genes involved in the metabolic pathways 
of MAP, vincristine and cyclophosphamide. One variant in ATP-binding cassette sub-
family C member 3 (ABCC3; rs4148416) and three variants in ABCB1 (rs4148737, 
rs1128503 and rs10276036 – the latter two in complete linkage disequilibrium) were 
identified in association with OS and EFS. ABCC3 and ABCB1 encode efflux transporters. 
ABCC3 is present in the liver, gallbladder, gut and kidney, is a known transporter of 
MTX, and suggested in cisplatin, doxorubicin, and vincristine transport. ABCB1 encodes 
P-glycoprotein, is involved in elimination of agents via bile and the kidney and is also 
known to be overexpressed in many tumors including multidrug-resistant osteosarcoma. 
P-glycoprotein is a transporter of MTX, doxorubicin and vincristine; although in 
osteosarcoma cell lines no evidence has been found for its involvement in resistance to 
MTX. The authors hypothesized that the variants might have an effect on the efflux of the 
chemotherapeutics and thereby influence the treatment efficacy. However, the functional 
consequences of the identified variants are yet unclear. Another variant in ABCB1, 
studied by Xiaohui et al., is also reported in association with a poor HR [19]. Findings 
similar to the study of Caronia were reported by Liu et al. in a Chinese population of 162 
patients with osteosarcoma, demonstrating a poor HR and higher risk of progression or 
an important player in treatment response, affecting the exposure and sensitivity to 
chemotherapeutic drugs. Gaining more insight into the germline genetic determinants 
involved in drug efficacy and toxicity (pharmacogenetics) is therefore very important. 
Pharmacogenetics holds the promise to contribute to the prediction of treatment efficacy 
and toxicity in patients with osteosarcoma and could provide a predictive genetic profile 
or algorithm that could be used to optimize treatment for the subgroup of patients prone 
to poor outcome or to developing toxicities. 
Pharmacogenetics of cancer treatment
The response to chemotherapeutic drugs used in cancer treatment is generally 
determined by a combination of clinical and genetic factors. Pharmacogenetics focuses 
on the inherited variability of drug response with regard to efficacy and toxicity. In 
osteosarcoma, efficacy is mostly investigated as survival (disease-free, progression-
free, event-free) and HR, and toxicity studies are mostly focused on ototoxicity and 
cardiotoxicity. Pharmacogenetics involves genetic variation in pharmacokinetics (PK), 
including transporters and drug metabolizing enzymes. These enzymes can be categorized 
in Phase I, responsible for reactions such as oxidation, reduction, and hydrolysis, and 
Phase II, responsible for conjugation reactions such as glucuronidation and glutathione 
conjugation. Enzymes of the CYP superfamily, gluthatione-S-transferases (GST) and 
uridine diphosphoglucuronosyltransferases (UGT) are known to catalyze the metabolism 
of the chemotherapeutics used in the treatment of osteosarcoma. Furthermore, most of 
the drug transport is covered by two types of transport superfamilies, namely ATP-binding 
cassette (ABC) efflux pumps and solute-linked carrier (SLC) influx transporters. Genetic 
variants in genes encoding these proteins can contribute to variation in drug levels that 
reach the target DNA due to reduced uptake and/or increased efflux, which on its turn 
can influence treatment efficacy and toxicity. On the other hand, pharmacogenetics also 
involves genetic differences in pharmacodynamics (PD), such as DNA repair mechanisms. 
Several DNA repair pathways, such as the nucleotide excision repair (NER) pathway, can 
protect from the deleterious effect of oxidative DNA damage. Variation in genes encoding 
such proteins can result in enhanced DNA repair and failure of apoptotic pathways 
induced by the chemotherapeutics, which also impacts efficacy.
 Different methods can be employed to explore pharmacogenetic markers, including 
candidate gene analysis, pathways-based gene analysis, and genome-wide association 
studies (GWAS). To date, the genome-wide method has been a challenge in osteosarcoma 
because of the need of large patient cohorts. Hence, almost all past pharmacogenetic 
studies in osteosarcoma are hypothesis-driven (candidate gene or pathway-based) to 
varying extent. In the few GWASes that included osteosarcoma patients, these patients 
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and inferior PFS and OS [31]. Unfortunately, the studies by Yang et al. [30] and Zhang et 
al. [28], not showing significance with OS in the meta-analysis, were analyzed separately, 
because originally the variant rs947894 assessed by these authors appeared to be a distinct 
SNP, whereas it has been merged with the rs1695 variant later on. Although the findings 
for rs1695 have been primarily consistent, confirmation in larger study cohorts and clinical 
validation is needed before it could be translated to clinical practice. Furthermore, another 
GSTP1 variant, rs1138272, has been shown to be associated with inferior EFS and OS in 
tumor DNA [26]. Another meta-analysis has also studied variants in multiple GST genes; 
however, multiple different phenotypes (toxicity, survival, osteosarcoma susceptibility) 
were studied together which makes it difficult to draw conclusions [32].
DNA repair
Of all the pathways discussed here, polymorphisms in NER genes involved in the repair 
of DNA adducts induced by cisplatin, which thereby influence cisplatin efficacy through 
variation in PD, have been investigated by the largest number of studies.
 A total of twelve studies have included variants in excision repair cross-
complementation group 1 (ERCC1) and/or excision repair cross-complementation 
group 2 (ERCC2) [26,30,33-42]. The ERCC1 variant rs11615 has been reported to 
be significantly associated only in studies of Chinese patient populations, showing 
conflicting results. Whereas four studies have suggested a good HR and improved OS 
for patients with the CC genotype [35,36,40,41], the same genotype was reported in 
association with inferior EFS or OS by others [37,39]. Of two studies that have also 
assessed the ERCC1 rs2298881 variant, only Sun et al. have found an association of 
the AC/CC genotypes with a poor HR and inferior OS [35,40]. ERCC2 variants have also 
been the subject of inconsistent results. Whereas patients with the rs13181 CC genotype 
showed improved EFS in an Italian study of 130 osteosarcoma patients, a Spanish study 
reported an association with a poor HR and inferior EFS, and Chinese study reported 
inferior OS [33,34,39]. A meta-analysis seeking to determine the effect of this variant has 
unfortunately only included two of the 12 studies that have investigated this variant. The 
Italian study has also determined improved EFS of patients carrying the rs1799793 AA 
genotype, and three other studies have shown similar findings demonstrating improved 
EFS or OS and a good clinical response [26,37,38]. However, Cao et al. have reported 
an association of this genotype with a poor HR, although no significance was reached in 
association with OS [40]. There are several differences between the studies, regarding 
inclusion of metastatic patients or nonmetastatic only, and ethnic background that could 
have contributed to the discrepancy in the results. Moreover, all studies are reporting 
on single and relatively small cohorts, often leading to large confidence intervals of the 
observed point estimates. Follow-up on these results is clearly needed because the 
studies carried out so far remain inconclusive. 
death in carriers of the C allele of the ABCB1 rs1128503 variant or the T allele of ABCC3 
rs4148416 [20]. However, conflicting results have been described in two other Chinese 
studies reporting the effect in the opposite direction for the ABCB1 variant rs1128503, 
and a study in which no association with this ABCB1 variant was detected at all [21-23]. 
A meta-analysis of the results of the abovementioned studies of ABCB1 and ABCC3 
and their association with the response revealed that ABCC3 rs4148416 and ABCB1 
rs1128503 were associated with response, the latter only in the two included Caucasian 
studies. However, the definition of response and the interpretation of the reported odds 
ratios (OR) are unclear from this meta-analysis [24].
 A recent study of 62 osteosarcoma patients specifically focusing on MTX-related genes 
has demonstrated an association of variant rs1051266 in the reduced folate carrier 1 
(RFC1) gene with survival after MTX-based chemotherapy [25]. Because this was the 
first reported study investigating this gene in this context, the result warrants replication in 
independent cohorts, and the true value of the association found is therefore not known.
 
Detoxification
Several members of the GST family have been studied in relation to the HR and survival of 
osteosarcoma patients. As the GST enzymes are known to be involved in the detoxification of 
the predominant chemotherapeutics in osteosarcoma treatment, cisplatin and doxorubicin, 
but also of agents used in specific protocols such as etoposide, ifosfamide and vincristine, 
variation in the genes causing differential enzymes activity is likely to be able to influence 
efficacy of these agents, for example by lowering intracellular drug levels. A total of nine 
studies have analyzed the role of GST mu 1 (GSTM1) and GST theta 1 (GSTT1) deletions 
[18,20,22,23,26-30]. Only a study of a Brazilian cohort of 80 osteosarcoma patients 
showed an association of the GSTM1 null genotype with increased risk of recurrence to the 
lungs. In addition, metastatic patients with GSTM1 or GSTT1 null genotype or homozygous 
GSTM3*A genotype showed inferior OS [27]. This is the only study that has stratified for 
metastatic osteosarcoma, which could have contributed to the unique findings. Windsor et 
al. have also detected an association of the GSTT1 null genotype with inferior progression-
free survival (PFS); however, significance was not maintained when corrected for primary 
site and metastatic disease [23]. 
 Primarily consistent findings have been reported for the GST pi 1 (GSTP1) gene. The 
GSTP1 rs1695 G allele or GG genotype has been reported in association with a poor HR 
in multiple studies [20,22,23,29]. Moreover, it has been linked to inferior survival (EFS, 
PFS, OS, depending on what has been studied) [20,22,23,28,29]. In contrast, one Chinese 
study that has not investigated the HR but the clinical response instead has identified the 
GG genotype in association with a good response (complete or partial remission) rather 
than a poor response; however, this did not translate into inferior OS [30]. A meta-analysis 
including the total of six studies has confirmed the association of the variant with a poor HR 
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doxorubicin were investigated, including PD-related genes (e.g. DNA repair and apoptosis 
related genes). A total of 384 SNPs in 54 candidate genes were genotyped for two cohorts 
of a total of 177 patients with osteosarcoma. In a meta-analysis, five variants were 
identified that were significantly associated with 5-year PFS: Fas ligand (FasL) rs763110, 
MutS homologue 2 (MSH2) rs4638843, caspase 3 (CASP3) rs2720376, ATP-binding 
cassette sub-family C member 5 (ABCC5) rs939338, and cytochrome P450 3A4 (CYP3A4) 
rs4646437. These genes were hypothesized to influence chemotherapy efficacy through 
differences in PD or in PK (the latter two). Risk stratification based on the combined effects 
of the risk alleles improved the ability to predict the 5-year PFS. Although this is the largest 
and most extensive study published to date with respect to patient numbers and coverage 
of metabolic pathways, validation in independent, larger cohorts is needed.
 On the basis of all of the above studies into drug efficacy, it currently remains difficult 
to draw firm conclusions regarding the most important genes deserving further follow-
up in prospective and functional validation studies, despite numerous candidate gene 
studies and several pathway-based studies. Large-scale studies with respect to numbers 
of patients and genes may be useful to pinpoint the role of these and previously not 
investigated genes in drug efficacy in patients with osteosarcoma.
Pharmacogenetics of drug toxicity
The ability to manage toxicities induced by chemotherapy is an important factor for 
the success of cancer treatment. Osteosarcoma patients receiving MAP therapy 
can experience severe side effects that are often dose-limiting. General side effects 
include cell-damaging effects, such as nausea and vomiting, myelosuppression, and 
immunosuppression. More specific side effects include nephrotoxicity, neurotoxicity, 
hepatotoxicity, hearing loss (ototoxicity) and cardiotoxicity. Pharmacogenetic markers 
can be a useful tool to predict the patient’s drug exposure and sensitivity to toxicities. 
With upfront knowledge on a patient’s susceptibility to specific side effects, alternative 
strategies or the use of protective agents can be considered to prevent treatment-related 
morbidity and mortality, and greatly improve the patient’s quality of life. Here we focus on 
the side effects of each of the chemotherapeutics in the MAP regimen that are studied in 
pharmacogenetic research in patients with osteosarcoma. An overview of the published 
studies is provided in Tables 2-4.
Cisplatin-induced ototoxicity
Ototoxicity is a major dose-limiting side effect of cisplatin. It occurs in 40-60% of cisplatin-
treated patients and is characterized by permanent, bilateral, sensorineural hearing 
loss [47]. There is substantial interindividual variation in ototoxicity, which is not fully 
 Other DNA repair genes for which significant associations have been reported include 
the xeroderma pigmentosum complementation group C (XPC) gene, showing a good 
HR but no improvement of EFS with the rs2229001 AC/CC genotype [33]. Furthermore, 
ERCC5 rs1047768 TT has been associated with a good clinical response and improved 
PFS and OS [43], and the rs2296147 variant with good clinical response and improved 
OS [44,45]. For MMS19 homolog, cytosolic iron-sulfur assembly component (MMS19L), 
conflicting results have been reported, showing association of the rs29001323 TT 
genotype with either good clinical response and improved OS [44,45] or the opposite 
effect [43].
 Another study has also explored the role of polymorphisms in two genes involved 
in the repair of cisplatin-induced interstrand crosslinks: DNA polymerase REV1 (DNA 
directed) (REV1) and REV3-like polymerase (DNA directed) zeta catalytic subunit 
(REV3L), in tumor DNA of 66 osteosarcoma patients [46]. Inferior EFS and OS were 
observed for patients harboring the REV1 variant rs3087403, as well as in a haplotype 
with the REVL3 variant rs462779, suggesting a role for the REV genes in the efficacy 
of cisplatin treatment. Furthermore, a Nibrin (NBN) haplotype was also associated with 
EFS, although not with OS [26]. Although these studies are still in need of independent 
validation, these findings point towards a role of genetic variation in multiple DNA repair 
genes in the treatment efficacy primarily of cisplatin.
Pathway-based studies
A few pharmacogenetic studies have taken a broader approach than candidate gene 
analysis and have investigated multiple genes known to be involved in the metabolism 
and transport of cisplatin and doxorubicin-based chemotherapy. In addition to the study 
by Caronia et al. reporting on the role of ABC transporters discussed above, two other 
pathway-based studies have been published. Windsor et al. have analyzed 35 variants in 
21 genes from the pathways of MAP chemotherapy in relation to HR and progression-free 
survival (PFS) in a cohort of 50 patients with osteosarcoma [23]. In addition to the results 
for GSTP1 discussed above, the variant ATP-binding cassette sub-family C member 
2 (ABCC2) 24C>T (rs717620) was associated with a poor HR, whereas the variant 
1958G>A (rs1950902) in methylenetetrahydrofolate dehydrogenase, cyclohydrolase and 
formyltetrahydrofolate synthetase 1 (MTHFD1) had a protective effect. However, the HR 
was not associated with PFS, making it difficult to interpret the clinical importance of 
the findings. No variants were found to be associated with PFS when corrected for the 
primary tumor site and metastatic status at diagnosis. However, the overrepresentation 
of survivors, because the study included only patients alive at the time of retrospective 
collection, might have limited the ability to detect associations with small effect sizes.
 A complete pathway-based approach was taken in a previous study from our group [42]. 
All genes known to be involved in the metabolism and transport pathways of cisplatin and 
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explained by clinical risk factors such as young age at diagnosis, cumulative cisplatin 
dose and cranial irradiation [48-50]. This has led to the hypothesis that variation in genes 
encoding drug metabolizing enzymes and transporters could also be determinants of the 
sensitivity to cisplatin-induced hearing loss. 
 Six small-scale candidate gene pharmacogenetic studies including osteosarcoma 
patients have investigated polymorphisms in candidate genes mostly based on their 
expression or function in the inner ear. The presumed mechanism underlying cisplatin-
induced hearing loss involves DNA damage and sensitivity of the cochlear cells to 
oxidative stress by the generation of toxic levels of reactive oxygen species (ROS) [51]. 
Accumulation of ROS leads to the depletion of the cochlear antioxidant enzyme system, 
including the GST enzymes. Peters et al. were the first to study genetic polymorphisms 
in five GST genes (GSTM1, GSTM3, GSTT1, GSTP1, and GSTZ1) in a cohort of 39 
cisplatin-treated young adults including 27 patients with osteosarcoma [52]. They have 
reported an increased frequency of the GSTM3*B allele in patients without hearing loss, 
indicating a protective effect. However, other studies could not detect associations of 
GST variants and ototoxicity, including a Brazilian study of 80 patients with osteosarcoma 
assessing GSTM3*B and variants of GSTM1 and GSTT1 [27,53].
 Riedemann et al. have studied Megalin, which is expressed by the marginal cells of 
the cochlea, encoding a multiligand endocytic receptor that is implicated to bind cisplatin 
because of its association with uptake of aminoglycosides [54]. In 50 pediatric cancer 
patients (N=38 with osteosarcoma) the variant rs2075252 was found to be associated with 
ototoxicity after treatment. In contrast, a Canadian study could not identify a significant 
association of cisplatin-induced ototoxicity and the Megalin rs2075252 variant [53]. 
 A fourth study has focused on NER genes in a cohort of 32 osteosarcoma patients, 
demonstrating an association of the rs2228001 SNP in the XPC gene with ototoxicity 
[33]. The authors suggested that the variant may decrease the DNA repair capacity, 
rendering outer hair cells in the inner ear susceptible to cisplatin.
 Spracklen et al. have assessed the role of polymorphisms in the Otos gene [55]. This 
gene encodes otospirallin, which is a protein involved in cochlear function and protection 
and has been implicated in the response to cisplatin in cell models [56]. In a cohort of 100 
cisplatin-treated adult cancer patients of varying ethnicity (N=10 with osteosarcoma), two 
SNPs (rs77124181 and rs2291767, in full LD in Caucasians) were found to be protective. 
Validation of this finding is needed, especially as the cohort was heterogeneous with 
respect to dosing and schedule, and as all osteosarcoma patients were reported to have 
developed ototoxicity. 
 Another recent candidate gene study has been reported by Lanvers-Kaminsky et al., 
investigating the solute carrier family 31 member 1 (SLC31A1) gene and solute carrier 
family 22 member 2 (SLC22A2), the latter because of its involvement in mediating 
the transport of cisplatin [57]. They determined that SLC22A2 variant rs316019 was N
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associated with cisplatin-induced hearing loss in a discovery cohort of pediatric patients 
including 41 osteosarcoma patients, and an adult cancer replication cohort.
 Other than the ototoxicity studies investigating a few genes, two studies have taken a 
broader approach, looking beyond specific candidate genes or metabolic pathways. This 
is also a more extensive approach than taken in the pharmacogenetic studies investigating 
drug efficacy reported so far, which could be inherent to the outcome, because generally 
in toxicity studies larger effect sizes are expected. This makes it possible to investigate 
large numbers of genes and still have sufficient power in a relatively small patient cohort. 
Ross et al. have interrogated 1,949 SNPs in 220 key genes in a discovery cohort and a 
replication cohort with a total of 162 pediatric cancer patients, including 40 patients with 
osteosarcoma [53]. They have identified variants in the thiopurine S-methyltransferase 
(TPMT; rs12201199, rs1142345, rs1800460) and catechol-O-methyltransferase (COMT; 
rs9332377, rs4646316) genes in association with cisplatin-induced hearing loss. In a 
separate study, the same group has replicated the findings of variants in the TPMT gene 
in an independent cohort of 155 patients [58]. However, these findings could not be 
consistently replicated by ourselves and others [59-61]. This lack of consistency could 
be attributed to the large heterogeneity of patient cohorts with respect to ethnicity and 
different cancers, the latter reflected by variation in treatment regimens. The controversy 
has been the subject of a debate, especially because the original findings led to a cisplatin 
label change by the US Food and Drug Administration, indicating the association of TPMT 
with ototoxicity [62,63]. 
Doxorubicin-induced cardiotoxicity
Cardiotoxicity is a major problem in the treatment with the anthracycline doxorubicin. It 
can present as acute, chronic or late onset heart failure and appears to be induced by 
oxidative stress in cardiomyocytes [64]. There is large variation in the susceptibility to 
anthracycline-induced cardiotoxicity (ACT) and the risk for ACT is increased with younger 
age, higher cumulative dose, and female sex [65]. However, these factors are not sufficient 
to accurately predict a patient’s sensitivity to developing ACT. Therefore, pharmacogenetic 
studies have investigated the potential role of genetic variants in drug metabolism genes. 
 A Brazilian study of 80 patients with osteosarcoma assessing GSTM1, GSTM3, and 
GSTT1 variants could not identify associations with cardiotoxicity [27]. However, the pilot 
study of Windsor et al. has suggested an association of the GSTP1 variant rs1695, not 
assessed in the Brazilian study, with a decrease in ejection fraction (EF) after end of 
treatment in a small scale MAP pathway-based study in 50 patients with osteosarcoma 
[23]. Furthermore, several larger studies specifically focusing on ACT in pediatric cancer 
patients, also including osteosarcoma patients, have been published by other research 
groups, as discussed below.
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 A large study of 487 pediatric cancer patients has investigated polymorphisms in carbonyl 
reductase genes, involved in the reduction of anthracyclines [66]. Carbonyl reductase 3 
(CBR3) variants were identified in association with ACT, although not when patients were 
treated with high doses as used in the treatment of osteosarcoma (cumulative dose 450 
mg/m2). However, the CBR3 variants were not found to be associated in another large 
study published simultaneously, in which 220 drug metabolism and transport genes were 
interrogated in a Canadian discovery cohort of 156 pediatric cancer patients, a Canadian 
replication cohort (N=188) and a Dutch replication cohort (N=96) [67]. Visscher et al. did 
however report on associations of variants in solute carrier family 28 member 3 (SLC28A3) 
and a number of other genes with ACT. An additional replication study from the same 
group has reported confirmation of variants of SLC28A3 and UDP glucuronosyltransferase 
family 1 member A6 (UGT1A6) in association with ACT, although the effect was only 
significant when the two Canadian cohorts of the original study and replication cohorts 
where combined, and the replication cohort also encompassed, in part, patients of the 
Dutch replication cohort included in the original publication [68].
 Another large study followed in which 363 pediatric cancer patients have been included 
in a two-stage design [69]. A total of 2,100 genes have been investigated in relation to ACT. 
This study did not include the previously reported variants in CBR3 and SLC28A3, but 
identified a new association of a variant in the hyaluronan synthase 3 (HAS3) gene. As this 
gene encodes an enzyme that produces the extracellular matrix component hyaluronan, 
which is also known to reduce ROS-induced cardiac damage, the authors suggested that 
the genetic variant might be linked to risk of ACT because of inadequate protection from 
ROS-induced damage and/or inadequate tissue remodeling.
 In a recent report from Visscher et al., the authors aimed to identify additional genetic 
variants that might have been missed in their previous study, by investigating over 300 
PK/PD genes in a discovery cohort and a replication cohort [70]. They have identified 
variants in the solute carrier family 22 member 7 (SLC22A7) and solute carrier family 22 
member 17 (SLC22A17) genes in association with ACT, which improved their previously 
reported genotype-guided risk prediction model. This publication was followed by a 
GWAS from the same group, in which a nonsynonymous variant in retinoic acid receptor 
γ (RARG) was found to be associated with ACT [71]. This has been the most extensive 
study with respect to the number of variants, and, as the authors state, it needs further 
follow-up to understand the role of RARG in ACT and to provide clinical validation.
Methotrexate toxicity
High-dose MTX often leads to toxicities including bone marrow suppression, renal failure, 
and hepatotoxicity. Treatment cycles are often delayed when these toxicities are not 
diminished before the start of the next cycle. The current practice of preventing these 
toxicities involves therapeutic monitoring of MTX plasma levels with leucovorin rescue No
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The next step
Most of the pharmacogenetic studies in osteosarcoma performed to date, especially with 
respect to drug efficacy, have used a candidate gene approach by design, investigating 
a limited number of genes involved in pharmacokinetic or pharmacodynamic pathways 
of MAP therapy. These studies have yielded promising results, strongly indicating a 
role of multiple genetic polymorphisms in the efficacy of chemotherapeutic treatment 
or sensitivity to toxicities. A logical next step is to take a broader approach, as certainly 
not all variation in the treatment efficacy and toxicity can be explained by the genetic 
variants studied and identified so far. In addition, the genetic component of the treatment 
response is likely to be a combination of multiple small genetic effects. 
Aim and outline of this thesis
The overall aim of this thesis is to identify genetic predictors of efficacy and toxicity of 
chemotherapeutic treatment in patients with osteosarcoma, which could ultimately be used 
to establish a prediction model to enable risk stratification and tailored treatment through 
optimization, or which could serve as new therapeutic targets for osteosarcoma treatment.
 All of the studies presented in this thesis involved patients with high-grade 
osteosarcoma. In the majority of the studies included in this thesis, we have used the 
comprehensive Drug Metabolizing Enzymes and Transporters (DMET) Plus array to 
assess genetic variants in genes related to drug absorption, distribution, metabolism and 
transport, in retrospectively collected osteosarcoma patients cohorts. As for a proportion 
of patients the only available source for germline DNA was normal formalin-fixed, paraffin-
embedded (FFPE) tissue, the performance and reliability of FFPE tissue-derived DNA on 
the DMET Plus array was examined, which is described in chapter 2. 
 The next two chapters are focused on the pharmacogenetics of chemotherapy-induced 
toxicities. In chapter 3, we report on the association of a variant in the ACYP2 gene with 
cisplatin-induced ototoxicity, which was previously identified in a GWAS in children with 
brain tumors, and confirmed in our osteosarcoma patient population. In chapter 4, we 
describe a study into the role of genetic variants in MTX-induced hepatotoxicity using the 
DMET Plus array. 
 Chapters 5-7 are focused on the pharmacogenetics of chemotherapy efficacy. In a 
previous pathway-based study by our group, five genetic markers were identified that could 
distinguish patients with good outcome from those with poor outcome. When combined in 
a genetic risk score, these markers were predictive of 5-year PFS. In chapter 5, we report 
on the validation of this genetic risk score in independent osteosarcoma patient cohorts. 
In chapter 6, we have employed the DMET Plus array to detect (additional) genetic 
in case of sustained high plasma levels, to minimize toxicities. However, leucovorin 
rescue may potentially reduce the desired antitumor effect depending on the dosage 
and the time point it is given. Upfront knowledge of the patient’s response to MTX could 
therefore be helpful in the prevention of MTX-induced toxicities and their consequences. 
Several pharmacogenetic studies have suggested a role of genetic variants in the 
interpatient variability of the response to high-dose (HD)-MTX, of which a few have 
included osteosarcoma patients. Windsor et al., taking a MAP pathway-based approach 
in 50 patients with osteosarcoma by selecting genes of the metabolic pathways of 
methotrexate, doxorubicin, and cisplatin, have suggested associations of variants of 
methylenetetrahydrofolate reductase (MTHFR) (1298A>C, rs1801131), ABCB1 (3435T>C, 
rs1045642), and ABCC2 (3563T>A, rs17222723) with anemia, leucopenia or mucositis 
as a result of HD-MTX treatment [23]. ABCB1 and ABCC2 are known transporters of 
MTX; however, the role of polymorphisms in the genes in the context of MTX treatment 
is not well established in osteosarcoma and other cancers, although another variant 
of ABCC2 was also related to MTX-induced toxicities in another small scale study of 
tumor DNA of 44 patients with osteosarcoma [72]. MTHFR encodes a key enzyme in the 
folate homeostasis and metabolism and is more widely studied in MTX-treated patients in 
relation to hepatotoxicity. Dogan et al. have reported an increased frequency of MTHFR 
variant 667C>T (rs1801133) in patients with osteosarcoma experiencing high alanine 
aminotransferase when compared to the general population, although no statistics could 
be performed owing to the very small number of patients (N=7) [73]. Jabeen et al. have 
recently reported an association of the same variant with hepatotoxicity in a candidate 
gene study of 62 patients with osteosarcoma [25]. However, the association of the 
667C>T variant and hepatotoxicity could not be confirmed by other studies, including 
a large meta-analysis also including patients with osteosarcoma [72,74-76]. Hence, the 
role of variants in this gene in MTX-induced toxicity still needs to be elucidated [77]. The 
RFC1 rs1051266 variant that was identified by Jabeen et al. in relation to survival after 
MTX-based therapy was not associated with MTX-induced toxicities in the same study 
[25]; however, a Korean study showed association of the variant with MTX serum levels 
and mucositis, indicating that this variant deserves follow-up studies to further elucidate 
its role not only with respect to survival but also toxicity after MTX treatment [76].
 In the candidate gene study of 44 osteosarcoma patients by Goricar et al., associations 
of a solute carrier organic anion transporter family member 1B1 (SLCO1B1) variant were 
found to influence MTX serum levels, although this did not translate into associations 
with MTX-induced toxicities [72]. Other variants in this organic anion transporter gene 
were previously found in association with MTX clearance in a large GWAS in patients 
with acute lymphoblastic leukemia, which was also validated by others [78,79]. Further 
validation in large cohorts of osteosarcoma patients is warranted to confirm the influence 
of SLCO1B1 variants on MTX PK and susceptibility to toxicities in this group of patients.
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variants associated with PFS and HR in our Dutch patient cohorts and collaborative 
cohorts. In chapter 7, we report on a DMET analysis focusing on the subgroup of 
patients with an inadequate drug response (progressive disease) already during first-line 
chemotherapeutic treatment.
 In the final chapter, the research described in this thesis is summarized and future 
research perspectives are given.
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Abstract
The Affymetrix Drug Metabolizing Enzymes and Transporters (DMET) Plus array covers 
1,936 markers in 231 genes involved in drug metabolism and transport. Blood- and 
saliva-derived DNA works well on the DMET array, but the utility of DNA from formalin-
fixed, paraffin-embedded (FFPE) tissue has not been reported for this array. As the ability 
to use DNA from FFPE tissue on the array could open the potential for large retrospective 
sample collections, we examined the performance and reliability of FFPE-derived DNA 
on the DMET Plus array. 
 Germline DNA isolated from archived normal FFPE tissue blocks stored for 3 to 19 
years and matched blood or saliva from 16 patients with osteosarcoma was genotyped 
on the DMET Plus array. Concordance was assessed by calculating agreement and the 
κ-statistic.
 We observed high call rates for both the blood- or saliva-derived DNA samples (99.4%) 
and the FFPE-derived DNA samples (98.9%). Moreover, the concordance among the 
sixteen blood- or saliva-derived DNA and FFPE DNA pairs was high (97.4%, κ=0.915).
 This is the first study showing that DNA from normal FFPE tissue provides accurate 
and reliable genotypes on the DMET Plus array compared with blood- or saliva-derived 
DNA. This finding provides an opportunity for pharmacogenetic studies in diseases with 
high mortality rates and prevents a bias in studies where otherwise only alive patients 
can be included.
Introduction
The contribution of genetic variation to interindividual variability of drug efficacy and 
toxicity profiles is widely acknowledged. The Affymetrix Drug Metabolizing Enzymes and 
Transporters (DMET) Plus array is a dedicated assay for pharmacogenetic applications 
as it genotypes 1,936 markers in 231 genes involved in drug absorption, distribution, 
metabolism, excretion and transport [1,2]. The array is based on molecular inversion 
probe (MIP) technology for the simultaneous genotyping of multiple polymorphisms in a 
single assay. Blood and saliva samples are used as the standard source of germline DNA 
for genotyping [3]. However, collection and storage of germline DNA have not routinely 
been performed in most clinical trials in the past. In particular, in pharmacogenetic 
studies in the field of oncology with cancers with low survival rates, the lack of stored 
blood or saliva can result in biased patient populations for research because the poor 
responders to therapy are likely to be missing. In such cases, stored formalin-fixed, 
paraffin embedded (FFPE) tissue is often the only available source for germline DNA. 
However, in the process of fixation and storage of FFPE samples, DNA degradation and 
DNA-protein cross-linkages result in reduced DNA quality, which can be challenging for 
PCR-based analysis [4,5]. Therefore, the use of archived tissue, which can be highly 
valuable for biomarker studies, first needs to be validated for the specific analysis [6]. 
 For several Affymetrix single nucleotide polymorphism (SNP) arrays, the performance 
of FFPE-derived DNA has been compared with DNA from fresh frozen tissue, revealing 
a high degree of concordance; however, these studies have primarily focused on copy 
number variations and chromosomal aberrations in tumor tissue [7-9]. In addition, 
Affymetrix has successfully demonstrated the suitability of FFPE-derived DNA for MIP 
technology using both normal and tumor FFPE samples [10]. DNA from FFPE tissue 
may also be suitable for genotyping by the DMET array; however, the DMET Plus array 
differs from standard MIP arrays because it performs an initial 36-plex multiplex PCR to 
preamplify genes known to have pseudogenes or close homologs. To date, no studies 
have reported the utility of DNA from FFPE samples as a template for the DMET Plus 
array, and no comparison of genotype performance with DNA from blood or saliva has 
been made. In the present study, the performance and reliability of FFPE-derived DNA on 
the DMET Plus array are assessed using a series of matched blood or saliva and normal 
FFPE samples from patients with osteosarcoma.
Genotyping FFPE tissue DNA on DMET array
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Materials and methods
DNA extraction
From 16 patients with primary, high-grade osteosarcoma treated at the Radboud 
university medical center (Nijmegen, The Netherlands), DNA was isolated from archived 
normal FFPE tissue and blood or saliva after obtaining written informed consent from 
the patients or parents. If clinically available, blood was used as the primary source for 
reference DNA; otherwise, saliva was used. The study was approved by the local ethics 
committee, and all tissue was handled according to the Code Proper Use of Human 
Tissue in The Netherlands (FEDERA, Federation of Dutch Medical Scientific Societies; 
www.federa.org; last accessed April 16, 2014).
 DNA was isolated from fresh EDTA whole blood samples (n=13) using the QIAamp DNA 
Blood Midi kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol. 
Saliva was collected (n=3) using the Oragene DNA saliva collection kit (DNA Genotek Inc., 
Kanata, Ontario, Canada), and DNA was extracted following the manufacturer’s instructions. 
 FFPE tissue-derived DNA from the same patients was obtained using stored FFPE 
tissue blocks from surgical resection specimens. At the time of resection, fresh tissue 
was fixed in 4% buffered formalin, processed routinely, and embedded in paraffin as 
described previously [11]. At the time of DNA isolation, the FFPE tissue blocks had been 
stored at room temperature for 3 to 19 years. Before DNA isolation, all tissue blocks 
were assessed by an experienced pathologist (U.F.) using hematoxylin and eosin-
stained slides. From a series of tissue blocks with optically distinguishable normal and/or 
malignant tissue, FFPE tissue blocks that contained only normal tissue were selected to 
ensure isolation of germline DNA only. All tissue blocks contained nondecalcified, normal 
soft tissue, including lung, muscle, skin, lymph node, or a combination. The FFPE tissue 
samples were sectioned using a microtome, which was cleaned with ethanol between 
cases to avoid contamination. Ten 20 µm tissue sections were used for isolation as 
described by Hagleitner et al. [11], with some adjustments. Samples were incubated in 
800 µL of 5% Chelex-100 (Bio-Rad, Veenendaal, The Netherlands) in TET lysis buffer [5 
mL of 1 mol/L Tris HCl, pH 8.5, 1 mL of 0.5 mol/L EDTA, pH 8.0, 250 µL of 20% Tween-20 
(Merck, Amsterdam, The Netherlands), and 493.75 ml of sterile water] and 80 µL of 
proteinase K solution (20 mg/mL; Roche Diagnostics, Almere, The Netherlands) for 16 
hours at 56°C in a Thermomixer (350 rpm), followed by 48 hours at 37°C with the addition 
of 80 µL of proteinase K at 0 and 24 hours. After a subsequent 10 minutes of incubation at 
95°C, the samples were centrifuged for 10 minutes at 16,000 x g and cleared by removal 
of the supernatant twice. Addition of 8 µL of RNase A (100 mg/µL; Qiagen catalog no. 
19101) to the supernatant was followed by 30 minutes of incubation at room temperature 
and 10 minutes at 80°C. The DNA was then purified using the QIAamp DNA Micro Kit 
(Qiagen), with buffer AW2 and 20 µL of AE twice applied instead of once. 
Quality control of DNA samples
To assess the quality of the DNA samples, a qualitative size range PCR was performed 
as described previously [11]. In brief, 50 ng of genomic DNA (based on NanoDrop 
measurements using Nanodrop 2000; Thermo Scientific, Breda, The Netherlands) from 
FFPE tissue (n=16) and one representative blood sample was included. The assay 
contained five primers sets that amplify fragments that range from 100 to 400 bp, as 
described previously [12]. MilliQ was included as negative control and 50 ng DNA 
from frozen tissue sections as a positive control for the assay. The PCR products were 
visualized and recorded in an ethidium bromide-stained 2% agarose gel using the Imago 
(Isogen Bioscience, IJsselstein, The Netherlands). 
Genotyping
Thirty-two DNA samples were genotyped using the DMET Plus array according to the 
manufacturer’s instructions (Affymetrix UK ltd, High Wycombe, United Kingdom) [1]. All 
samples were normalized to 60 ng/µL based on Nanodrop measurements, and 17 µl 
(1.02 µg DNA) per sample was used for genotyping. Genotypes were calculated with 
DMET console software 1.3 using Dynamic Genotype Boundaries algorithm version 2. 
 In addition, the 16 blood- or saliva-derived DNA samples were genotyped for 381 
markers, of which 13 SNPs were overlapping with the DMET Plus panel, using a custom-
based assay on the Illumina BeadArray platform (Illumina Inc,. San Diego, CA). Genotypes 
were calculated using Illumina Genome Studio software version 2008.1 (Illumina Inc.).
Statistical analysis
Genotyping results of the 16 DNA pairs from blood or saliva and FFPE tissue were 
evaluated for call rate and SNP and copy number variation concordance. Call rates were 
derived from the DMET console software calculation, which is the percentage of SNPs 
successfully genotyped per sample, excluding no calls but including possible rare allele 
(PRA) calls. PRA calls are assigned by the DMET console software to probe signals 
that fall out of the range of the training data because the variant alleles were rarely 
or not observed in assay development. For each marker, the concordance between 
the genotypes obtained from the blood- or saliva-derived DNA and the FFPE-derived 
DNA was determined by calculation of the percentage of genotype agreement and the 
κ-statistic. The κ-statistic measures agreement beyond chance alone; a κ-statistic of 0 
indicates chance agreement, whereas a κ-statistic of 1 indicates complete agreement. The 
overall agreement and overall κ-statistic were calculated as the mean of the agreement 
and κ of all markers. The analyses were performed using R version 3.0.2 (http://www.r-
project.org) and included no calls and PRA calls. In addition, genotype concordance was 
calculated for each DNA pair with and without inclusion of PRA calls (i.e. the percentage 
of markers with the same genotype call for DNA from blood or saliva and FFPE tissue 
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of the total number of markers, excluding those with no calls and/or PRA for DNA from 
either source). Calculations per pair were performed using Microsoft Excel (Microsoft 
Corp, Redmond, WA). 
 Assessment of associations of SNPs with DNA source (blood or saliva versus FFPE 
tissue) was performed by logistic regression analysis using PLINK software version 
v1.07 (http://pngu.mgh.harvard.edu/purcell/plink; last accessed April 14, 2014) [13]. P < 
0.05 was used as significance level, without correction for multiple testing because of the 
exploratory nature of this analysis.
Results
To assess the suitability of DNA isolated from FFPE tissue for the DMET Plus array, 
germline DNA derived from FFPE tissue and matched blood or saliva samples as high 
quality reference material was collected from 16 patients with osteosarcoma. The average 
yield of the FFPE-derived DNA samples was 12.2 µg (range, 1.93 to 36.8 µg); hence, 
isolation yielded sufficient DNA from all FFPE samples for downstream array analysis.
Quality of DNA isolated from FFPE tissue 
Prior to DMET analysis, the quality of all FFPE tissue-derived DNA samples was evaluated 
by size range PCR. The reference blood DNA revealed bands up to 400 bp using gel 
electrophoresis, whereas the FFPE DNA samples showed amplicon sizes ranging from 
100 to 300 bp, with a reduced intensity of the largest fragment visible in most cases 
(Figure 1).
Genotype call rates
All DNA samples from blood, saliva, and FFPE tissue were successfully genotyped by the 
DMET Plus array. The mean ± SD call rate for all blood- or saliva-derived DNA samples 
was 99.4% ± 0.30% (Table 1). For the FFPE-derived DNA samples, the mean ± SD call 
rate was 98.9% ± 1.0%. Fourteen FFPE DNA samples had call rates >98%, which is the 
threshold recommended by the manufacturer (Table 1) [1]. The two FFPE DNA samples 
with lower call rates (96.32% and 96.53%) were, however, still within a range suitable 
for genetic association studies, in which a minimum of 95% is considered acceptable. 
Although these samples were also observed to have small amplicon sizes in the size 
range PCR (maximum, 100 bp), indicative of reduced DNA quality, this correlation was 
not consistent among the other samples with similar fragment sizes. However, a reduction 
in the signal intensity of the 100-bp band was observed specifically in the two samples 
with lower call rates.
Table 1. Genotyping call rate and concordance per blood- or saliva-derived DNA and FFPE DNA pair.
  Call rate, % Genotype concordance, %
Sample no. Blood or saliva FFPE tissue Excluding no calls Excluding no calls and PRAs
1 99.48 99.38 99.48 99.84
2 99.74 99.07 99.37 99.84
3 99.59 99.64 99.48 99.84
4 99.07 99.69 99.37 99.89
5 99.22 99.43 99.42 99.89
6 99.33 96.32 97.46 98.42
7 98.81 99.27 99.26 99.79
8 98.91 98.55 98.78 99.25
9 99.17 99.17 98.89 99.37
10 99.48 99.38 99.16 99.68
11 99.48 99.43 98.90 99.53
12 99.53 99.22 98.85 99.31
13 99.53 98.76 98.84 99.26
14 99.90 99.17 98.90 99.37
15 99.12 96.53 98.54 98.97
16 99.69 99.74 99.48 99.69
Sample call rates and genotype concordance for DNA derived from blood (samples 1 to 13), saliva 
(samples 14 to 16), and matching FFPE tissue on the Affymetrix Drug Metabolizing Enzymes and 
Transporters Plus array. 
FFPE, formalin-fixed, paraffin-embedded; PRA, possible rare allele.
Figure 1. Quality of DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tissue. The size ranges 
of the PCR products of 16 DNA samples from FFPE tissue are given. Lane B is the representative DNA 
sample from blood (matching with FFPE sample no. 7); lane M, 100-bp ladder. 
M  B   1    2   3   4   5   6    7   8   M   9  10 11 12  13 14 15  16  M
100 bp
400 bp
300 bp
200 bp
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Genotype concordance
To analyze the reliability and accuracy of the genotype calling of FFPE-derived DNA 
samples by the DMET Plus array, the genotype concordance was calculated for the 
paired blood- or saliva- derived DNA and FFPE DNA genotyping results (Table 2). Of the 
1931 markers, 1061 showed no genetic variation in our population, which is expected 
based on the known minor allele frequencies and previous DMET studies [14-16]. The 
genotype concordance was calculated with all markers and with only the 870 polymorphic 
markers. The overall agreement with all markers included was 97.4% with a κ-statistic 
of 0.915. The κ-statistic calculated per marker ranged from -0.143 (TPMT rs1800460, 
CYP21A2 rs72552757) to 1 (e.g. CHST3 rs4148943, FMO3 rs1736557), excluding the 
markers that were monomorphic, for which the κ-statistic was also defined as 1. Analysis 
of the concordance of the 35 genes with a very important pharmacogene (VIP) status 
(PharmGKB, http://www,pharmgkb.org, last accessed July 14, 2014) covered by the 
DMET Plus array revealed an overall concordance of 96.6% with a κ-statistic of 0.884, 
ranging from a mean of 68.8% for the markers in SLC19A1 to 100% in e.g. COMT and 
GSTT1 (Supplementary Table S1). 
 In addition, the genotype concordance was calculated per blood- or saliva-derived 
DNA and FFPE DNA pair to assess the potential link between concordance and FFPE 
DNA call rate (Table 1). Genotype concordance excluding no calls and PRAs exceeded 
99.2% with the exception of the two pairs of which the FFPE DNA samples showed 
call rates <98%. Of seven markers miscalled in more than five blood- or saliva-derived 
DNA and FFPE DNA pairs, the cluster plots of four markers were considered unreliable. 
Without these markers, the genotype concordance would be somewhat higher; therefore, 
the reported concordances are slightly underestimated. Furthermore, the copy number 
calling was 100% concordant across the samples.
 The genotypes obtained from the blood- or saliva-derived DNA samples were validated 
for a subset of 13 SNPs, which were included on the Illumina BeadArray platform as well. 
Genotypes of these SNPs (rs1045642, rs1128503, rs2231142, rs1801243, rs1005695, 
rs3787728, rs1056892, rs776746, rs1138272, rs1800566, rs689453, rs10898, rs4407290) 
were 100% concordant with the genotypes obtained using the DMET Plus array.
Discordant results
Of the 799 mismatches among the 30,896 SNP-sample pair comparisons, most (81.1%) 
involved no calls or PRA calls (i.e. switches from a genotype call in blood or saliva 
DNA to no call or PRA call in FFPE tissue DNA or vice versa and PRA call to no call or 
vice versa). The remaining genotype to genotype switches were dominated by switches 
of homozygous calls to heterozygous calls (11.01%), followed by heterozygous to 
homozygous switches (6.26%), homozygous to homozygous (either common or variant 
allele) switches (1.13%) and allele deletions or gains (0.5%).
Of all markers, those with the 20% lowest κ values (all κ<0.4) were considered poorly 
concordant, excluding markers with a low κ but agreement >80% because for those 
markers the κ value is strongly affected by a low minor allele frequency. Visual inspection 
revealed that only 9 of the 42 markers had a call rate <80% across all 32 samples, 
indicating that the marker concordance is not highly linked to the general marker call 
rate. For 28 of 42 markers, the cluster plots were considered unreliable (Supplementary 
Table S2).
 In addition, we assessed whether the discordant results were randomly distributed by 
testing for associations of the 1,931 markers with DNA source (blood or saliva versus 
FFPE tissue), including genotype calls only. Thirteen markers had significant differences 
in minor allele frequencies between blood or saliva and FFPE DNA samples (P<0.05). Of 
these markers, nine were excluded because of unreliable cluster plots (CYP11B1 rs4534, 
CYP2A6 rs4079369, CYP2A7 rs4079366, CYP2B6 rs36079186, CYP2C9 rs1057910, 
CYP2D6 rs5030865, CYP2D6 rs61736512, SULT1A2 rs1059491, TBXAS1 rs8192868), 
leaving four SNPs (FMO6 rs2272797, CYP2B6 rs2279343, CYP39A1 rs2277119, and 
GSTM1 rs74837985), with only the latter (agreement 56.3%, κ=0.420) not overlapping 
with the top 42 markers with lowest concordance.
 The 42 markers with the most discordant results also included markers located in 
genes for which the DMET Plus array performs automated haplotype calling and 
phenotype translation. Because calling and translation automatically involve all markers 
per gene, discordances in haplotype and subsequent phenotype results were observed 
in one or more sample pairs for CYP2B6, CYP2C9, CYP2D6, SLCOB1, TBXAS1, TPMT, 
and UGT1A1.
Overall agreement and κ-statistic were calculated with all 1931 markers and with only the 870 
polymorphic markers: markers for which the minor allele was detected in at least one sample.
Table 2. Overall genotyping concordance.
 Marker Agreement, % κ-statistic
All markers 97.4 0.915
Polymorphic markers 94.3 0.812
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Discussion
There is a large worldwide collection of stored FFPE tissue, which can be highly valuable 
for providing germline DNA for genetic studies. In this study, we examined the utility of 
DNA isolated from normal FFPE tissue blocks for analysis on the DMET Plus array, which 
is a useful tool for pharmacogenetic studies. We found that the DNA isolated from FFPE 
tissue performs well on the array and yields high quality data. Not only did we observe 
high call rates, but importantly we also noted that the concordance with genotyping 
results of matching blood or saliva samples was high. These data indicate that DNA from 
FFPE tissue can be reliably used as a template for the DMET Plus array.
 Factors related to tissue fixation and storage affect the quality of the DNA that can be 
recovered from the specimen. SNP arrays based on MIP technology may be an optimal 
solution for working with such degraded DNA because of the small target DNA sequences 
(minimum target length of 40 bp). A previous study by Wang et al. using an Affymetrix 
MIP array with a panel of 50,000 markers found a mean call rate of 98.9% for DNA from 
normal FFPE tissue samples, similar to the mean call rate observed in the current study 
[10]. Hence, our data for the DMET Plus array extend these observations, suggesting 
that even though the DMET procedure includes a multiplex PCR step, this MIP-based 
array is indeed suitable for the successful genotyping of DNA of reduced quality. The 
combination of the multiplex PCR step to preamplify regions in genes with pseudogenes 
and close homologs and the MIP technology has previously been found to yield reliable 
genotypes in these challenging genes (e.g. CYP2D6, UGT1A1) in a validation study of 
the DMET Plus array using blood samples [17]. Our study reveals that reliable genotypes 
can be obtained for markers of these challenging genes even in the context of FFPE-
derived DNA.
 In our study, we obtained reliable genotyping results from FFPE-derived DNA samples 
on the DMET Plus array, even for the samples with degraded DNA based on the size 
range PCR. Apparently, the primers for the DMET Plus array have been designed in 
such a way that they are very close to the SNP of interest. On the basis of our test panel, 
the prescreening of samples based on the size range PCR does not appear to be an 
essential control to determine whether samples are of sufficient quality for further DMET 
analysis. We observed two samples with relatively low call rates, which corresponded to 
a mild decrease in concordance compared to samples with call rates >98%. Therefore, 
we suggest evaluating the call rates of FFPE-derived DNA samples before further genetic 
analyses because we found that low call rates are related to a lower concordance 
between blood or saliva and FFPE tissue. Therefore, the call rates are related to the 
reliability of the data. In case call rates of a small number of samples are too low for 
reliable association analysis, these samples could still be included in a meta-analysis 
together with the DMET genotyped samples by specifically genotyping the significantly 
associated markers using other genotyping methods (e.g. TaqMan allelic discrimination 
assays) [11].
 The analysis of the discordant results indicated that certain SNPs were nonrandom 
miscalled. Despite the limited number of samples in the association analysis, it cannot be 
excluded that genotyping results for the four SNPs that were found to be associated with 
DNA source are systematically unreliable in FFPE DNA samples. Therefore, we suggest 
caution when including these SNPs in association analyses with the (clinical) outcome 
of interest. The same applies to the reported list of markers with poor concordance, 
since these markers are prone to discrepancies as well. However, as indicated, some 
of these markers show unreliable genotype clustering, which might not only explain the 
sensitivity to sample quality variation but might indicate the necessity to exclude them 
from further analyses regardless of the sample type used as DNA source. The VIP genes 
covered by the DMET Plus array had good overall concordance; for those VIP genes that 
had the least agreement, this could be explained by the presence of markers reported 
here to have poor concordance. As subsequently expected, the discordant markers were 
found to impact the haplotype calling and phenotype translation as performed by the 
DMET console software, which is explained by absent or incorrect genotype calls in the 
FFPE DNA samples. Hence, exclusion of the reported discordant markers is warranted 
in manual translation, but could still affect reliability because of the missing genotypes. 
However, of the alleles that had poor concordance and that are used in clinical guidelines, 
most are expected to have a low impact because of their low allele frequency.
 We used only normal FFPE tissue sections to isolate germline DNA, avoiding different 
genotyping results in DNA from FFPE tissue compared with blood or saliva because of 
somatic alterations in tumor DNA. The issue of using tumor DNA in pharmacogenetic 
studies has been subject of debate, and although germline DNA is preferred, recent 
studies have provided evidence that DNA from FFPE tumor tissue blocks may be used 
as a valid alternative in pharmacogenetic cancer studies when no other samples are 
available [18,19]. However, in the current study, discordant results that may be produced 
when using FFPE tumor tissue on the DMET Plus array are not explored.
 Our published optimized protocol for DNA isolation from FFPE tissue for TaqMan SNP 
assays could also optimally be used in the current study for the generation of samples 
suitable for downstream use on the DMET Plus array [11]. For single SNP assays, not only 
nondecalcified but also decalcified FFPE tissue has been shown to be useful. However, 
for the DMET analysis 1.02 µg of DNA (60 ng/µL) is needed per sample, which is often 
difficult to obtain from tissues decalcified with formic acid because this treatment makes 
the recovery of DNA even more challenging. Therefore, no samples from decalcified 
FFPE tissue could be included in the current study. A similar limitation of the use of 
FFPE-derived DNA for the DMET array may also arise in case researchers are restricted 
to tissues with low abundance of nuclei, from which the necessary quantity of DNA cannot 
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be recovered. Whole genome amplification based on multiple displacement amplification 
has been reported to provide accurate results on the DMET Plus array and may provide 
a solution, although caution should be taken when using input material of low quality [20]. 
To date, there are no reports on the reliability of whole genome amplification of FFPE-
derived DNA for use on the DMET Plus array.
 In conclusion, we found that high-quality genotype data can be obtained using the 
DMET Plus array on DNA isolated from FFPE samples. This provides opportunities for 
pharmacogenetic studies to make use of archival tissue resources to analyze individuals 
not otherwise available for sampling. 
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Gene No. of markers on DMET (no. of polymorphic markers) Agreement % κ
ABCB1 40 (17) 94.8 0.907
ADH1A 7 (3) 100 1.00
ADH1B 6 (3) 100 1.00
ADH1C 5 (1) 100 1.00
AHR 6 (3) 97.9 0.807
ALDH1A1 7 (3) 99.1 0.857
COMT 5 (2) 100 1.00
CYP1A2 17 (4) 100 1.00
CYP2A6 19 (9) 92.4 0.736
CYP2B6 23 (14) 87.8 0.580
CYP2C19 18 (4) 99.3 0.935
CYP2C8 11 (4) 98.9 0.818
CYP2C9 18 (6) 95.8 0.796
CYP2D6 30 (16) 82.7 0.725
CYP2E1 10 (7) 98.1 0.830
CYP2J2 9 (2) 99.3 0.889
CYP3A4 25 (6) 99.3 0.946
CYP3A5 14 (3) 98.7 0.852
DPYD 18 (6) 97.9 0.899
G6PD 6 (6) 99.0 0.979
GSTP1 5 (2) 100 1.00
GSTT1 6 (6) 100 1.00
HMGCR 6 (2) 100 1.00
NAT2 16 (6) 98.0 0.912
NQO1 7 (4) 100 1.00
NR1I2 15 (3) 100 1.00
PTGIS 12 (1) 100 1.00
SLC19A1 5 (3) 68.8 0.526
SLC22A1 25 (11) 95.0 0.769
SLCO1B1 18 (8) 95.8 0.860
SULT2A1 6 (1) 100 1.00
TPMT 8 (6) 87.5 0.382
TYMS 5 (0) 100 1.00
UGT1A1 32 (10) 96.9 0.949
VKORC1 10 (10) 99.4 0.987
Supplementary Table S1. Genotyping concordance between blood or saliva-derived DNA and FFPE-
derived DNA for the VIP genes on the DMET Plus array.
Overall agreement and κ-statistic calculated per VIP gene with all markers per gene included.
Supplementary data
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        No. of mismatches        
SNP Gene(Allele) Agreement % κ Incl. No Calls. 
PRAs
Excl. No 
Calls. PRAs
Hom > 
Het
Het > 
Hom
Hom > 
Hom
Reliability 
automated 
clustering
rs2235022 ABCB1 31.3 0.000 11 0 0 0 0 -
rs28381915 ABCB1 0.0 0.000 16 0 0 0 0 -
rs4148807 ABCB4 56.3 0.000 7 1 0 1 0 -
rs17216324 ABCC2 6.25 0.000 15 0 0 0 0 -
rs1473870 CHST2 68.8 0.000 5 0 0 0 0 -
rs1064349 CHST8 75.0 0.366 4 0 0 0 0 +
rs28693844 CHST9 75.0 0.000 4 1 1 0 0 -
rs4534 CYP11B1 12.5 0.034 11 7 0 7 0 -
rs72549371 CYP1B1 18.8 0.000 13 0 0 0 0 +
rs72552758 CYP21A2 12.5 0.000 14 0 0 0 0 -
rs72552757 CYP21A2 75.0 -0.143 4 0 0 0 0 +
rs4079369 CYP2A6 18.8 0.000 13 10 10 0 0 -
rs4079366 CYP2A7 56.3 0.000 7 5 5 0 0 +
rs36079186 CYP2B6(*27) 50.0 0.000 8 4 4 0 0 -
rs3745274 CYP2B6(*6) 56.3 0.345 7 6 6 0 0 -
rs2279343 CYP2B6(*4) 37.5 0.111 10 9 9 0 0 +
rs1057910 CYP2C9(*3) 50.0 0.323 8 3 0 3 0 -
rs35742686 CYP2D6(*3) 75.0 0.200 4 4 0 0 0 -
rs5030865 CYP2D6(*14 or *8) 0.0 0.000 16 14 14 0 0 -
rs61736512 CYP2D6(*29) 6.25 0.000 15 1 0 1 0 -
rs72549352 CYP2D6(*21) 0.0 0.000 16 0 0 0 0 -
rs72549357 CYP2D6(*15) 0.0 0.000 16 0 0 0 0 -
rs2277119 CYP39A1 43.8 0.258 9 3 3 0 0 +
rs7541966 FMO4 50.0 0.185 8 0 0 0 0 -
rs2272797 FMO6 25.0 0.111 12 4 4 0 0 +
rs72552786 PON1 25.0 0.035 12 0 0 0 0 +
rs11150606 PRSS53 62.5 0.000 6 0 0 0 0 +
rs1051269 SLC19A1 50.0 0.000 8 0 0 0 0 -
rs12659 SLC19A1 31.3 0.174 11 1 0 1 0 -
Supplementary Table S2. DMET Plus markers showing lowest concordance. 
        No. of mismatches        
SNP Gene(Allele) Agreement % κ Incl. No Calls. 
PRAs
Excl. No 
Calls. PRAs
Hom > 
Het
Het > 
Hom
Hom > 
Hom
Reliability 
automated 
clustering
rs35546288 SLC22A1 75.0 0.000 4 0 0 0 0 +
rs55918055 SLC22A1 75.0 0.000 4 0 0 0 0 +
rs11231820 SLC22A11 68.8 0.000 5 0 0 0 0 +
rs4149015 SLCO1B1(*17) 56.3 0.152 7 3 3 0 0 -
rs72547527 SULT1A1(*4) 18.8 0.000 13 0 0 0 0 -
rs1059491 SULT1A2 43.8 0.200 9 5 0 5 0 -
rs35044222 SULT1A3 0.0 -0.004 16 0 0 0 0 -
rs35044222 SULT1A3 12.5 0.018 14 0 0 0 0 -
rs8192868 TBXAS1(*7) 12.5 0.000 14 11 0 11 0 -
rs1800460 TPMT(*3B) 62.5 -0.143 6 1 0 1 0 +
rs4124874 UGT1A1(*60) 62.5 0.356 6 3 1 1 1 +
rs104894539 VKORC1 18.8 -0.056 13 0 0 0 0 -
rs13336384 VKORC1 75.0 -0.103 4 0 0 0 0 -
All markers with κ<0.4 and agreement <80%. Of the reported variants, Clinical Pharmacogenetics 
Implementation Consortium guidelines are available for the low frequency alleles TPMT*3B and the 
CYP2D6 alleles, as well as for CYP2C9*3 and SLCO1B1*17.
PRA: possible rare allele; Hom: homozygous call; Het: heterozygous call.
Supplementary Table S2. Continued
Adverse Drug 
Reactions
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Abstract
Objective: Irreversible hearing loss is a frequent side effect of the chemotherapeutic 
agent cisplatin and shows great interpatient variability. The variant rs1872328 in the 
ACYP2 gene was recently identified as a risk factor for the development of cisplatin-
induced ototoxicity in children with brain tumors. We aimed to replicate this finding in 
patients with osteosarcoma. 
 Methods: An independent cohort of 156 patients was genotyped for the rs1872328 
variant and evaluated for the presence of cisplatin-induced ototoxicity. 
 Results: A significant association was observed between carriership of the A allele and 
cisplatin-induced ototoxicity after end of treatment (P=0.027). 
 Conclusion: This is the first study replicating the association of ACYP2 variant 
rs1872328 with cisplatin-induced ototoxicity in patients with osteosarcoma who did not 
receive potentially ototoxic cranial irradiation. Hence, the ACYP2 variant should be 
considered a predictive pharmacogenetic marker for hearing loss, which may be used to 
guide therapies for patients treated with cisplatin.
Introduction
Cisplatin is an important component of the chemotherapeutic treatment of a variety 
of solid tumors, including osteosarcoma. A frequent side effect of cisplatin treatment 
is ototoxicity, which occurs in 40-60% of the patients [1]. Ototoxicity is characterized 
by irreversible, bilateral, sensorineural hearing loss, which is a serious complication 
especially in the pediatric population because of its impact on speech and language 
development. Moreover, ototoxicity is one of the main reasons for dose reductions or 
even termination of cisplatin treatment.
 Several clinical risk factors for cisplatin-induced ototoxicity have been described, 
including young age at diagnosis (<5), cumulative cisplatin dose, use of additional ototoxic 
drugs such as carboplatin, and cranial irradiation [2-5]. However, these parameters are 
not sufficient to reliably predict cisplatin-induced ototoxicity. To tailor the treatment for 
the individual patient and avoid ototoxicity, there is a need to predict this side effect at 
the start of treatment. This would enable treatment optimization to minimize the risk to 
susceptible groups, for example, by using protective agents.
 A number of publications indicate that genetic factors might be useful predictors; 
however, most of these studies involve a limited number of patients without replication 
in a second population [6-9]. In addition, the most promising candidate gene study 
published to date, suggesting that genetic variants in the COMT and TPMT genes are 
linked to cisplatin-induced ototoxicity, could not be consistently replicated by ourselves 
and others [10-13].
 Recently, Xu et al. identified a genetic variant (rs1872328) in ACYP2 that predisposes 
to precipitous hearing loss in children with newly diagnosed embryonal brain tumors, 
using a genome-wide association approach including 238 patients and a replication 
cohort of 68 patients [14]. The ACYP2 gene encodes an acylphosphatase expressed in 
muscle and the cochlea and may be involved in hair cell development [14,15]. The variant 
in this gene might also be related to cisplatin-induced hearing loss in other diseases 
where slightly different treatment regimens are used. 
 Patients with osteosarcoma are treated with a high cumulative dose of cisplatin 
and, in addition, no (cranial) irradiation is applied, which is a confounding factor for 
cisplatin-induced hearing loss. Hence, this patient population represents an excellent 
group to study the generalizability of the ACYP2 gene variant to predict cisplatin-induced 
ototoxicity. Therefore, we investigated an independent osteosarcoma patient cohort and 
carried out a meta-analysis including the previously published study [14], resulting in a 
total population of 462 patients. 
ACYP2 associated with cisplatin ototoxicity
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Methods
Patient cohort
A cohort of Dutch patients with primary, high-grade osteosarcoma treated with cisplatin 
was retrospectively recruited at the Radboud university medical center (Nijmegen), the 
University Medical Center of Groningen (Groningen), Leiden University Medical Center 
(Leiden) and the Emma Children’s Hospital/Academic Medical Center (Amsterdam), 
The Netherlands. Eligibility also included a maximum age at diagnosis of 45 years, that 
is, only patients from the first osteosarcoma incidence peak were included. From the 
total cohort, those patients were included for whom audiometric data were available 
from at least end of treatment (N=156, all treated between 1984 and 2013). All patients 
were of self-reported European descent, except for one patient originating from Brazil. 
Data on co-administration of other potentially ototoxic drugs such as carboplatin and 
vincristine were recorded [16,17]. None of the patients was treated with cranial irradiation 
or otoprotective agents. Germline DNA was extracted from blood or saliva using the 
QIAamp DNA Blood Midi kit (Qiagen, Venlo, The Netherlands) and collection kits from 
DNA Genotek (Kanata, Ontaria, Canada), respectively. From patients who had died 
before inclusion, germline DNA was isolated from paraffin-embedded tissue samples as 
described previously [18]. The study protocol was approved by the Institutional review 
board of the Radboud university medical center (Commissie Mensgebonden Onderzoek 
Regio Arnhem Nijmegen) and approval for inclusion of patients in other institutes was 
obtained from institutional ethics committees; all patients and/or parents provided written 
informed consent.
Ototoxicity
All audiometric assessments were age appropriate and performed by conventional or 
play audiometry under standardized conditions as part of routine clinical monitoring for 
cisplatin-related hearing loss.
 Grading was based on the ear with the worst hearing as assessed by the latest 
measurement available, that is, the exact follow-up time is different for each patient. 
Hearing loss was retrospectively classified according to the Chang grading system [19]. 
In case of known hearing loss at baseline, ototoxicity was graded based on the change 
in the Chang score as suggested by Chang and colleagues.
Genotyping
Genotyping for the ACYP2 variant rs1872328 was performed using a Kaspar-On-Demand 
(KOD) assay (LGC Genomics, Hoddesdon, UK). Genotyping was carried out in a volume 
of 5 µL containing 10 ng of genomic DNA, 2.5 µL of KASP 5000 V4.0 High ROX (2x; 
LGC Genomics) and 0.0625 µL of the KASPar assay (40x), and 1.44 µL of MilliQ grade 
water. Each amplification for the KASPar assay was performed by an initial denaturation 
at 94°C for 15 min, followed by 10 cycles of denaturation at 94°C for 20 s and annealing/
extension at 61°C for 60 s including a drop of 0.6°C for each cycle. This was followed 
by 26 cycles of denaturation at 94°C for 10 s and annealing/extension at 55°C for 60 
s, followed by 4 cycles of denaturation at 94°C for 20 s and annealing/extension at 
57°C for 60 s. This was carried out on a 7500FAST Real-Time PCR System (Applied 
Biosystems, Nieuwerkerk aan den Ijssel, The Netherlands). Genotypes were scored 
using the algorithm and software (v2.0.6) supplied by Applied Biosystems. Nontemplate 
controls (3%) as well as duplicates between plates were included as quality controls for 
genotyping.
Statistical analysis
Statistical differences in demographic data between patients who had hearing loss (Chang 
score > 0) and patients without hearing loss (Chang score = 0) were assessed using the 
Fisher exact, Pearson X2-test, or Mann-Whitney U-test as appropriate. Reported P-values 
are two-sided and are considered statistically significant if less than 0.05. To assess the 
effect of the genotype on susceptibility to ototoxicity, the data were dichotomized into score 
0 versus scores 1-4. The association between genotype (A carriers vs. homozygous G) 
and ototoxicity was assessed using a 2x2 table (Fisher exact). All analyses were carried 
out using SPSS package, version 20 (SPSS Inc., Chicago, Illinois, USA). Meta-analysis of 
the data of ototoxicity after the end of treatment (Chang score >0), kindly provided by the 
authors of the original genome-wide association study (GWAS) publication, was carried 
out using a fixed-effects model in Review Manager, 5.3 (The Cochrane Collaboration, 
Oxford, UK). On the basis of the discovery cohort of Xu and colleagues with a minor 
allele frequency of 0.046 and trait prevalence of 0.61, a sample size of 156 patients was 
calculated to have 80% power to detect significant associations (P<0.05) with odds ratios 
of 7.5 and higher. For this, the genetic power calculator Quanto (University of Southern 
California, California, USA) was used [20].
Results
Of a total of 156 patients included, 77 (49.4%) presented with ototoxicity (Chang score 
>0) and 36 (23.1%) patients showed clinically relevant ototoxicity (Chang score ≥2a). 
No significant differences in patient characteristics were observed between patients 
with hearing loss (Chang score >0) and those without hearing loss (score=0) (Table 1). 
Therefore, no clinical covariates are included in the genetic analysis. A total of 12 patients 
were additionally treated with other ototoxic chemotherapeutic agents (Table 1). In 22 
(14.1%) patients, the (cumulative) cisplatin dose was reduced because of ototoxicity 
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Chang score = 0 Chang score > 0
  (N=79) (N=77) P-value
Age at diagnosisa (years)
Median (range) 14.2 (5.1-42.4) 14.0 (3.4-43.9) 0.94
Sex (male)
[n (%)] 39 (49.4) 45 (58.4) 0.26
Cumulative cisplatin dose (mg/m2)
Median (range) 480 (200-600) 480 (140-720) 0.07†
Concomitant drugs [n (%)]
Vincristine 2 (2.5) 7 (9.1) 0.10
Carboplatin 2 (2.5) 1 (1.3) 1.0
Follow-up (days)
Median (range) 686 (17-7,061) 830 (1-9,344) 0.91
Table 1. Patient demographics of the osteosarcoma cohort.
Table 2. Genotype frequencies on the basis of ototoxicity severity.
aPatients ≥18 years (N=33): Chang score = 0 N=12; Chang score > 0 N=21.
†No trend is observed on exclusion of patients with dose reductions because of ototoxicity: P=0.429; 
therefore, cisplatin dose is not included as a covariate.
GG genotype [n (%)] A carriers [n (%)]
Chang score = 0 (N=79) 79 (100) 0 (0)
Chang score = 1 (N=40) 37 (92.5) 3 (7.5)
Chang score ≥ 2a (N=36) 34 (94.4) 2 (5.6)
Figure 1. Forest plot of meta-analysis of ACYP2 variant rs1872328. Meta-analysis of published cohorts 
and present study using a fixed-effects model. For effect size estimation, Review Manager has corrected 
for the zero-cell counts by adding a fixed value of 0.5 to all cells of the study results table. 
95% CI, 95% confidence interval of odds ratio; M-H, Mantel-Haenszel method.
and in 24 (15.4%) patients because of other cisplatin-induced toxicities. The cumulative 
cisplatin dose did not significantly differ between patients with and without hearing loss 
(Table 1), also after exclusion of patients with dose reductions because of ototoxicity 
(P=0.429). Baseline audiograms were missing for 54 (34.6%) patients, of whom all except 
one were aged less than or equal to 40 years and therefore not expected to present with 
age-related baseline hearing loss. From 102 patients with baseline measurements, six 
patients showed hearing loss before the start of cisplatin treatment. The distribution of 
the follow-up times until the last ototoxicity evaluation was comparable between patients 
with and without ototoxicity (Supplementary Figure S1). In patients without ototoxicity, 
similar to patients with ototoxicity, the majority of patients evaluated within 2 years after 
the end of cisplatin therapy survived more than 2 years after treatment, that is, detection 
of potential ototoxicity in this group was not limited by early follow-up because of short 
survival [21]. 
Five patients were heterozygous AG for the ACYP2 variant rs1872328; all other patients 
were homozygous GG. Patients carrying the A allele represented 6.5% of the patients 
with cisplatin-induced ototoxicity and 3.2% of all patients, corresponding to a minor 
allele frequency of 0.016. No deviation from Hardy-Weinberg equilibrium was observed 
(P=0.78). A statistically significant association was observed between carriership of the 
A allele and cisplatin-induced ototoxicity: 72 (47.7%) patients with the homozygous GG 
genotype developed cisplatin-induced ototoxicity, whereas ototoxicity was observed in 
all five patients with the AG genotype (P=0.027). After grouping of patients on the basis 
of the severity of ototoxicity, the association was still significant (P=0.033), although we 
did not observe an increase in the number of patients carrying the A allele with increased 
ototoxicity severity (Table 2). 
 A meta-analysis of the present study and the cohorts of the previously published 
study [14], including a total of 462 patients, also indicated a significant association of the 
ACYP2 variant with ototoxicity, with a pooled odds ratio of 14.7 (P=0.001) (Figure 1).
Discussion
Permanent hearing loss induced by cisplatin is a serious complication in the treatment 
of patients with solid tumors including osteosarcoma. In a recent GWAS in children with 
embryonal brain tumors, a variant in the ACYP2 gene was identified as a pharmacogenetic 
marker for cisplatin-induced ototoxicity [14]. In the present study, we have replicated the 
previously reported association of the ACYP2 variant with cisplatin-induced ototoxicity in 
an independent cohort of patients with osteosarcoma and additionally validated the effect 
in a meta-analysis with the cohorts from the previously published study. Not only does this 
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confirm the association but it also indicates that the association applies to different types 
of cancer with different treatment protocols, for example, in patients who did not receive 
cranial irradiation. Although there are still patients without the variant who presumably 
develop ototoxicity, the results have implications for the proportion of patients who carry 
this variant. The ACYP2 gene may be a useful marker to screen patients at diagnosis to 
enable informed clinical decisions on cisplatin treatment for patients carrying the A allele, 
including dose adjustments, alternative strategies, or use of protective agents.
 Replication of pharmacogenetic findings is an essential step towards clinical 
implementation, but is frequently not achieved [22], which could be attributed to false-
positive findings in the original study or because of reasons such as differences in 
treatment protocols and phenotyping, biased or heterogeneous patient populations, and 
insufficient sample sizes. Especially in pediatric solid tumor studies, patient numbers can 
be limited because of low disease prevalence. In the present study, we could replicate 
the finding by Xu and colleagues, even though our osteosarcoma cohort was treated with 
a higher cumulative cisplatin dose compared with the brain tumor study. 
 Furthermore, we have studied the largest osteosarcoma patient cohort for 
pharmacogenetic research to date, which, despite its relatively small size, is sufficiently 
large to detect significant genetic associations with large effect sizes. The fact that we 
did detect the ACYP2 association in this relatively small cohort indicates that the ACYP2 
variant is a genetic predictor with a large effect size.
 Although multiple variants in the ACYP2 gene were potentially associated in the study 
by Xu et al. [14], we focused on the only genome-wide significant top hit, which was also 
the only variant reported to be replicated within the original study. Now that our study 
confirms the involvement of the ACYP2 gene in cisplatin-induced ototoxicity, it would be 
interesting to investigate other variants within the same region. Sequencing the gene 
would be an elegant approach, which was not performed in the present study due to 
limited sample size. This could indicate additional common variants but also rare variants 
with potentially larger effect sizes. This would enhance the predictability of ototoxicity on 
the basis of genetic variation in ACYP2; however, this requires large scale studies.
 In the GWAS by Xu and colleagues, the ACYP2 variant was detected in a regression 
model treating ototoxicity as a time-dependent variable. In the present study, only the 
ototoxicity after ending treatment was analyzed as we could not carry out the time-to-
event analysis because of the retrospective data collection. However, the association 
could still be confirmed when considering ototoxicity at end of treatment as the phenotype, 
which is still highly relevant for clinical practice as it shows that ACYP2 can be used to 
identify patients at risk of developing cisplatin-induced ototoxicity irrespective of time.
 In previous studies, younger age, higher cumulative cisplatin doses, concomitant 
ototoxic drugs, and cranial irradiation have been reported as risk factors for cisplatin-
induced ototoxicity. However, in our osteosarcoma cohort, patients did not receive 
cranial irradiation and none of the other clinical variables was found to be a predictor 
of ototoxicity. In clinical practice, in specific patients groups in which these factors 
are present and may vary significantly, the predictive value of these factors might be 
considered in combination with the genetic risk.
 In our patient cohort as well as the two cohorts from the original study, the ACYP2 
variant allele was only present in patients presenting with ototoxicity. The resulting 
zero-cell count in the groups without ototoxicity carrying the A allele affected the meta-
analysis of all three studies because of difficulties in estimating odds ratios. However, 
the specialized meta-analysis software Review Manager corrected for this and thereby 
computational problems could be avoided. 
 In conclusion, we have shown that the previously reported association of an ACYP2 
variant with cisplatin-induced hearing loss in pediatric brain tumor patients could 
be replicated in an independent cohort of patients with osteosarcoma who did not 
receive potentially ototoxic cranial irradiation. Further characterization of the molecular 
mechanism underlying this association and prospective studies to validate the clinical 
utility are needed. The ACYP2 variant should be considered a predictor of cisplatin-
induced hearing loss in patients with osteosarcoma or other solid tumors and may 
contribute toward personalized treatment.
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Figure S1. Distribution of follow-up time from end of cisplatin therapy to last ototoxicity evaluation. 
Histogram plots are given for both patients without ototoxicity (A) and with ototoxicity (B), and include 
indication of survival after end of cisplatin therapy based on a cut-off of 2 years. 
Supplementary data
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4Abstract 
Hepatotoxicity is a frequent and serious side effect in high-dose methotrexate (HD-MTX) 
treatment. We explored the contribution of 1,936 genetic variants in 231 drug absorption, 
distribution, metabolism and elimination (ADME) genes to interindividual variation in MTX 
plasma levels and hepatotoxicity in HD-MTX-treated osteosarcoma patients.
 An osteosarcoma cohort (N=114) was genotyped using the DMET array. Genetic 
variants significantly associated with MTX plasma levels at 48 hours after MTX infusion 
were assessed for association with MTX-induced hepatotoxicity (CTCAE grade 3/4) by 
logistic regression.  
 Upon analysis of 1,250 HD-MTX courses, 32 genetic variants were associated with 
48 hour MTX plasma levels. Of these variants, GSMT3 rs1799735 was associated with 
frequent hepatotoxicity (protective effect: OR 0.13 [0.02-0.73], P=0.021).
 This is the first study in osteosarcoma patients in which a broad range of ADME genes 
was explored in relation to MTX plasma levels and HD-MTX-induced hepatotoxicity, 
indicating a role for a genetic variant in GSTM3. 
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Introduction
Methotrexate (MTX) is an antifolate agent widely used in the treatment of cancer. In 
high doses (≥1 g/m²), it is an important component of many chemotherapeutic protocols 
in pediatric malignancies, including osteosarcoma [1]. This bone tumor constitutes 
approximately 3% of all childhood cancers and is, despite its rarity, the most common 
primary malignancy of the bone in children and adolescents [2,3]. Together with cisplatin 
and doxorubicin, high-dose methotrexate (HD-MTX) forms the backbone of the treatment 
of osteosarcoma.  
 Hepatotoxicity is one of the most frequent side effects of HD-MTX and is a reason for 
delayed continuation of the chemotherapeutic treatment, which is inversely related to 
survival [4]. As exposure to high MTX levels is often related to hepatotoxicity, therapeutic 
monitoring of MTX plasma levels is employed during the first days after infusion, together 
with appropriate leucovorin rescue and intensive hydration to minimize HD-MTX-induced 
side effects. However, hepatotoxicity is still commonly observed and prolonged leucovorin 
rescue in case of high MTX plasma levels might reduce the desired antitumor effect of HD-
MTX, leading to decreased treatment efficacy. A better understanding of the factors that 
contribute to interindividual pharmacokinetic and pharmacodynamic variability may allow 
upfront identification of patients at risk of toxic MTX exposure and thereby prevention of 
HD-MTX-induced hepatotoxicity, which may involve dose reduction although this is not 
without the concern of reducing efficacy as well.
 Clinical risk factors do not sufficiently explain interindividual differences in response to 
HD-MTX, both regarding MTX-levels and toxicities, and several studies have suggested 
a role of genetic variation [5]. A genome-wide association study (GWAS) in patients 
with acute lymphoblastic leukemia (ALL), has identified variants in the organic anion 
transporter gene SLCO1B1 to be associated with MTX clearance [6,7]. For osteosarcoma 
patients, treated with even higher cumulative doses than ALL patients, a few small 
pharmacogenetic studies have been reported. A Slovenian study assessing tumor DNA of 
44 osteosarcoma patients, has also suggested a role of SLCO1B1 in MTX clearance, and 
of ABCC2 in hepatotoxicity [8]. Contradicting results have been reported on associations 
of an MTHFR genetic variant and hepatotoxicity [9-11]. All these studies were based 
on a small number of candidate genes, and more comprehensive investigation of 
drug metabolism and transporter genes is warranted. Therefore, in the present study 
the Affymetrix Drug Metabolizing Enzymes and Transporters (DMET) Plus genotyping 
platform was used, which covers 1,936 variants in 231 genes involved in drug absorption, 
distribution, metabolism and elimination (ADME) [12]. The aim of this exploratory study 
was to identify genetic variants associated with 48 hour MTX plasma levels and HD-MTX-
induced hepatotoxicity in HD-MTX-treated patients with osteosarcoma.
Pharmacogenetics of methotrexate hepatotoxicity
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Materials and methods 
Patients and treatment
A cohort of 114 patients with primary, high-grade osteosarcoma was retrospectively 
collected at the Radboud university medical center (Nijmegen), the University Medical 
Center of Groningen (Groningen), Leiden University Medical Center (Leiden) and the 
Emma Children’s Hospital/Academic Medical Center (Amsterdam), The Netherlands. All 
patients were treated between 2003 and 2014 and clinical data were retrospectively 
collected from medical records. Inclusion criteria for this study were: age ≤45 years, self-
reported Caucasian ethnicity, and treatment according to the EURAMOS-1 protocol (also 
including patients diagnosed outside of the trial recruitment period, but treated according 
to the same scheme) [13]. The study protocol was approved by the institutional review 
board of the Radboud university medical center (Commissie Mensgebonden Onderzoek 
Regio Arnhem Nijmegen), and approval for inclusion of patients in other institutes was 
obtained from institutional ethics committees. All patients and/or parents provided written 
informed consent.
 All patients received a maximum of 12 courses HD-MTX (12 g/m² per course) as a 
4 hour infusion. Leucovorin rescue (for all patients 15 mg/m² according to protocol) was 
started 24-28 hours after start of MTX infusion and was prolonged if MTX plasma levels 
were >0.40 µmol/L at 48 hours. In addition to MTX, all patients received doxorubicin 
(maximum cumulative dose: 450 mg/m²) and cisplatin (maximum cumulative dose: 
480 mg/m²), with or without additional ifosfamide/etoposide or interferon-α.  
Methotrexate plasma levels and toxicity
MTX plasma levels were routinely monitored by a fluorescence polarization immunoassay 
(TDx/FLx, Abott Diagnostics, The Hague, The Netherlands), or enzyme immunoassay 
(for 3 of 114 patients) (Syva Emit TDM assay, Siemens Healthcare, Hoofddorp, The 
Netherlands), without differences in reference values. The MTX plasma levels measured 
48 hours after initiation of each MTX infusion were used for the analysis. 
 Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) plasma 
levels were determined five to nine days after each MTX infusion. Grading of ALAT or 
ASAT toxicity was performed according to the Common Terminology Criteria for Adverse 
Events (CTCAE) v4.03 of the National Cancer Institute. 
DNA isolation
Germline DNA was isolated from blood (N=54) using the QIAamp DNA Blood Midi kit 
(Qiagen, Venlo, The Netherlands), or from saliva (N=53) using the Oragene saliva 
collection kit (DNA Genotek, Kanata, Ontario, Canada) according to the manufacturer’s 
protocols. From patients who had passed away before inclusion (N=7), DNA was isolated 
from normal formalin-fixed, paraffin-embedded (FFPE) tissue as described previously 
[14,15].
Genotyping 
The DNA samples were genotyped for 1,936 genetic variants using the Affymetrix DMET 
Plus array according to the manufacturer’s instructions (Affymetrix UK Ltd, High Wycombe, 
UK). All samples were normalized to 60 ng/μL based on NanoDrop measurements 
(NanoDrop 2000; Thermo Scientific, Breda, The Netherlands). Genotypes were calculated 
with DMET console software 1.3 using the Dynamic Genotype Boundaries version 
2 algorithm. Variants were excluded from analysis if the genotype cluster plots were 
considered unreliable, being plots with genotype calling showing merged clusters without 
distinct cluster boundaries. Additional stringent evaluation of the genotype clustering in 
combination with expected genotype frequencies was carried out for variants significant 
in association analysis. Samples and variants were excluded if call rates <0.9, minor 
allele frequency (MAF) <0.01 and/or deviating from Hardy-Weinberg equilibrium (HWE) 
(P-value <0.0001). Five copy number variants, 46 X-chromosomal variants, and one tri-
allelic variant present on the array were not included in the analyses. Quality control was 
based on genotypes of a larger previously described osteosarcoma cohort (N=316), from 
which the 114 patients included in the present study were selected [16].
Statistical analysis
High MTX levels are linked with the development of MTX-induced toxicities [17]. 
Therefore, first the association analyses between genetic variants and MTX plasma 
levels were performed to select genetic variants that were likely to be the most relevant 
for the development of hepatotoxicity, based on the assumed mechanism. 
 Associations of genotypes with 48h MTX plasma levels were assessed by Generalized 
Estimating Equation (GEE) analysis using STATA (Stata Corporation, College Station, 
TX, USA). This is an extended linear regression model that takes into account the 
correlation between the repeated measurements within individual patients. Analyses 
were performed both treating the MTX levels as a continuous variable (ln transformed 
plasma levels) and as a dichotomized categorical variable (based on cut-off at 0.40 µmol/L 
at 48h). Regression coefficients/odds ratios (OR) and corresponding 95% confidence 
intervals were generated for each variant under the assumption of an additive model. For 
analysis, genotypes were coded as 0 [homozygous for major allele], 1 [heterozygous] or 
2 [homozygous for minor allele]. 
 Genetic variants associated with 48h MTX plasma levels were selected for association 
analysis with hepatotoxicity as outcome, using logistic regression analysis in PLINK 
(v1.07)[18]. Hepatotoxicity was defined as elevated ALAT and/or ASAT levels after one 
or more MTX infusions, on the basis of dichotomized CTCAE grades: grade 0, 1 versus 
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2 [no toxicity] and grade 3 and 4 [toxicity]. Patients without recorded ALAT levels for any 
of the MTX infusions were excluded. In addition, patients with frequent hepatotoxicity 
(elevated ALAT and/or ASAT levels after ≥4 of the MTX infusions) were compared to 
patients without hepatotoxicity. Both analyses were also performed with the patients 
showing grade 2 ALAT and/or ASAT levels included as cases instead of controls, as this 
is clinically considered as moderate hepatotoxicity, though without consequences for 
further treatment. Potential associations of age at diagnosis or sex with 48h MTX plasma 
levels were tested using linear and logistic GEE models (with MTX levels as continuous 
or dichotomized variable). Associations of sex, age at diagnosis or cumulative MTX dose 
with hepatotoxicity were assessed by the Pearson chi-square or Mann-Whitney U test as 
appropriate using IBM SPSS Statistics version 20 (SPSS Inc., Chicago, Ill, USA). 
 Additionally, association of the MTX plasma levels with 5-year progression-free 
survival (PFS) (time interval from diagnosis to progression or recurrence) was assessed 
by Cox proportional hazards models in SPSS, with either all repeated measurements as 
independent variable or the mean plasma level for each patient. All reported P-values are 
two-sided and were considered statistically significant if <0.05. No correction for multiple 
testing was performed because of the exploratory character of the study. 
Results 
 
Patient characteristics
The 114 included patients with osteosarcoma received a total of 1,368 MTX courses, with 
a median of 12 courses per patient (range 2-12) (Table 1). Reasons for cancelled courses 
included poor physical conditions of the patient (whether or not caused by the treatment), 
a patient’s own request, or death. MTX plasma level data at 48 hours was available for 
1,250 courses, for which in 264 (21.1%) courses MTX plasma levels >0.40 µmol/L were 
observed. Neither sex nor age at diagnosis was significantly associated with the MTX 
plasma levels (both as continuous or dichotomized parameter). The 48h MTX plasma 
levels were not associated with 5-year PFS (P=0.926 both with the mean plasma level or 
all measured plasma levels as covariable). Eighty-three patients developed hepatotoxicity 
(grade 3 or 4 of ALAT and/or ASAT) after at least one HD-MTX course; of all patients with 
elevated ASAT levels, also elevated ALAT levels were observed after one of the courses. 
Hepatotoxicity (grade 3 or 4 of ALAT and/or ASAT) was observed in 259 of 800 courses 
for which data were available. In 74 of the 259 courses (28.6%) with hepatotoxicity, MTX 
plasma levels >0.40 µmol/L were observed. Age at diagnosis was significantly associated 
with hepatotoxicity (P= 0.022) and frequent hepatotoxicity (P= 0.000052) (Table 2).
Table 1. Characteristics of 114 osteosarcoma patients.
aWith inclusion of patients showing grade 2 ALAT and/or ASAT toxicity as cases n=99 (94.3%).
Table 2. Analysis of association between clinical factors and hepatotoxicity.
Genotyping
All 114 DNA samples were successfully genotyped using the DMET Plus array. Of the 
1,884 variants included in the quality control, 90 variants were excluded based on 
unreliable clusterplots, 28 variants were excluded because of genotype call rates of <0.9 
and 1,056 variants because of a MAF of <0.01. All variants left were in HWE. After quality 
control, 710 variants were left for analysis.
Genetic variants associated with MTX plasma levels and 
hepatotoxicity
In univariable GEE association analyses, 69 variants were significantly associated with 
48 hour MTX plasma levels (continuous variable) and 58 variants with high 48 hour 
MTX plasma levels (dichotomized based on cut-off at 0.40 µmol/L), of which 35 variants 
were significantly associated in both analyses. Three of the 35 variants, ALDH3A2 
Age at diagnosis in years, median (range) 14.9 (5.6-43.0)
Male gender (n; %) 64 (56.1%)
Number of MTX courses, median (range) 12 (2-12)
MTX cumulative dose, g/m², median (range) 144 (24-144)
MTX plasma level at 48 hours, µmol/L, median (range) 0.25 (0.05-82.3)
MTX plasma level >0.40 µmol/L at 48 hours,  n courses (%) 264 (21.1%)
Elevated ALAT, n/total (%) 83/105 (79.0%)
Elevated ASAT, n/total (%) 40/103 (38.8%)
Hepatotoxicity (elevated ALAT and/or ASAT), n (%) 83a (79.0%)
Frequent hepatotoxicity, n/total (%) 28/50 (26.7%)
No hepatotoxicity Hepatotoxicity
N=22 N=83 P
Male gender, n (%) 12 (54.5%) 45 (54.2%) 0.978
Age at diagnosis, median (range) 16.4 (8.91-43.0) 14.3 (5.61-42.4) 0.022
MTX cumulative dose, median (range) 144 (48-144) 144 (48-144) 0.313
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rs72547554, PPARD rs7771474, and POR rs2286824, were excluded after additional 
stringent evaluation of the genotype clustering, leading to 32 remaining variants in 22 
genes (Table 3). Only those variants that were not only associated with the plasma levels 
as a continuous variable but also associated with clinically high MTX levels (in logistic 
regression analysis with levels ≥0.40 µmol/L), were selected for association analysis with 
hepatotoxicity, to increase the chance of testing the most relevant variants in relation to 
hepatotoxicity. 
 In multivariable analysis including age at diagnosis, none of the variants showed 
a significant association with hepatotoxicity, but when only patients with frequent 
hepatotoxicity (i.e. after ≥4 of 12 courses) were included, the Glutathione S-Transferase 
Mu 3 (GSTM3) variant rs1799735 (delAGG) (GSTM3*B) was significantly associated 
with frequent hepatotoxicity, with an odds ratio of 0.126 (95% CI 0.022-0.728, P=0.021) 
indicating a protective effect of the deletion. Association analyses also including patients 
with moderate hepatotoxicity (grade 2) as cases did not reveal significant associations 
with (frequent) hepatotoxicity.
Table 3. Genetic variants significantly associated with 48 hour MTX plasma levels.
MTX levels dichotomized MTX levels continuous
Gene SNP Chr Minor allele MAF OR 95% CI P Coefficient 95% CI P
EPHX1 rs2234698 1 C 0.018 11.01 4.33 27.96 <0.001 0.88 0.42 1.34 <0.001
CYP2B6 rs34223104 19 C 0.018 3.81 2.03 7.14 <0.001 0.48 0.27 0.68 <0.001
CYP2C8 rs1058930 10 G 0.057 3.08 1.76 5.39 <0.001 0.42 0.11 0.73 0.009
CYP1B1 rs1056837 2 T 0.420 0.57 0.41 0.81 0.002 -0.15 -0.25 -0.04 0.006
SLC6A6 rs2341970 3 T 0.252 0.48 0.30 0.76 0.002 -0.19 -0.31 -0.07 0.002
CYP1B1 rs1056836 2 G 0.415 0.58 0.41 0.83 0.002 -0.14 -0.25 -0.04 0.008
ATP7B rs1801244 13 C 0.461 1.78 1.20 2.64 0.004 0.15 0.03 0.26 0.012
ATP7B rs1801243 13 G 0.469 1.76 1.19 2.60 0.005 0.15 0.03 0.26 0.012
CHST1 rs2028985 11 A 0.070 0.39 0.20 0.76 0.006 -0.29 -0.46 -0.12 0.001
ATP7B rs1051332 13 A 0.452 1.74 1.17 2.59 0.006 0.14 0.02 0.25 0.024
CDA rs602946 1 A 0.013 0.10 0.02 0.53 0.007 -0.27 -0.49 -0.05 0.019
CYP2A6 rs1137115 19 A 0.327 1.64 1.14 2.36 0.008 0.13 0.01 0.26 0.039
UGT1A8 rs17863762 2 A 0.009 0.71 0.54 0.92 0.011 -0.21 -0.35 -0.07 0.003
ADH1B rs6413413 4 T 0.009 0.15 0.04 0.66 0.012 -0.70 -1.01 -0.39 0.000
CYP2F1 rs57670668 19 C 0.004 0.71 0.55 0.93 0.012 0.18 0.10 0.26 0.000
UGT1A6 rs17863783 2 T 0.035 0.33 0.13 0.83 0.019 -0.27 -0.51 -0.03 0.025
ATP7B rs7334118 13 G 0.022 0.24 0.08 0.80 0.020 -0.13 -0.25 0.00 0.043
MTX levels dichotomized MTX levels continuous
Gene SNP Chr Minor allele MAF OR 95% CI P Coefficient 95% CI P
PPARD rs6457813 6 T 0.026 0.33 0.13 0.84 0.020 -0.28 -0.48 -0.08 0.007
UGT8 rs4148254 4 T 0.022 0.25 0.08 0.80 0.020 -0.43 -0.70 -0.16 0.002
SULT1E1 rs3736599 4 A 0.083 0.50 0.28 0.91 0.023 -0.26 -0.40 -0.12 0.000
CHST10 rs3748930 2 C 0.469 0.67 0.46 0.97 0.032 -0.13 -0.23 -0.02 0.018
SLC22A1 rs34130495 6 A 0.018 0.15 0.02 0.90 0.038 -0.18 -0.32 -0.04 0.012
ABCC4 rs1189466 13 T 0.053 0.37 0.14 0.95 0.038 -0.21 -0.41 0.00 0.046
ABCC4 rs1678339 13 A 0.053 0.37 0.14 0.95 0.038 -0.21 -0.41 0.00 0.046
CYP2A13 rs1709082 19 G 0.070 1.90 1.03 3.52 0.040 0.27 0.02 0.52 0.033
CHST10 rs1530031 2 A 0.467 0.68 0.46 0.98 0.041 -0.12 -0.23 -0.02 0.020
GSTM3 rs1799735 1 delAGG 0.118 0.54 0.29 0.98 0.044 -0.17 -0.31 -0.03 0.015
SLC22A14 rs149738 3 G 0.456 1.42 1.01 2.01 0.045 0.11 0.01 0.21 0.029
SLC22A14 rs171248 3 C 0.456 1.42 1.01 2.01 0.045 0.11 0.01 0.21 0.029
SLC22A14 rs183574 3 C 0.456 1.42 1.01 2.01 0.045 0.11 0.01 0.21 0.029
EPHX1 rs1051741 1 T 0.110 0.52 0.27 0.99 0.045 -0.16 -0.32 0.00 0.045
CHST10 rs3828193 2 C 0.478 0.72 0.51 1.00 0.048 -0.11 -0.20 -0.02 0.020
MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confidence interval.
Effect sizes and 95% CI are reported for the minor allele, an OR<1 and coefficient<0 indicate a 
protective effect of the minor allele.
Variants within CHST10, SLC22A14, CYP1B1, ATP7B (except for rs7334118), and ABCC4 are in linkage 
disequilibrium with r2>0.8.
Discussion
The candidate gene approach studies of MTX in osteosarcoma patients have previously 
shown encouraging results; however, most studies focused on functional genetic 
variants involved in MTX metabolism. In this study, we have looked beyond these 
candidate genes to explore associations of genes that are not known to be related to 
MTX pharmacokinetics. By analyzing a large number of variants in genes coding for drug 
metabolizing enzymes and transporters, genetic variants in 22 genes were found to be 
associated with high MTX plasma levels, of which the intronic GSTM3 variant rs1799735 
showed an association with frequent hepatotoxicity. 
Table 3 continued.
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 The present study is the first to report an association of GSTM3 with MTX plasma 
levels and hepatotoxicity. The gene encodes a glutathione S-transferase which is known 
for detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, 
environmental toxins and products of oxidative stress, by conjugation with glutathione 
[19,20]. Another member of the GST family, Glutathione S-Transferase Mu 1 (GSTM1), 
has previously been implicated in drug-induced hepatotoxicity by a study demonstrating 
resistance to acetaminophen-induced hepatotoxicity in GSTM1-null mice [21]. For 
understanding of the relation between GSTM3 and HD-MTX-induced hepatotoxicity, 
further research into the role of GSTM3 in the MTX processing pathway is required. The 
AGG deletion is reported to generate a recognition site for the transcription factor YY1, 
which is known to regulate gene expression from intragenic sites [22]. YY1 has been 
suggested to act as a GSTM3 inducer [23]. We therefore speculate that carrying the 
rs1799735 variant leads to increased glutathione levels, which by scavenging of radicals 
is protective for hepatotoxicity. 
 Of the genes found in association with MTX plasma levels, only ATP-Binding Cassette 
Sub-Family C (CFTR/MRP) Member 4 (ABCC4) is an established player in the metabolic 
route of MTX. ABCC4 is involved in the transport of various organic anions and exogenous 
agents (including MTX) out of the cell. Both ABCC2 and ABCC4 are involved in MTX 
clearance via the kidneys [24]. In addition, ABCC4 is expressed in hepatocytes, where it 
transports most of the MTX from the liver cells into the blood circulation. In line with our 
results, studies in ALL patients have already indicated associations of ABCC4 variants with 
MTX plasma levels, though both SNPs identified in the present study were not investigated 
in the previous studies [25,26]. The previously reported ABCC4 variants in association with 
MTX levels (rs9516519 and rs868853) were not investigated in the present study and are 
not in LD with any of the ABCC4 variants covered by the DMET array. 
 The top three of associated genes with 48 hour MTX plasma levels were all 
biotransformation enzymes: Microsomal Epoxide Hydrolase 1 (EPHX1), cytochrome 
P450 2B6 (CYP2B6) and cytochrome P450 2C8 (CYP2C8). EPHX1 is involved in the 
activation and detoxification of epoxides and is expressed in most tissues [27]. Two 
different variants in this gene, with opposing effects and not in LD, were significantly 
associated with the MTX plasma levels. The identified variants are not in LD with two 
other well-studied EPHX1 variants (rs1051740 and rs2235922) with a functional effect 
on the enzyme activity, of which the rs1051740 variant was present on the DMET array 
but was not related to MTX plasma levels in our study [28]. CYP2B6 and CYP2C8 both 
encode hepatic enzymes involved in the metabolism for a wide variety of drugs including 
antineoplastic agents, but both have not been previously linked to MTX [29,30].
 The DMET Plus array includes the functional polymorphism in SLCO1B1 (rs4149056), 
which is shown to be significantly associated with MTX clearance in a GWAS in patients 
with ALL and in a small osteosarcoma study [6-8]. Analyzing this variant in relation to 
MTX plasma levels in our osteosarcoma patients did not reveal this association (P=0.51). 
This difference in studies might be explained by the different cohorts used (patients 
with ALL and osteosarcoma, respectively). Furthermore, different endpoints are used, 
being MTX clearance, mucositis and infection in the GWAS, and MTX plasma levels and 
increased liver enzymes in the present study. The osteosarcoma study by Goricar et al. 
has analyzed tumor DNA, which may also introduce differences in study results.
 The definition of hepatotoxicity in this study was based on the CTCAE criteria, which 
is commonly used in oncology. By considering only grade 3 and 4 as toxicity, we have 
chosen a more strict definition of hepatotoxicity (>5x upper limit of normal) than the 
Drug-Induced Liver Injury (DILI) guidelines (>3x upper limit of normal), to improve clinical 
relevance of the results in the context of treatment for which high levels of toxicity are 
accepted to improve patient survival [31]. 
 The power of this exploratory study was limited because of the relatively low patient 
number for an association study. Therefore, we have performed a two-step approach, 
by first selecting genetic variants predictive of MTX plasma levels as an intermediary 
endpoint, and subsequently analyzing only significantly associated genetic variants for 
their relation with hepatotoxicity. Inclusion of genetic variants in the association analysis 
with hepatotoxicity was further restricted by selecting only genetic variants that were 
associated with both continuous and dichotomized data for MTX levels. Furthermore, 
to make optimal use of the available data, we have included all available repeated 
measurements of the MTX plasma levels in the analyses. 
 In conclusion, we have identified variants in genes associated with elevated MTX plasma 
levels and hepatotoxicity, which are largely unknown to play a role in these processes. 
Pinpointing the role of these genes in MTX processing will be important to understand 
interpatient variability in the MTX response and will subsequently lead to optimized MTX 
treatment for osteosarcoma patients. Replication and functional validation of the results 
in larger cohorts is needed, in order to make these results clinically applicable.
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Abstract
Despite multi-agent chemotherapeutic treatment, osteosarcoma patients relapse 
frequently while survival rates have not improved significantly over the past decades. 
We have previously identified five genetic markers that could distinguish patients with 
good outcome from those with poor outcome, which can potentially be used for risk 
stratification at diagnosis. Here, we assessed the reproducibility of these findings in three 
independent osteosarcoma cohorts.
 A Dutch cohort (N=191), Spanish cohort (N=95), and English cohort (N=51) of patients 
with high-grade osteosarcoma were genotyped for FasL rs763110, MSH2 rs4638843, 
CASP3 rs2720376, ABCC5 rs939338, and CYP3A4 rs4646437. Differences in 5-year 
progression-free survival (PFS) based on the combined effect of these variants, calculated 
as a genetic risk score, were assessed by the log rank test. Associations of the individual 
variants with 5-year PFS were determined in a meta-analysis using Cox proportional 
hazards models, with a total of 446 patients (including data from our previous study, 
N=177), excluding the English cohort for which significantly superior PFS was observed.
 Genotyping of all variants except for rs4646437 was successful in all cohorts. In the 
Dutch cohort, the genetic risk score showed marginally significant differences in 5-year 
PFS (P=0.062). Although not significant in the other cohorts separately, in the combined 
Dutch and Spanish cohort PFS significantly differed based on the number of risk alleles 
(P=0.040). Meta-analysis (of the Dutch and Spanish cohorts) also including the two 
original cohorts, confirmed significant associations of the individual variants in MSH2 
and ABCC5 with 5-year PFS. 
 We confirmed the association of our previously reported genetic risk score with PFS 
in two independent cohorts of patients with osteosarcoma. This provides a rationale 
for prospective testing in larger cohorts and may eventually contribute to prediction of 
treatment outcome and optimization of therapy for patients with osteosarcoma.
Introduction 
Osteosarcoma is a bone tumor that mainly affects children, adolescents, and young 
adults. Although rare, it is the most common primary bone sarcoma. The backbone 
of chemotherapy for osteosarcoma consists of cisplatin and doxorubicin and in some 
protocols methotrexate (MTX). The introduction of this multi-agent chemotherapy in 
the 1970s, in addition to surgery, has given a major improvement in survival rates from 
below 20% to 60-65% [1]. However, osteosarcoma patients still relapse frequently and no 
further improvements in survival have been achieved since [2]. The absence of reliable 
predictive factors for risk stratification has resulted in uniform treatment schedules for 
osteosarcoma patients [3]. Hence, there is a need to optimize current treatment strategies 
and to develop novel approaches for the treatment of osteosarcoma patients. 
 Insights into the pharmacogenetics of treatment response in patients with osteosarcoma 
may contribute to upfront risk stratification. In an exploratory study focusing on genes of 
the metabolic pathways of cisplatin and doxorubicin [4], we previously identified significant 
associations of five genetic markers (Fas Ligand (FasL) rs763110, MutS homologue 2 
(MSH2) rs4638843, Caspase 3 (CASP3) rs2720376, ATP-binding cassette sub-family 
C member 5 (ABCC5) rs939338, and Cytochrome P450 3A4 (CYP3A4) rs4646437) 
with treatment outcome. Combining these variants in a genetic risk score (GRS) was 
predictive of 5-year progression-free survival (PFS) in two combined cohorts of a total 
of 172 patients with osteosarcoma [4]. Further analysis using independent cohorts is 
important to confirm the associations and assess the robustness of these findings. 
Therefore, in the present study we assessed the reproducibility of the association of the 
GRS with 5-year PFS in three independent osteosarcoma cohorts from The Netherlands, 
Spain, and England.
Materials and methods
Patient cohorts
A Dutch cohort of 191 patients with osteosarcoma, unrelated to the cohorts investigated 
in the original study, was retrospectively recruited at the Radboud university medical 
center (Nijmegen), the University Medical Center of Groningen (Groningen), Leiden 
University Medical Center (Leiden) and the Emma Children’s Hospital/Academic Medical 
Center (Amsterdam), The Netherlands. All patients were treated between 1982 and 
2013 and the clinical data was retrospectively collected from medical records. Eligibility 
required the following criteria: diagnosis of primary high-grade osteosarcoma with or 
without metastatic disease, age ≤45 years, treatment with cisplatin and doxorubicin-
based chemotherapy, and self-reported Caucasian ethnicity. Patients were treated as 
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described previously [4]. The study was approved by the Institutional review board of 
the Radboud university medical center (Commissie Mensgebonden Onderzoek Regio 
Arnhem Nijmegen), and approval for inclusion of patients in other Dutch institutes was 
obtained from institutional ethics committees. All patients and/or parents provided written 
informed consent.
 For confirmation of the positive findings in the Dutch cohort, two cohorts of high-
grade osteosarcoma patients treated with cisplatin and doxorubicin-based chemotherapy 
from Spain (N=95, diagnosed between 1985 and 2014) and England (N=51, diagnosed 
between 2002 and 2008) were used. Information on treatment has been reported 
previously [5,6]. The same inclusion criteria as used in the Dutch cohort were applied, 
with the exception of ethnicity. The study was approved by the local ethics committees 
and written informed consent was obtained from parents and/or patients. 
Genotyping methods
From the Dutch cohort, germline DNA was isolated from blood or saliva of patients alive, 
or from normal formalin-fixed paraffin-embedded (FFPE) tissue of deceased patients, as 
described previously [4]. Details on DNA isolation of the Spanish and English cohorts has 
been previously reported [5,6]. Genotyping of the cohorts was performed for five single 
nucleotide polymorphisms (SNPs) selected on the basis of their significant association 
with 5-year PFS in the meta-analysis of the two cohorts from the original study, and 
improved significance compared to the discovery cohort alone [4]. KASP-On-Demand 
(KOD) assays were used for FASL rs763110 and CYP3A4 rs4646437; KASP-By-Design 
(KBD) assays were used for MSH2 rs4638843 and CASP3 rs2720376, all according to 
the manufacturer’s protocol (LGC Genomics, Hoddesdon, UK). The ABCC5 rs939338 
variant was determined using a TaqMan allelic discrimination assay (C___8759155_20) 
according to the manufacturer’s protocol (ThermoFisher, Nieuwegein, The Netherlands). 
Fluorescence was measured with a 7500FAST Real-Time PCR System (ThermoFisher). 
Genotypes were scored using the algorithm and software (v2.0.6) supplied by 
ThermoFisher. Blanks (3%) as well as duplicates between plates were included as quality 
controls for genotyping.
Statistical analysis
Statistical differences in demographic data between cohorts were assessed by the Fisher 
exact or Pearson chi-square test (in case of dichotomized variables), Kruskal-Wallis or 
Mann-Whitney U test (in case of linear variables), or Cox proportional hazards analysis 
(in case of PFS). Five-year PFS was defined as the interval between diagnosis and 
disease progression/recurrence (=event) and was estimated using the Kaplan–Meier 
method. Patients without disease recurrence at the date of last follow-up were censored 
at that date. Associations of clinical variables with 5-year PFS were assessed by Cox 
regression analysis. The data analysis plan involved two stages: (1) assessment of 
the reproducibility of the association of GRS with 5-year PFS in a cohort that is very 
similar to the original study cohorts (i.e. the Dutch cohort), and (2) further testing of the 
reproducibility of the GRS association in two individual cohorts from abroad (Spanish 
and English cohorts). The GRS was constructed as in our previous study; differences in 
5-year PFS between the patients, grouped by their number of risk alleles, were assessed 
using the log rank test. Only patients successfully genotyped for all variants included 
in the GRS analysis were included in the GRS calculation. The predictive accuracy of 
the GRS was quantified using Harrell’s C-statistic (which can range from 0.5, indicating 
prediction equal to chance, to 1.0, indicating perfect prediction, with 0.8 and higher 
considered strong predictive accuracy), based on Cox regression analysis of the 5-year 
PFS with the GRS as covariable. Association analysis of the individual SNPs with 5-year 
PFS was carried out by multivariable Cox regression analysis including MTX treatment 
as covariable, in line with the original study. The results of the separate cohorts were 
meta-analyzed using a fixed effects or random effects (in case of large heterogeneity: 
I2>50) model in METAL [7]. All other analyses were performed using SPSS package 
version 22 (SPSS Inc., Chicago, Ill, USA). Reported P-values are two-sided and are 
considered statistically significant if <0.05.
Results
Patient population
The study was carried out in two stages, with as a first stage assessment of reproducibility 
of previous findings using a Dutch cohort which is similar to the original study cohorts, 
and subsequent confirmation in two different patient populations using a Spanish cohort 
and an English cohort. The patient demographics for each cohort are provided in Table 
1. From the Dutch cohort, 17 of 191 patients were excluded based on failed genotyping 
for all variants, which might be explained by potentially poor quality FFPE tissue-derived 
DNA of 15 of these patients. Several differences were observed in baseline characteristics 
between the cohorts. The patients in the Spanish cohort were significantly younger than 
the patients in the Dutch and English cohorts (P<0.001). In addition, more patients were 
treated with high-dose MTX in the Spanish and English cohorts than in the Dutch cohort 
(P<0.001). Moreover, in the English cohort a poor histologic response was much less 
frequently observed than in the Dutch and Spanish cohorts (P<0.001), and 5-year PFS 
was ~20% higher compared to the other cohorts (P=0.037). This might be a reflection of 
differences in inclusion of patients, because in the English cohort the patients who had 
died (and most likely with poor PFS) before the time of retrospective patient recruitment 
were not included. For this reason, this is considered a bias in the selected population. 
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Only in the Dutch cohort, the poor histologic responders showed significantly inferior 
5-year PFS (P=0.001); in all cohorts the presence of primary metastases was significantly 
associated with inferior 5-year PFS. Therefore, the GRS analysis also included 
stratification for metastases at diagnosis, in line with the original study. However, as the 
histologic response and PFS are both a reflection of the response to chemotherapy, the 
histologic response was not adjusted for as this would unintentionally remove variation 
resulting in overcorrection. Although not significantly associated with PFS in the different 
cohorts, treatment with MTX was included as covariable in the single SNP analysis, in 
line with the original study.
Table 1. Demographic data of patients included in the cohorts.
Dutch cohort 
(N=174)
Spanish cohortc 
(N=95)
English cohortd 
(N=51)
P-value overalle
Age at diagnosis, median (range) 16.4 (3.4-45.8) 14.0 (1.9-34.6) 17.0 (10.0-39.0) <0.001§
Male gender, n (%) 100 (57.5%) 53 (55.8%) 29 (56.9%) 0.965
Axial tumor, n (%) 7 (4.0%) 2 (2.1%) 3 (5.9%) 0.499
Primary metastases, n (%) 24 (13.8%) 17 (17.9%) 6 (11.8%) 0.538
MTX treatmenta, n (%) 90 (51.7%) 84 (95.5%) 51 (100%) <0.001¶
Poor histologic responseb, n (%) 84 (53.8%) 49 (55.1%) 11 (22.0%) <0.001#
5-year PFS 55.5% 58.2% 74.5%      0.037+
MTX, methotrexate; PFS, progression-free survival.
a Data available on MTX treatment for each cohort: Dutch N=174, Spanish N=88, English N=51.
b Data available on histologic response for each cohort: Dutch N=156, Spanish N=89, English N=50.
c Ethnicities Spanish cohort: Caucasian N=90 (94.7%), Latin American N=4 (4.2%), Romani N=1 (1.1%).
d  Ethnicities English cohort: Caucasian N=36 (70.6%), Afro-Caribbean N=8 (15.7%), Indian/Asian N=7 
(13.3%).
e P-values are given for overall tests including all three cohorts. Significant associations (P<0.05): 
§English vs. Spanish and Spanish vs. Dutch cohort P<0.001; ¶Dutch vs. English or Spanish cohort 
P<0.001; #English vs. Dutch or Spanish cohort P<0.001;+English vs. Dutch cohort P= 0.013.
Genotyping
Of the five variants included in the genotyping, the CYP3A4 rs4646437 variant was not 
reliably determined, most likely because of close homology of the primer binding region 
with another genomic region. The average call rate of the four remaining variants was 
0.95. FASL rs763110 and ABCC5 rs939338 were not in Hardy Weinberg equilibrium 
(P=0.032 for both variants), in both cases driven by the Dutch cohort. However, this was 
not considered a reason for exclusion because this might be attributed to the number of 
drop-outs and/or to analysis in a diseased population [8]. Moreover, samples genotyped 
in duplicate showed positive results, and genotypes of 92 additional healthy control 
samples were in HWE for both variants. No major differences in minor allele frequencies 
were observed between the cohorts (Supplementary Table S1).
Genetic risk score analysis
The genetic risk score was calculated using the four variants rs763110, rs4638843, 
rs2720376, and rs939338 (for comparison with the PFS based on the GRS of the four 
variants in the original study, see Supplementary Figure S1). After grouping of patients 
by the number of risk alleles similar to the original study (0-1, 2-3, 4-5, more than 5 risk 
alleles), we observed marginally significant differences in 5-year PFS in the Dutch cohort 
(P=0.062) (Figure 1A). Whereas patients carrying no or one risk allele showed a 5-year 
PFS of 72.4%, and 66.2% with 2-3 risk alleles, the patients carrying 4-5 risk alleles showed 
significantly inferior PFS of 42.1% (P=0.042 compared to 0-1 allele; P=0.023 compared 
to 2-3 alleles). Subsequent analysis in the Spanish validation cohort did not reveal overall 
significant differences in PFS, although the survival curves of the different GRS groups also 
showed divergence between the groups with the smallest and largest number of risk alleles 
(Figure 1B). Though not significant, the opposite effect of the GRS on PFS was observed 
in the English cohort (Supplementary Figure S2), which is also reflected in the combined 
analysis of all three cohorts, in which the PFS differences between the GRS groups were 
absent (Figure 1C). The observation of the opposite effect in the English cohort may be 
attributed to the aforementioned differences in PFS and selection of patients that were 
included between the English cohort and the Dutch and Spanish cohort. After analysis of 
the data, we recognized that the English cohort was not appropriate for validation because 
of the combination of its selected population and small sample size; however, we chose to 
follow the original analysis plan for GRS analysis in the individual cohorts. Furthermore, 
because of the discrepancy in PFS, we carried out a combined analysis including only the 
Dutch and Spanish cohort, which revealed significant differences in 5-year PFS between 
the GRS groups (P=0.040) (Figure 1D). Patients carrying no or one risk allele showed a 
5-year PFS of 78.5%, compared to a 5-year PFS of 59.5% in patients carrying 2-3 risk 
alleles, 48.0% with 4–5 alleles, and 57.1% with more than 5 risk alleles (P=0.040). After 
stratification based on metastatic status at diagnosis, the patients without metastases at 
diagnosis showed a significant difference in PFS based on the GRS (P=0.021) with a 
pattern similar to the complete group of patients (Supplementary Figure S3). In the patients 
with metastases at diagnosis, the GRS was not significantly associated with PFS, although 
markedly inferior PFS was observed in each GRS group compared to the complete group 
of patients, with the exception of the one patient carrying more than 5 risk alleles. 
 The predictive accuracy of the GRS was determined combining the two cohorts from 
the original study with the Dutch and Spanish cohorts of the present study, resulting in a 
C-statistic of 0.61. 
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Figure 1. Five-year PFS based on GRS. A: Dutch cohort (N=150), patients with 0-1 risk allele showed 
a 5-year PFS of 72.4% compared to 66.2% with 2–3 risk alleles, 42.1% with 4–5 alleles, and 75.0% with 
>5 risk alleles. B: Spanish cohort (N=90), patients with 0-1 risk allele showed a 5-year PFS of 90.0% 
compared to 50.3% with 2–3 risk alleles, 60.0% with 4–5 alleles, and 33.3% with >5 risk alleles. C: 
Dutch, Spanish, and English cohort combined (N=283), patients with 0-1 risk allele showed a 5-year 
PFS of 71.1% compared to 61.3% with 2–3 risk alleles, 55.9% with 4–5 alleles, and 62.5% with >5 risk 
alleles. D: Dutch and Spanish cohort combined (N=240), patients with 0-1 risk allele showed a 5-year 
PFS of 78.5% compared to 59.5% with 2–3 risk alleles, 48.0% with 4–5 alleles, and 57.1% with >5 risk 
alleles; with significant difference between the 0-1 and 4-5 risk alleles groups (P=0.006).
A B
D
Meta-analysis associations of individual SNPs
Association analysis of the individual SNPs with 5-year PFS was carried out using 
multivariable Cox regression analysis, including MTX treatment as covariable, similar 
to the original study. In meta-analysis of the results of the two cohorts of the original 
study (N=177) and the Dutch and Spanish cohorts, resulting in a total population of 446 
patients, significant associations with 5-year PFS were observed for MSH2 rs4638843 
(HR 1.63 [1.21-2.20]; P=0.002) and ABCC5 rs939338 (HR 1.36 [1.10-1.68]; P=0.005), 
with the same direction of effect in all cohorts and increased significance compared to the 
results of the meta-analysis of the original cohorts only (Table 2).
Table 2. Associations with 5-year PFS in combined meta-analysis of original study cohorts and Dutch 
and Spanish cohorts.
SNP Gene Allele HR 95% CI P-value I2
rs4638843 MSH2 C 1.63 1.21-2.20 0.002 5
rs939338 ABCC5 G 1.36 1.10-1.68 0.005 0
rs763110 FASL T 1.23 0.99-1.53 0.065 20.7
rs2720376 CASP3 G 0.80 0.55-1.15 0.22 59.4
95% CI, 95% confidence interval; HR, hazard ratio.
HR and 95% CI are reported for the minor allele, a HR<1 indicates a protective effect of the minor allele 
and risk of an event for the major allele.
Meta-analysis for each of the variants was performed with a fixed effects or random effects model 
depending on the corresponding heterogeneity (I2) as indicated in the table.
Discussion
One of the current challenges on the road to optimization of treatment of osteosarcoma 
is to identify those patients at risk of a poor outcome. We have previously explored 
several pharmacogenetic markers associated with treatment response in a cohort of 
osteosarcoma patients [4]. In the present study, we have confirmed the association of a 
genetic risk score based on these markers (FasL rs763110, MSH2 rs4638843, CASP3 
rs2720376, ABCC5 rs939338) with 5-year PFS in independent cohorts. In addition, we 
have confirmed the association of two of the individual SNPs with PFS in a meta-analysis 
also including the two cohorts of the original study. 
 In the current study, we were unable to analyze the role of the rs4646437 marker located 
in the CYP3A4 gene, which encodes the CYP3A4 enzyme involved in the metabolism 
of both cisplatin and doxorubicin. However, even with exclusion of this marker from the 
genetic risk score calculation, the association of the score with 5-year PFS remained 
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significant in the patient group of the original study, and the same trend was observed in 
the Dutch cohort, reaching significance in the combined Dutch and Spanish cohort.
 Both the GRS analysis and meta-analysis were carried out with the (combined) 
Dutch and Spanish cohorts, excluding the English cohort. The reason for this was the 
discrepancy of the PFS in the English cohort compared to the other cohorts, probably 
due to its relatively small sample size (51 eligible patients, 43 patients successfully 
genotyped for the four genetic variants and therefore included in the GRS analysis) and 
approach in patient inclusion, i.e. patients who had died before the start of retrospective 
patient recruitment were not included in the study. Unfortunately, this may indicate a 
selection of patients with relatively favorable PFS. Probably, inclusion of the deceased 
patients, which would result in more events, would be needed to obtain conclusive results 
for this cohort. In addition to the expected overrepresentation of survivors, the English 
cohort is also different from the other cohorts with respect to time frame of inclusion, MTX 
treatment, and ethnic background. However, increases in survival due to for example 
improved supportive care in the more recent time frame are often relatively subtle, and 
the proportion of patients with overall MTX treatment is similar to the Spanish cohort. 
Furthermore, (overall) survival differences between ethnicities, if any, are directed 
towards inferior survival in black patients [9]. Therefore, these factors are not expected 
to have substantial impact on the 5-year PFS such as observed in the English cohort.
 Most pharmacogenetic studies in osteosarcoma to date have not been reproduced 
or have shown inconsistent findings. In general, demonstration of reproducibility of 
pharmacogenetic findings is of vital importance in the process to clinical implementation, 
but often not achieved [10]. The approach of the current study was to assess the 
reproducibility of our previous results in a cohort similar to the cohorts in the original study 
with regard to the approach and criteria of inclusion (also of deceased patients), inclusion 
sites, treatment protocols, and ethnicity (i.e. only Caucasian origin), as a first step to 
assess the relevance of the findings. This was extended to assessment of reproducibility 
of the findings in cohorts that differ from the original study, with regard to inclusion sites, 
treatment protocols, and ethnicity, as a separate stage. Following this approach, we have 
been able to validate our previously reported finding of the association of the GRS with 
5-year PFS. This was not only the case in the Dutch cohort, but also to some extent in 
the Spanish cohort, indicating its robustness. Although the association of the GRS with 
PFS was not statistically significant in the Spanish cohort alone, the differences in PFS 
between the risk score groups were in similar direction as in the Dutch cohort, which 
is also reflected by the significant association after combining both cohorts. Although 
these results are promising, the reproducibility was not complete for all risk score groups 
as the PFS of the small proportion of patients carrying more than 5 risk alleles was not 
significantly different in the analyses and was even better in the Dutch cohort compared 
to patients carrying 4 to 5 risk alleles. This might be related to the small sample size of 
the group of patients carrying more than 5 risk alleles and/or the fact that these patients 
also carried at least two risk alleles of the two variants not individually confirmed in 
the meta-analysis, which are therefore not expected to have a dominant contribution to 
the PFS. Furthermore, the association of the GRS with PFS could not be confirmed in 
the English cohort, indicating that the association may not be 100% robust, although it 
should be noted that significant differences in PFS were observed as indicated above. 
 As patients with localized or metastatic disease are known to have a different 
prognosis, also in the three cohorts in this study, stratification on the basis of metastatic 
status at diagnosis was performed. The results indicated that this improved the ability 
to differentiate patients based on the GRS; with overall inferior PFS for each risk score 
group in metastatic patients compared to patients without metastases at diagnosis. 
However, also here the analysis of patients carrying more than 5 risk alleles was limited 
because of low numbers, and this should be further investigated in larger populations.
 The association of two of the individual variants (MSH2 rs4638843 and ABCC5 
rs939338) with 5-year PFS was validated in a meta-analysis. Therefore, these may be 
especially interesting candidates to follow-up for functional characterization. Both genes 
were selected for analysis in the original pathway-based study based on the described 
relation to cisplatin and/or doxorubicin metabolism and transport [4]. Biological validation 
could be useful to determine whether the identified variants are the causal variants 
themselves or whether they are linked to the actual causal variant. In addition, it could 
provide additional evidence and a biological rationale for further research towards 
translation to a clinical setting. Furthermore, it may give more insight into the mechanisms 
underlying the drug response.
 Although the number of patients included in this study is relatively high for osteosarcoma 
because of its rarity, the number of patients is rather low for validation studies. This may 
have limited the ability to significantly confirm the associations in each individual cohort. 
Therefore, we suggest further confirmatory studies in larger (prospective) cohorts, 
before clinical implementation of the risk score. In addition, the predictive accuracy of 
the genetic risk score based on the four identified variants is relatively low, indicating 
that these specific pharmacogenetic variants alone are not sufficient to fully discriminate 
patients prone to have a poor treatment response from those with a good outcome. 
This implicates that additional (non) genetic risk factors would be needed to be able to 
construct a predictive model. The selection of genes for the original study was based 
on the known role in metabolic routes of cisplatin or doxorubicin. On the basis of the 
current consistent results, indicating that indeed pharmacogenetics may play a role in the 
treatment response in osteosarcoma, further research into genes not directly related to 
these agents would be worthwhile. As it is most likely that the tumor genetics and biology 
contribute to variation in treatment response, this should also be further characterized 
[11]. In the future, the findings of the current study, combined with additional predictive 
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factors, may provide a clinical tool for risk stratification. The next step will be to consider 
what the alternative options would be for patients prone to have a poor response to 
standard chemotherapy.
 In conclusion, we have confirmed the association of a genetic risk score based on four 
pharmacogenetic variants with PFS in patients with osteosarcoma. This may provide 
a basis for pharmacogenetic profiling in the future and could contribute to treatment 
optimization for patients with osteosarcoma. 
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Supplementary data
Figure S1. Five-year PFS of the 
original study cohort (N=172) based 
on GRS calculated without the 
CYP3A4 rs4646437 variant. Patients 
with 0-1 risk allele showed a 5-year 
PFS of 80.2% compared to 69.4% 
with 2–3 risk alleles, 46.4% with 
4–5 alleles, and 16.7% with >5 risk 
alleles.
Figure S2. Five-year PFS based on 
GRS in the English cohort (N=43). 
Patients with 0-1 risk allele showed 
a 5-year PFS of 42.9% compared to 
73.7% with 2–3 risk alleles, 87.5% 
with 4–5 alleles, and 100% with >5 
risk alleles.
Figure S3. Five-year PFS based on GRS of Dutch and Spanish cohort combined, stratified for metastatic 
status at diagnosis. A: Patients without metastases and with 0-1 risk allele showed a 5-year PFS of 
82.9% compared to 65.3% with 2–3 risk alleles, 49.3% with 4–5 alleles, and 50.0% with >5 risk alleles. 
B: Patients with metastases and with 0-1 risk allele showed a 5-year PFS of 53.3% compared to 21.1% 
with 2–3 risk alleles, 41.7% with 4–5 alleles, and 100% with >5 risk alleles.
Table S1. Minor allele frequencies of the four variants in each cohort.
SNP Allele
Dutch cohort 
(N=174)
Spanish cohort 
(N=95)
English cohort 
(N=51)
rs763110 T 0.338 0.378 0.439
rs4638843 C 0.111 0.139 0.089
rs939338 G 0.409 0.332 0.480
rs2720376 G 0.416 0.457 0.480
A B
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6Abstract
Upfront prediction of efficacy of chemotherapy for osteosarcoma may enable treatment 
optimization and improvement of outcome. Pharmacogenetic studies of the cisplatin and 
doxorubicin metabolic pathways have indicated a role of genetic variants in treatment 
response in osteosarcoma. As the complex metabolism of drugs used in osteosarcoma 
treatment may involve a broader range of genetic factors, we investigated a comprehensive 
set of 1,936 variants in 231 genes known to be involved in drug metabolism and transport.
 In a discovery stage including two Dutch cohorts of high-grade osteosarcoma patients 
(N=139 and N=177), germline DNA was genotyped using the Drug Metabolizing Enzymes 
and Transporters (DMET) Plus array. Associations of genetic variants with histologic 
response to preoperative cisplatin and doxorubicin-based chemotherapy, and with 5-year 
progression-free survival (PFS) were evaluated using multivariable logistic regression 
models and Cox proportional hazards models, respectively. Statistically significant 
findings were validated in Spanish (N=100) and English (N=54) cohorts.
 After meta-analysis of the Dutch cohorts, significant associations of 23 genetic 
variants with 5-year PFS were identified. Of these markers, the ABCB1 rs17064 variant 
was independently validated in the Spanish cohort (P=0.014), and showed increased 
significance in association with 5-year PFS in a combined meta-analysis of the Dutch 
and Spanish cohorts (HR for T allele 1.89, P=0.001), excluding the English cohort which 
showed markedly higher PFS. Seven variants in five other genes (ABCC4, ABCC5, 
ABCG1, SLC22A5, and SLC22A14) were also significantly associated with PFS in 
combined meta-analysis of the Dutch and Spanish cohorts. With addition of the English 
cohort to the combined meta-analysis, six of the eight variants remained significantly 
associated with PFS. Of 15 genetic variants associated with histologic response in the 
discovery phase, the top associated variants could not be confirmed in the validation 
cohorts.
 This is the first pharmacogenetic study in osteosarcoma patients employing a 
comprehensive absorption, distribution, metabolism, and excretion (ADME) pathway 
analysis in relation to PFS. We have identified associations of genetic variants of multiple 
drug transporters with outcome after chemotherapy-based treatment. After validation in 
larger cohorts, functional validation and prospective testing, these markers are of potential 
interest for the development of new treatment strategies and optimizing current therapy.
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Introduction
In patients with osteosarcoma, no substantial improvements in outcome after 
chemotherapy-based treatment have been achieved in the past decades. Treatment 
consists of a combination of surgery and chemotherapy, mostly based on cisplatin, 
doxorubicin, and in some protocols methotrexate (MTX), and is similar for all patients. 
Although this combination of drugs is the most effective one and used in various protocols, 
the treatment is successful in a subset of patients, with cure rates approaching 60-70% for 
patients with non-metastatic disease and 20-40% for patients with metastatic disease [1]. 
To improve outcome, upfront identification of patients at risk of a poor therapy response 
is essential to further optimize therapy.
 Metastatic status at diagnosis is the only consistent prognostic factor, but is not 
sufficient to explain the complete range of differences in outcome. The histologic 
response after preoperative chemotherapy is often used as a measure of drug response 
at the time of surgery, but it is not available for risk stratification at diagnosis and has not 
been confirmed as a consistent predictor of treatment outcome [2,3]. As interindividual 
variation in drug response is in part determined by genetic variation, pharmacogenetic 
approaches to identify genetic predictors of treatment response in osteosarcoma 
have gained attention in recent years. Multiple candidate gene studies as well as a 
few pathway-based gene studies have suggested a role of pharmacogenetic markers 
in the treatment response in osteosarcoma [4,5]. In a previous pathway-based gene 
study from our group, covering the metabolic pathways of cisplatin and doxorubicin, we 
identified candidate genes associated with 5-year progression-free survival (PFS) [6]. 
Nevertheless, the presence of these genetic variants was not sufficient to fully predict 
treatment response, suggesting the involvement of additional genes. Therefore, we set 
out to assess a more extensive set of genes involved in drug metabolism and transport, 
including genes not previously connected to cisplatin or doxorubicin metabolism. We 
performed a large scale screening of 1,936 genetic variants in 231 drug metabolism 
and transporter genes in Dutch osteosarcoma patients to investigate associations with 
treatment response, followed by validation in independent cohorts of osteosarcoma 
patients.
Materials and methods
Patient cohorts
For discovery, two Dutch cohorts of osteosarcoma patients were included: cohort I 
with 139 patients retrospectively recruited at the Radboud university medical center 
(Nijmegen) and the University Medical Center of Groningen (Groningen); cohort II with 
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177 patients from Leiden University Medical Center (Leiden) and the Emma Children’s 
Hospital/Academic Medical Center (Amsterdam), The Netherlands. These cohorts were 
based on the two cohorts investigated in our previous pathway-based study, with addition 
of an inclusion site (Amsterdam) to cohort II and additional patients because of ongoing 
recruitment at the other sites [6]. All patients were diagnosed between 1975 and 2013; 
clinical data was retrospectively collected from medical records. Patients were included 
if they were diagnosed with primary high-grade osteosarcoma with or without metastatic 
disease, aged ≤45 years, treated with cisplatin and doxorubicin-based chemotherapy, 
and of self-reported Caucasian ethnicity. Treatment of patients was either according 
to institutional standard therapy consisting of cisplatin (maximum cumulative dose 
600 mg/m2) and doxorubicin (maximum cumulative dose 450 mg/m2), or according to 
the standard schedule as given in the EURAMOS-1 trial, which consisted of cisplatin 
(maximum cumulative dose 480 mg/m2), doxorubicin (maximum cumulative dose 450 
mg/m2) and additionally high-dose MTX (maximum cumulative dose 144 g/m2), with or 
without additional ifosfamide and etoposide, or interferon-α [7]. The study was approved 
by the institutional review board of the Radboud university medical center, and approval 
for inclusion of patients in other Dutch institutions was obtained from institutional ethics 
committees. Written informed consent was provided by all patients and/or parents.
 Two high-grade osteosarcoma cohorts treated with cisplatin and doxorubicin-based 
chemotherapy from Spain (N=100, diagnosed between 1985 and 2014) and England 
(N=54, diagnosed between 2002 and 2008) were used for validation of the significant 
findings in the Dutch cohorts. Information on treatment has been reported previously 
[4,5]. The same inclusion criteria were applied as used in the Dutch cohorts, except for 
ethnicity. The study was approved by the local ethics committees and written informed 
consent was provided by patients and/or parents. 
Genotyping methods
From the two Dutch cohorts, germline DNA was isolated from blood or saliva of patients 
alive, or from normal formalin-fixed paraffin-embedded (FFPE) tissue of deceased 
patients, as described previously [8]. The DNA samples were genotyped for 1,936 
genetic variants using the Affymetrix DMET Plus array according to the manufacturer’s 
instructions (Affymetrix UK Ltd, High Wycombe, UK). Genotypes were calculated with 
DMET console software 1.3 using the Dynamic Genotype Boundaries version 2 algorithm. 
Variants were excluded from association analysis if the genotype cluster plots were 
considered unreliable, being plots with genotype calling showing merged clusters without 
distinct cluster boundaries. Additional stringent evaluation of the genotype clustering in 
combination with expected genotype frequencies was carried out for variants significant 
in association analysis. Samples and variants were excluded from analysis if call 
rates <0.9, minor allele frequency (MAF) <0.01 and/or deviating from Hardy-Weinberg 
equilibrium (HWE) (P-value <0.0001). Five copy number variants, 46 X-chromosomal 
variants and one tri-allelic variant present on the array were not included in the analyses. 
 Information on germline DNA isolation of the English and Spanish validation cohorts 
has been previously reported [4,5]. Genotyping of the validation cohorts was carried 
out for 20 of the 23 variants that were significantly associated with 5-year PFS in the 
discovery stage (P<0.05), excluding three variants that were in linkage disequilibrium (on 
the basis of r2≥0.8) with any of the 20 variants and that had higher P-values than their 
linked variants. In addition, the validation cohorts were genotyped for the top three genes 
significantly associated with histologic response (P<0.01) in the Dutch cohorts, including 
one variant (SLC25A27 rs9381468) that was genotyped for association analysis of both 
endpoints. A more stringent significance threshold was applied for selection of variants 
relevant for validation of association with histologic response, because this endpoint may 
be less robust as it may be more sensitive to interobserver and sampling differences, in 
spite of standard definitions. For the validation cohort the following genetic variants were 
genotyped with KASP-On-Demand (KOD) assays: CDA rs818202, CHST5 rs2641806, 
SLC22A14 rs171248, SLC22A5 rs274548, SLC22A5 rs274558, SLC25A27 rs9381468, 
and UGT2B15 rs1902023; KASP-By-Design (KBD) assays were used for ABCB1 
rs17064, ABCB4 rs2109505, ABCC4 rs3742106, ABCC5 rs562, ABCC5 rs7636910, 
ABCG1 rs3788007, CA5P rs1364182, CYP39A1 rs7761731, FMO3 rs2266782, 
SULT1E1 rs3822172, and VKORC1 rs2884737, all according to the manufacturer’s 
protocol (LGC Genomics, Hoddesdon, UK). The ABCC2 rs2273697 (C__22272980_20), 
ABCC2 rs717620 (C___2814642_10), ABCC5 rs939338 (C___8759155_20), and 
SLC7A8 rs2268877 (C___2486192_1_) variants were determined using a TaqMan 
allelic discrimination assay according to the manufacturer’s protocol (ThermoFisher, 
Nieuwegein, The Netherlands). For validation of the results for ABCC5 rs939336, the 
closely linked ABCC5 rs939338 variant (r2=0.98) was determined, as this was one of the 
variants that was also associated with 5-year PFS in our previous study [6]. Fluorescence 
was measured with a 7500FAST Real-Time PCR System (ThermoFisher). Genotypes 
were scored using the algorithm and software (v2.0.6) supplied by ThermoFisher. 
Blanks (3%) as well as duplicates between plates were included as quality controls for 
genotyping.
Statistical analysis
Statistical differences in demographic data between cohorts were assessed by the 
Fisher exact, Pearson chi-square, Mann-Whitney U test, or Cox proportional hazards 
analysis as appropriate. Five-year PFS was defined as the interval between diagnosis 
and disease progression/recurrence (=event) and was estimated using the Kaplan–Meier 
method. Patients without disease recurrence at the date of last follow-up were censored 
at that date. For analysis of the histologic response, a good response was defined as 
SNPs in ADME genes and osteosarcoma treatment response
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≥90% necrosis after preoperative chemotherapy. Associations of clinical variables with 
5-year PFS were assessed by Cox regression analysis; for histologic response the Fisher 
exact or Pearson chi-square test were used. 
 The data analysis plan involved association analysis of the individual SNPs in both 
Dutch cohorts, and subsequent validation in each of the validation cohorts. The discovery 
stage included both Dutch cohorts that were analyzed using the complete DMET data 
and subsequently meta-analyzed for identification of overall significant associations. 
After association analysis of the positive findings from the discovery stage in the 
individual validation cohorts, meta-analysis of both discovery and validation cohorts was 
subsequently carried out if any of the tested variants showed P<0.1 in the validation 
cohorts. 
 To assess the effect of a genetic variant on the histologic response, the data were 
dichotomized to good/poor response. Associations between genetic variants and the 
histologic response were assessed by multivariable logistic regression analysis in PLINK 
using the command --logistic (additive model) (PLINK v1.07) [9]. Associations between 
genetic variants and 5-year PFS were assessed using Cox proportional hazards models 
using the specialized GenABEL package (additive model) [10] in R (version 3.1.0, http://
www.r-project.org), which we validated using SPSS v22 (SPSS Inc., Chicago, Ill, USA). 
The results of the separate cohorts were meta-analyzed using a fixed-effects or random-
effects (in case of large heterogeneity: I2>50) model in METAL [11]. 
 A genetic risk score (GRS) was constructed as in our previous study [6] based on 
genetic variants significantly associated with 5-year PFS; differences in 5-year PFS 
between the patients, grouped by their number of risk alleles, were assessed using the 
log rank test. Only patients successfully genotyped for each variant were included in 
the GRS calculation. All analyses were performed using SPSS unless stated otherwise. 
Reported P-values are two-sided and are considered statistically significant if <0.05. 
No correction for multiple testing was applied because of the exploratory nature of the 
discovery stage.
Results
Patient population
The study was carried out following a two-stage approach, with a discovery stage using 
two Dutch cohorts, and independent validation in a Spanish cohort and an English 
cohort. From both Dutch cohorts, three patients were excluded based on a genotype 
call rate lower than 0.9, resulting in 136 and 174 patients in the Dutch cohorts I and 
II, respectively. The clinical characteristics of patients in each of the four cohorts 
are provided in Table 1. From Dutch cohort I, 18 of 136 patients were excluded from 
association analysis of 5-year PFS because of ongoing treatment (N=1) or because they 
were not treated with neoadjuvant cisplatin and doxorubicin (N=17); from Dutch cohort II, 
9 of 174 patients were excluded for the latter reason. From the validation cohorts, in total 
8 patients were excluded from association analysis of 5-year PFS because they were 
not treated with neoadjuvant chemotherapy or not specifically with neoadjuvant cisplatin 
and/or doxorubicin (Spanish cohort N=4, English cohort N=3) or because no follow-up 
data was available (Spanish cohort N=1). No substantial differences were observed in 
baseline characteristics between the total cohorts and the patients eligible for 5-year PFS 
analysis (for comparison see Supplementary Table S1). 
 The Dutch cohorts significantly differed with respect to age at diagnosis, MTX 
treatment, and histologic response (Table 1). In Dutch cohort I, patients were slightly 
younger, more often treated with (neoadjuvant) MTX (because of differences in standard 
treatment protocols) and a poor histologic response was less frequently observed 
compared to Dutch cohort II. Despite the difference in poor responders, the Dutch 
cohorts did not significantly differ with regard to 5-year PFS. Due to these baseline 
differences, the genetic analyses of the Dutch cohorts were carried out using a meta-
analysis. Furthermore, the English cohort had a significantly lower percentage of poor 
histologic responders (22.0%) compared to the other cohorts, 5-year PFS was ~15% 
higher than observed in the Dutch and Spanish cohorts (Supplementary Figure S1), and 
5-year overall survival was superior to the other cohorts. Especially the high 5-year PFS 
in the English cohort may be a reflection of differences in inclusion of patients, as in the 
English cohort patients who were deceased (and most likely showing poor PFS) at the 
time of retrospective patient recruitment were not included. This is therefore considered a 
bias in the selected population. With respect to the histologic response, all patients of the 
English cohort were treated with HD-MTX preoperatively, which might have an influence 
on the histologic response, as indicated below.
 In both Dutch cohorts, no significant differences were observed between good and poor 
responders with regard to the number of neoadjuvant cycles of cisplatin and doxorubicin 
and/or neoadjuvant cisplatin and doxorubicin dosage. In addition, none of the clinical 
variables included in Table 1 were significantly associated with histologic response in 
all cohorts. However, neoadjuvant MTX treatment was predictive of a good histologic 
response in cohort I (P=0.021). Because of the potential influence of MTX treatment on 
the histologic response, which may also partially explain the above-mentioned difference 
in histologic response between Dutch cohort I and II, neoadjuvant treatment with MTX 
was included as clinical covariable in the genetic association analyses of histologic 
response. Analysis of the clinical variables with 5-year PFS revealed a significant 
association of the presence of metastases at diagnosis with inferior PFS (P=0.002 and 
P=0.001 for cohort I and II, respectively); the same association was observed in the 
validation cohorts. As no other clinical variables were significantly associated with PFS in 
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all cohorts, only metastatic status at diagnosis was included as clinical covariable in the 
genetic association analyses of PFS. The association of a poor histologic response with 
inferior PFS was only significant in Dutch cohort II (P=0.001) and marginally significant 
in Dutch cohort I (P=0.06). Adjusting for the histologic response would unintentionally 
remove variation resulting in overcorrection, as histologic response and PFS are both a 
measure for the treatment response.
Table 1. Demographic data of all patients in the discovery and validation cohorts, N=464.
Discoverya Validationb
Dutch cohort I 
(N=136)
Dutch cohort II 
(N=174)
Spanish cohort 
(N=100)
English cohort 
(N=54)
Age at diagnosis, median (range) 15.7 (5.6-41.1) 17.5 (3.4-45.8) 14.0 (1.9-34.6) 17.5 (10.0-44.0)
Male gender, n (%) 73 (53.7%) 98 (56.3%) 55 (55.0%) 31 (57.4%)
Axial tumor, n (%) 5 (3.7%) 7 (4.0%) 3 (3.0%) 3 (5.6%)
Primary metastases, n (%) 23 (16.9%) 25 (14.4%) 19 (19.0%) 7 (13.0%)
MTX totalc, n (%) 92 (67.6%) 80 (46.0%) 88 (94.6%) 51 (100%)
MTX neoadjuvantd, n (%) 73 (53.7%) 50 (40.2%) 32 (36.0%) 50 (100%)
Poor histologic responsee, n (%) 81 (69.8%) 75 (48.7%) 49 (54.4%) 11 (22.0%)
5-year PFSf 60.5% 60.8% 58.2% 74.5%
5-year OS 76.3% 75.9% 82.4% 88.9%
MTX, methotrexate; PFS, progression-free survival; OS, overall survival.
a  Dutch cohorts I and II significantly differed with respect to age at diagnosis (P=0.038), MTX treatment 
total (P<0.001) and neoadjuvant (P=0.018), and poor histologic response (P=0.001).
b  Ethnicities English cohort: Caucasian N=38 (70.4%), Afro-Caribbean N=8 (14.8%), Indian/Asian 
N=8 (14.8%); Spanish cohort: Caucasian N=94 (94.0%), Latin American N=5 (5.0%), Romani N=1 
(1.0%).
c  Data available on MTX treatment total (neoadjuvant and/or adjuvant): Dutch cohorts all patients, 
Spanish cohort N=88, English cohort N=51. dData available on MTX treatment neoadjuvant: Dutch 
cohorts all patients, Spanish cohort N=89, English cohort N=50. eData available on histologic response 
for each cohort: Dutch cohort I N=116, Dutch cohort II N=154, Spanish cohort N=90, English cohort 
N=50. fPatients eligible for PFS analysis: Dutch cohort I N=118, Dutch cohort II N=165, Spanish cohort 
N=95, English cohort N=51.
Association analysis of histologic response
Of the 1,884 variants included in the quality control of both Dutch cohorts, 90 variants 
were considered unreliable after primary screening of clusterplots. In addition, 36 (cohort 
I) and 32 (cohort II) variants were excluded because of genotype call rate <0.9, and 1,069 
(cohort I) and 1,093 (cohort II) variants because of MAF <0.01. All remaining variants 
were in HWE. After quality control, 689 and 669 variants were included in the association 
analyses of Dutch cohort I and cohort II, respectively. In multivariable analysis of genetic 
variants and histologic response, including neoadjuvant MTX treatment as covariable, 
18 genetic variants in 12 genes showed significant association with histologic response 
in meta-analysis of the results of the two Dutch cohorts. After stringent evaluation of 
the genotype clusterplots, three of these variants (GSTO1 rs4925, and VKORC1 
rs2359612 and rs9923231) were excluded, resulting in 15 remaining variants in 11 genes 
(Supplementary Table S2). All variants showed the same direction of effect in the two 
Dutch cohorts. 
 To validate the most significant findings of the meta-analysis of the Dutch cohorts, 
three variants were investigated in the Spanish and English validation cohorts. The three 
variants, ABCC2 rs717620, SLC25A27 rs9381468, and VKORC1 rs2884737, showed 
an average call rate of 0.96 and were in HWE (P>0.05). The validation cohorts were 
analyzed similar to the Dutch cohorts, although in the English cohort no correction for 
MTX treatment was applied as all patients received MTX. None of the variants were 
validated in association with histologic response. The T allele of the ABCC2 rs717620 
variant was associated with poor histologic response in the English cohort as reported 
previously [4]; the opposite effect compared to the findings in the Dutch cohorts.
Table 2. Association analysis results of top associated variants with histologic response in discovery 
and validation stage.
Discovery Validation
Meta-analysis Dutch cohorts Spanish cohort English cohort
SNP Gene Chr Minor allele OR 95% CI P OR 95% CI P OR 95% CI P
rs717620 ABCC2 10 T 0.473 0.30-0.76 0.002 1.29 0.63-266 0.490 4.46 1.42-14.00 0.011
rs9381468 SLC25A27 6 T 1.746 1.21-2.52 0.003 0.99 0.49-2.01 0.974 0.81 0.34-1.93 0.637
rs2884737 VKORC1 16 G 0.570 0.38-0.86 0.007 0.81 0.43-1.52 0.506 0.70 0.20-2.51 0.586
Chr, chromosome; OR, odds ratio; 95% CI, 95% confidence interval.
OR is given for a poor histologic response; OR and 95% CI are reported for the minor allele, an OR<1 
indicates a protective effect of the minor allele and risk of poor histologic response for the major allele. 
All reported results are adjusted for neoadjuvant treatment with MTX.
Association analysis of 5-year PFS
In the discovery stage, multivariable analysis of genetic variants and 5-year PFS, including 
metastases at diagnosis as covariable, showed significant associations of 27 SNPs in 
21 genes in meta-analysis of the results of the Dutch cohorts. Four of these variants 
(ABCB11 rs7602171, CYP2D6 rs1058164, CYP2F1 rs7246981, and PPARG rs3856806) 
were excluded after additional inspection of the genotype clusterplots, leading to 23 
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significant variants in 17 different genes (Table 3). In both Dutch cohorts, the same 
direction of effect was observed for all variants (Supplementary Table S3). 
 Based on our findings in the discovery phase, 20 variants (excluding three markers 
in LD) were investigated in the validation cohorts. All variants were in HWE (P>0.05) 
and had an average call rate of 0.97. After association analysis of the validation cohorts 
similar to the Dutch cohorts, the ABCB1 rs17064 variant was independently validated 
in the Spanish cohort (P=0.014). The ABCC5 rs562 was significantly associated with 
5-year PFS in the English cohort; however, with opposite direction of effect compared to 
the Dutch cohorts. Although we realized after analysis of the data that the English cohort 
was not suitable for validation due to its selected population combined with small sample 
size, we chose to follow the original analysis plan for analysis in the individual cohorts. 
Furthermore, as the 5-year PFS in the English cohort was substantially different from the 
Dutch and Spanish cohorts, we carried out a meta-analysis including only the Dutch and 
Spanish cohorts. Carriers of the T allele of ABCB1 rs17064 showed inferior 5-year PFS 
(HR=1.89, P=0.001, after correction for multiple testing Padjusted=0.017), with a stronger 
association compared to the meta-analysis of the Dutch cohorts alone. Seven other 
variants (ABCC4 rs3742106, ABCC5 rs562 and rs939336, ABCG1 rs3788007, SLC22A5 
rs274548 and rs274558, SLC22A14 rs171248) were also significantly associated with 
5-year PFS, with stronger associations than observed in the meta-analysis including 
the Dutch cohorts only, though these associations did not survive correction for multiple 
testing. Seven of the eight variants remained significant upon addition of age at diagnosis 
as covariable in the analysis, and the other variant, SLC22A14 rs171248, remained 
marginally significant (Supplementary Table S3). Addition of the English cohort to the 
meta-analysis (correcting for metastases only) showed similar results; only two of the 
eight variants, both in ABCC5, were not significantly associated with 5-year PFS, both 
variants showed large heterogeneity (I2>50) (Supplementary Table S3). 
 A genetic risk score for PFS was calculated on the basis of the eight variants associated 
with 5-year PFS in meta-analysis of the Dutch and Spanish cohorts (Figure 1). Patients 
were grouped by each two consecutive risk scores; patients with ten or more unfavorable 
alleles were grouped together to ensure sufficient sample size for analysis. Patients 
with 2-3 risk alleles showed a 5-year PFS of 86.5% compared to a 5-year PFS of 65.8% 
in patients carrying 4-5 risk alleles, 71.1% with 6-7 alleles, 45.2% with 8-9 alleles, and 
34.9% with 10-14 risk alleles (overall P<0.001).
Table 3. Meta-analysis results of 5-year PFS association analysis in discovery stage.
SNP Gene Chr Minor allele MAF HR 95% CI P
rs171248 SLC22A14 3 C 0.456 1.45 1.11-1.91 0.007
rs2641806 CHST5 16 C 0.311 0.68 0.50-0.92 0.012
rs939336 ABCC5 3 T 0.399 1.38 1.07-1.78 0.014
rs17064 ABCB1 7 T 0.071 1.71 1.11-2.62 0.015
rs562 ABCC5 3 A 0.472 1.39 1.06-1.84 0.018
rs149738 SLC22A14 3 G 0.451 1.38 1.05-1.81 0.020
rs7636910 ABCC5 3 G 0.408 0.73 0.56-0.95 0.021
rs2109505 ABCB4 7 T 0.221 1.40 1.04-1.87 0.025
rs183574 SLC22A14 3 C 0.448 1.36 1.04-1.79 0.027
rs1364182 CA5P 16 T 0.083 0.54 0.31-0.94 0.030
rs2266782 FMO3 1 A 0.427 1.35 1.03-1.76 0.030
rs274558 SLC22A5 5 G 0.410 0.75 0.57-0.98 0.036
rs818202 CDA 1 A 0.383 1.32 1.02-1.72 0.036
rs274548 SLC22A5 5 T 0.146 1.48 1.02-2.15 0.037
rs3742106 ABCC4 13 G 0.413 1.34 1.01-1.78 0.041
rs3788007 ABCG1 21 A 0.196 0.68 0.47-0.99 0.042
rs1902023 UGT2B15 4 G 0.489 0.74 0.55-0.99 0.044
rs3822172 SULT1E1 4 G 0.141 0.65 0.43-0.99 0.045
rs7761731 CYP39A1 6 A 0.265 1.33 1.00-1.77 0.047
rs2738792 CHST5 16 T 0.106 0.59 0.35-0.99 0.047
rs2273697 ABCC2 10 A 0.213 1.38 1.00-1.90 0.047
rs2268877 SLC7A8 14 C 0.214 1.38 1.00-1.90 0.048
rs9381468 SLC25A27 6 T 0.491 1.32 1.00-1.74 0.050
Chr, chromosome; MAF, minor allele frequency; HR, hazard ratio; 95% CI, 95% confidence interval.
HR and 95% CI are reported for the minor allele, a HR <1 indicates a protective effect of the minor 
allele and risk of poor histologic response for the major allele. All reported results are adjusted for the 
presence of metastases at diagnosis.
MAF is reported for the total of 283 patients included in the meta-analysis of the two Dutch cohorts.
Variants within CHST5 and SLC22A14 are in linkage disequilibrium with r2>0.8.
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Table 4. Association analysis results of 5-year PFS in validation stage.
Spanish cohort English cohort Meta-analysisDutch and Spanish cohorts
SNP Gene Chr Minor allele HR 95% CI P HR 95% CI P HR 95% CI P
rs17064 ABCB1 7 T 2.59 1.21-5.54 0.014 0.55 0.07-4.43 0.577 1.89 1.30-2.74 0.001
rs562 ABCC5 3 A 1.59 0.96-2.64 0.070 0.38 0.17-0.89 0.026 1.44 1.13-1.83 0.003
rs3742106 ABCC4 13 G 1.56 0.98-2.47 0.058 0.80 0.36-1.78 0.589 1.40 1.10-1.78 0.006
rs274558 SLC22A5 5 G 0.60 0.34-1.06 0.079 0.86 0.42-1.76 0.679 0.72 0.56-0.92 0.008
rs939336a ABCC5 3 T 1.27 0.77-2.10 0.354 0.44 0.18-1.06 0.068 1.36 1.08-1.70 0.009
rs3788007 ABCG1 21 A 0.50 0.23-1.11 0.087 1.54 0.61-3.89 0.357 0.64 0.46-0.90 0.010
rs274548 SLC22A5 5 T 1.54 0.72-3.28 0.268 1.60 0.77-3.33 0.210 1.49 1.07-2.08 0.018
rs171248 SLC22A14 3 C 0.90 0.56-1.45 0.667 1.00 0.41-2.45 0.991 1.29 1.02-1.63 0.035
rs3822172 SULT1E1 4 G 0.88 0.42-1.84 0.736 1.66 0.52-5.27 0.388 0.70 0.49-1.01 0.056
rs2109505 ABCB4 7 T 0.88 0.46-1.68 0.700 0.74 0.24-2.25 0.597 1.29 0.99-1.68 0.060
rs818202 CDA 1 A 1.00 0.64-1.57 0.995 1.51 0.72-3.18 0.280 1.23 0.98-1.55 0.071
rs2273697 ABCC2 10 A 1.03 0.57-1.85 0.935 0.91 0.27-3.05 0.876 1.29 0.98-1.71 0.074
rs7636910 ABCC5 3 G 1.18 0.70-2.00 0.532 0.75 0.27-2.08 0.582 0.81 0.64-1.02 0.077
rs2268877 SLC7A8 14 C 0.77 0.41-1.45 0.413 1.30 0.43-3.91 0.644 1.23 0.92-1.63 0.163
rs2266782 FMO3 1 A 0.84 0.50-1.43 0.523 0.61 0.23-1.58 0.306 1.20* 0.81-1.78 0.35
rs9381468 SLC25A27 6 T 0.79 0.47-1.32 0.370 1.48 0.73-2.99 0.278 1.15* 0.80-1.67 0.45
rs1902023 UGT2B15 4 G 1.30 0.80-2.13 0.287 0.62 0.28-1.38 0.242 0.89* 0.61-1.28 0.52
rs7761731 CYP39A1 6 A 0.72 0.42-1.23 0.224 1.06 0.47-2.37 0.897 1.13* 0.75-1.71 0.56
rs1364182 CA5P 16 T 1.60 0.80-3.19 0.184 0.51 0.14-1.89 0.312 0.82* 0.38-1.76 0.61
rs2641806 CHST5 16 C 1.64 1.02-2.64 0.042 0.48 0.15-1.51 0.208 0.90* 0.52-1.58 0.73
Chr, chromosome; HR, hazard ratio; 95% CI, 95% confidence interval.
HR and 95% CI are reported for the minor allele, a HR <1 indicates a protective effect of the minor 
allele and risk of poor histologic response for the major allele. All reported results are adjusted for the 
presence of metastases at diagnosis.
*I2>50.
a  Results for the English and Spanish cohort are given for rs939338: the genotyped variant in these 
cohorts.
Figure 1. Five-year PFS based on GRS in the Dutch and Spanish cohorts combined (N=364). The 
GRS is based on eight markers significantly associated with 5-year PFS in meta-analysis of Dutch and 
Spanish cohorts. Patients with 2-3 risk alleles showed a 5-year PFS of 86.5% compared to 65.8% with 
4-5 risk alleles, 71.1% with 6-7 alleles, 45.2% with 8-9 alleles, and 34.9% with 10-14 risk alleles.
Discussion
In recent years, pharmacogenetic studies have explored the opportunity to distinguish 
osteosarcoma patients prone to have a poor response to chemotherapy from those 
who will benefit from the treatment, by studying candidate genes in the metabolic 
pathways of the chemotherapeutics used in antitumor treatment. In the present study, 
we have taken the next step by interrogating a comprehensive set of drug metabolism 
and transporter genes to detect associations with response to chemotherapy. We have 
identified eight genetic variants associated with 5-year PFS, of which an ABCB1 variant 
was independently validated in one of the validation cohorts. Seven other variants were 
significantly associated with 5-year PFS in a combined meta-analysis of discovery and 
validation cohorts. 
 In addition to 5-year PFS, the histologic response was included as endpoint in our 
study, as in clinical practice this is used as a marker of the response to neoadjuvant 
chemotherapy, and as the basis for stratification in past trials, based on its presumed 
predictive capacity of outcome. Remarkably, in only one of the four cohorts (Dutch cohort 
II) included in the present study, the histologic response was associated with 5-year PFS. 
Moreover, despite significant differences in poor responders between the two Dutch cohorts, 
this did not translate into a difference in PFS. This is in line with trials of intensified treatment 
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leading to better histologic response but not to significantly improved outcome [2,3]. In the 
genetic association analysis, none of the markers most significantly associated in the Dutch 
cohorts could be validated. Conflicting results were obtained on the T allele of the ABCC2 
rs171620 variant, which had been previously shown to be associated with poor histologic 
response in the English cohort [4] and confirmed in our analysis of the same cohort, but 
which showed a protective effect in the Dutch cohorts. As analysis of the Spanish cohort did 
not provide significant results, the influence of this variant on the histologic response remains 
doubtful. A possible explanation for the discrepancy between the results of the Dutch and 
English cohorts is the large difference in the proportion of poor histologic responders. The 
extremely small proportion of poor responders in the English cohort might be attributed to 
the absence of patients who had died before the time of retrospective patient inclusion, 
of whom a substantial proportion is expected to have had a poor histologic response, 
even though the link between the histologic response and survival may not be absolute as 
indicated above. The 100% neoadjuvant MTX treatment in the English cohort, compared to 
lower percentages in the other cohorts, may also have influenced the histologic response, 
as neoadjuvant MTX treatment was related to the histologic response in Dutch cohort 1.
 In the English cohort, not only a poor histologic response was less frequently observed 
than expected, also the 5-year PFS (and OS) was substantially higher than in the other 
cohorts, which we consider to have the same cause. Unfortunately, this may indicate that a 
different sample of patients was selected, and together with the relatively small sample size, 
the results of the English cohort were considered inconclusive for this study. For this reason, 
the GRS analysis was only carried out with the combined Dutch and Spanish cohorts. Aside 
from the expected overrepresentation of survivors, the English cohort also differs from 
the other cohorts with respect to ethnic background, MTX treatment, and time frame of 
inclusion. However, the percentage of patients with overall MTX treatment is similar to the 
Spanish cohort. Furthermore, (overall) survival differences between ethnicities, if any, are 
directed towards inferior survival in black patients [12], and improvement in survival due to 
for example better supportive care in the more recent time frame is often relatively subtle. 
Hence, these factors are not expected to have substantial impact on the 5-year PFS such 
as observed in the English cohort.
 The GRS analysis included eight genetic variants in six different genes associated with 
5-year PFS in meta-analysis of the Dutch and Spanish cohorts, to evaluate the combined 
effect on PFS. Hence, of two genes (ABCC5 and SLC22A5), two variants per gene were 
included in the analysis. As the LD between the variants within these genes was only partial 
(r2<0.8), inclusion of both variants per gene was not expected to have led to overestimation, 
as each allele may still have an additional effect. 
 The rs17064 variant independently validated in relation to PFS is located in the 
ABCB1 (ATP-binding cassette, sub-family B member 1) gene. This gene encodes 
ABCB1 (P-glycoprotein), an efflux transporter involved in elimination through bile and the 
kidneys; and MTX, doxorubicin and vincristine are among its known substrates [13]. At 
the tumor level, this transporter has received attention as previous studies have indicated 
that ABCB1 overexpression in osteosarcoma is related to doxorubicin resistance and 
treatment response [14-16], and an ABCB1/ABCC1 inhibitor has been shown to revert 
ABCB1/ABCC1-mediated doxorubicin resistance of osteosarcoma in vitro [17]. Germline 
pharmacogenetic studies in osteosarcoma have reported conflicting results regarding the 
influence of ABCB1 variants on treatment response: other variants of ABCB1, including 
rs1128503 and rs1045642, have been reported in association with histologic response 
and/or survival [5,18], but have shown opposite results [19,20] or lack of association [4] 
in other studies. These variants are both included on the DMET array, but were also not 
significantly associated with either histologic response or 5-year PFS in the present study. 
The variant identified in the present study has not been studied before in osteosarcoma, 
but in an ovarian cancer pharmacogenetic study in which other ABCB1 variants were 
associated with outcome after platinum-based treatment, though not rs17064 [21]. The 
functional consequence of the variant is not known, but as the variant is located in the 
3’UTR of the gene, it might have an effect on expression, or alternatively it may not be 
the causal variant itself but be linked to a functional variant. Another transporter gene 
that was significant in the PFS analysis is ABCC5 (ATP-binding cassette sub-family C 
member 5), which was also identified in our pathway-based study [6]. Of both the rs562 
variant in the 3’UTR and the synonymous rs939336 variant, an eQTL study has linked the 
risk alleles to increased ABCC5 expression [22], which on its turn has been implicated 
in cisplatin and doxorubicin resistance [23,24]. As the synonymous rs939336 variant 
covered by the DMET array is almost completely linked to the rs939338 variant detected 
in our previous study, this finding may in fact be considered as an internal validation 
with another genotyping platform. We also identified an intronic variant in ABCG1 
(ATP-binding cassette sub-family G member 1), which encodes an efflux transporter of 
cholesterol in various cell types [25]. Interestingly, ABCG1 variants have been linked to 
overall survival after platinum-based chemotherapy in non-small cell lung cancer [26]. 
Another association found was of an 3’UTR variant in ABCC4 (ATP-binding cassette sub-
family C member 4). This gene encodes an efflux transporter known to function in brain, 
liver and kidneys. ABCC4 has been implicated in cisplatin-resistance in gastric cancer 
[27]. Moreover, overexpression of ABCC4 has been correlated with multidrug resistant 
osteosarcoma [28]. Furthermore, two other genes, SLC22A5 (Solute carrier family 22 
member 5) and SLC22A14 (Solute carrier family 22 member 14) were found in relation 
to PFS in the present study that encode transporters located in the kidneys. SLC22A5 
is involved in the reabsorption of carnitine and has been implicated in cisplatin-induced 
nephrotoxicity [29,30]. SLC22A14 (or OCTL2) is an organic cation transporter which has 
not been previously linked to transport of anticancer drugs [31].
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 All genes identified in the current study are coding for drug transporters; although a large 
number of phase I and phase II metabolic enzymes were covered by the DMET array, none 
of these were significant in our study. Although previous candidate gene or pathway-based 
pharmacogenetic studies in osteosarcoma have indicated a role of variation in various 
glutathione-S-transferase genes in the treatment response, with mostly consistent findings 
for the GSTP1 rs1695 variant which is also included on the DMET array, we could not 
confirm these findings [4,18,19,32-35].
 To our knowledge, this is the largest pharmacogenetic study in osteosarcoma to date 
with regard to the number of included patients, inclusion of validation cohorts, and the 
number of investigated genes and markers. However, we acknowledge that the sample 
size is still relatively low for detection of genetic associations, reflecting the low incidence 
of osteosarcoma. Although significant results were obtained, we may have missed other 
associations, as differences between good and poor responders may have been limited 
by the low number of patients. In the context of genetic association analysis with relatively 
small cohorts, we have applied less stringent procedures for selection of variants to take 
forward to validation, i.e. we did not correct for multiple testing, and we only investigated 
the potential influence of age as additional covariable in the PFS analysis after validation of 
markers. In addition, the Dutch cohorts were heterogeneous regarding treatment protocols. 
Part of the patients received only two drugs (cisplatin and doxorubicin), whereas other 
patients also received additional drugs (mostly only MTX), which might give a more favorable 
outcome. However, as there was no effect of the presence of MTX in the treatment regimen 
on PFS in our cohorts, the influence of the differences in treatment regimens on the results 
is probably limited. Furthermore, both the genetic background of the tumor which might 
also influence the chemotherapy response, and tumor-specific mutations in drug transporter 
genes have not been taken into account in the study. The latter may in general not be of 
major impact on transporter genes, as DNA derived from tumor and blood or saliva has been 
shown to provide highly concordant genotypes of variants involved in drug metabolism and 
transport [36]. Nonetheless, it would be very interesting to compare that at the tumor level in 
osteosarcoma, as has been done ever since the early nineties and has been published as 
predictive factor already at that time [14].
 For patients carrying risk variants, the question arises as to how this could be applied 
for treatment optimization in the future. In general, for variants in genes related to 
pharmacokinetics, increasing the dose might give a more favorable outcome. However, this 
is complicated by the risk of toxicities of chemotherapeutic treatment for osteosarcoma. 
Moreover, as drug transporters such as ABCB1 are not only present in typical drug 
processing organs but also in the tumor itself, prediction of the effect of a genetic variant 
may also require characterization at the tumor level. Alternatively, a poor predictive profile 
may facilitate identification of patients for whom alternative treatment, once it is available, 
is preferred. 
 In conclusion, we have contributed to the evidence for a role of ABCB1 variants in the 
response to cisplatin and doxorubicin-based chemotherapy, and have revealed novel 
associations of other transporters not known to be directly related to the chemotherapeutics 
used in the treatment of osteosarcoma. Together with the genetic variants previously 
identified in our pathway-based study, the associations of the present study warrant 
further confirmation in homogeneous large cohorts, and functional validation to provide 
additional evidence and increase our understanding of the treatment response in 
osteosarcoma. In the future, a set of validated markers might provide a useful tool for 
upfront risk stratification of patients with osteosarcoma to eventually optimize current 
therapy.
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Supplementary data
Table S1. Demographic data of eligible patients for PFS analysis in the discovery and validation cohorts.
Discoverya Validationb
Dutch cohort I 
(N=118)
Dutch cohort II 
(N=165)
Spanish cohort 
(N=95)
English cohort 
(N=51)
Age at diagnosis, median (range) 15.6 (5.6-41.1) 17.1 (3.4-45.8) 14.0 (1.9-34.6) 17.0 (10.0-39.0)
Male gender, n (%) 64 (54.2%) 93 (56.4%) 53 (55.8%) 29 (56.9%)
Axial tumor, n (%) 5 (4.2%) 7 (4.2%) 2 (2.1%) 3 (5.9%)
Primary metastases, n (%) 22 (18.6%) 24 (14.5%) 17 (17.9%) 6 (11.8%)
MTX total, n (%) 77 (65.3%) 76 (46.1%) 84 (95.5%) 51 (100%)
MTX neoadjuvant, n (%) 65 (55.1%) 70 (42.4%) 30 (35.3%) 50 (100%)
Poor histologic response, n (%) 80 (69.6%) 75 (48.7%) 49 (55.1%) 11 (22.0%)
5-year PFS 60.5% 60.8% 58.2% 74.5%
5-year OS 73.6% 75.4% 83.6% 88.2%
MTX, methotrexate; PFS, progression-free survival; OS, overall survival.
a  Dutch cohorts I and II significantly differed regarding age at diagnosis (P=0.049), MTX treatment total 
(P=0.001) and neoadjuvant (P=0.036), and poor histologic response (P=0.001).
b  Ethnicities English cohort: Caucasian N=36 (70.6%), Afro-Caribbean N=8 (15.7%), Indian/Asian 
N=7 (13.3%); Spanish cohort: Caucasian N=90 (94.7%), Latin American N=4 (4.2%), Romani 
N=1 (1.1%).
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Table S2. Complete association analysis results of histological response in the Dutch cohorts.
Dutch cohort I Dutch cohort II Meta-analysis Dutch cohorts
SNP Gene Chr Minor allele OR 95% CI P OR 95% CI P OR 95% CI P
rs717620 ABCC2 10 T 0.66 0.33-1.33 0.243 0.36 0.19-0.68 0.002 0.47 0.30-0.76 0.002
rs9381468 SLC25A27 6 T 2.13 1.17-3.87 0.013 1.55 0.98-2.46 0.064 1.75 1.21-2.52 0.003
rs2884737 VKORC1 16 G 0.53 0.27-1.04 0.064 0.60 0.36-1.00 0.049 0.57 0.38-0.86 0.007
rs8050894 VKORC1 16 C 0.60 0.33-1.09 0.093 0.60 0.37-0.98 0.041 0.60 0.41-0.88 0.008
rs246221 ABCC1 16 C 2.18 1.05-4.53 0.038 1.46 0.88-2.43 0.147 1.66 1.09-2.52 0.017
rs2301157 SLC10A2 13 T 0.70 0.38-1.31 0.264 0.61 0.38-0.97 0.037 0.64 0.44-0.93 0.019
rs9934438 VKORC1 16 T 0.64 0.35-1.15 0.135 0.64 0.39-1.04 0.073 0.64 0.44-0.93 0.020
rs11572080 CYP2C8 10 A 0.43 0.17-1.06 0.066 0.53 0.19-1.46 0.219 0.47 0.24-0.92 0.028
rs2295475 XDH 2 T 0.72 0.39-1.32 0.292 0.62 0.38-1.00 0.050 0.66 0.45-0.96 0.029
rs17708472 VKORC1 16 T 1.68 0.79-3.59 0.179 1.69 0.92-3.11 0.090 1.69 1.05-2.72 0.030
rs1801265 DPYD 1 C 0.78 0.41-1.49 0.454 0.57 0.34-0.96 0.034 0.65 0.43-0.97 0.034
rs2860840 CYP2C18 10 T 0.51 0.27-0.97 0.042 0.78 0.48-1.27 0.315 0.67 0.45-0.99 0.042
rs2020861 FMO2 1 G 1.93 1.03-3.60 0.041 1.27 0.81-1.97 0.299 1.46 1.01-2.09 0.042
rs3740066 ABCC2 10 T 0.83 0.44-1.54 0.550 0.61 0.38-0.98 0.040 0.68 0.47-0.99 0.046
rs1442477 ADH7 4 A 0.38 0.05-2.97 0.353 0.24 0.05-1.16 0.075 0.28 0.08-0.99 0.048
Chr, chromosome; OR, odds ratio; 95% CI, 95% confidence interval.
OR is given for a poor histologic response; OR and 95% CI are reported for the minor allele, an OR<1 
indicates a protective effect of the minor allele and risk of poor histologic response for the major allele. 
All reported results are adjusted for neoadjuvant treatment with MTX.
Figure S1. Five-year PFS of all patients included in the study for discovery (Dutch cohorts) and validation 
(English and Spanish cohorts).
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7Abstract
Despite (neo)adjuvant chemotherapy in primary osteosarcoma or first-line chemotherapy 
in patients presenting with metastatic disease, some patients progress already during 
first-line systemic treatment and thus have a very poor prognosis. Here we investigated 
whether patients with an inadequate response to treatment have a distinctive 
pharmacogenetic profile, by applying a large scale screening including 1,936 genetic 
markers in 231 drug metabolism and transporter genes.
 Germline DNA from 287 Dutch high-grade osteosarcoma patients treated with cisplatin 
and doxorubicin-based chemotherapy was genotyped using the DMET Plus array. 
Associations between genetic variants and progressive disease (primary tumor and/or 
metastasis growth or formation up to 3 months after end of adjuvant chemotherapy or 
first-line treatment in case of primary metastatic disease; and/or inadequacy to reach 
complete remission at the end of therapy for primary localized or primary metastatic 
osteosarcoma) were assessed using logistic regression models. Genetic variants 
significantly associated with progressive disease were validated in an independent 
cohort of 146 patients from Spain and England, followed by a second validation using a 
cohort of 28 patients from Australia.
 In multivariable association analyses of genetic variants and progressive disease, 
adjusted for the presence of primary metastases, sex and age at diagnosis, 10 genetic 
variants in 6 genes were uniquely associated (P<0.05) with progressive disease. Of 
these variants, SLC7A8 rs1884545 was independently validated, and showed increased 
significance in meta-analysis of all cohorts combined (OR 0.22 [0.07-0.63], P=0.005). 
Three other variants, CYP8B1 rs6771233, SLC22A2 rs316003, and SLC22A5 rs274548, 
were also significantly associated in meta-analysis of all cohorts. 
We have identified genetic variants specifically associated with an inadequate drug 
response, defined as progressive disease, in patients with osteosarcoma. This analysis 
represents the first step towards identifying patients for whom chemotherapeutic 
treatment is ineffective and should be further explored in additional patient cohorts.
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Introduction 
Osteosarcoma is a malignant bone tumor that mainly affects children and adolescents. 
Although the number of people affected by osteosarcoma is low (worldwide 3-4 patients 
per million), the disease is ranked as one of the most frequent causes of cancer related 
death in young patients [1]. The disease has a great impact on the patient’s life, as 
treatment requires an intensive combination of chemotherapy, often disabling surgery, 
and prolonged periods of rehabilitation. Despite this harsh treatment regimen, some 
patients fail to respond to the treatment showing no response or even tumor growth 
during primary treatment. Already for decades the backbone of chemotherapy in the first-
line treatment of osteosarcoma consist of a combination containing at least cisplatin and 
doxorubicin. However, these inadequately responding patients underscore the need for 
alternative medical treatment options at presentation. Several trials, mainly focusing on 
osteosarcoma patients with recurrent disease, have indicated that a number of patients 
(10-45%) show an objective response to second line treatment [2-7]. In addition, although 
few, new drugs are in the pipeline with promising results for clinical implementation 
for patients with progressive or recurrent disease. Recognition of patients that do not 
benefit from current chemotherapy schedules at an early phase in treatment is therefore 
important. 
 Although the genetics and biology of the tumor are likely to contribute to the 
heterogeneous response to treatment, we postulate that germline variants in drug 
metabolizing enzymes or transporters may also contribute to this observed heterogeneity. 
Pharmacogenetics holds the promise to discover germline genetic variants predictive 
of the drug response in individual patients. Most studies aimed at identifying germline 
genetic variants predictive of treatment outcome in osteosarcoma have used survival as 
the main clinical endpoint. However, patients with progressive disease, who may have a 
distinctive pharmacogenetic profile, have not been widely considered as a subgroup. The 
few studies comparing patients showing a good clinical response (complete and partial 
responders) to patients with a poor response (stable or progressive disease) investigated 
only a few candidate genes involved in DNA repair (CCNH, ERCC1/2/5/6, MMS19L and 
XPC) and GSTP1, a gene involved in detoxification of exogenous and endogenous 
compounds [8-12]. Significant associations of genetic variants in ERCC2/5, MMS19L, 
XPG and GSTP1 with clinical response have been identified. However, validation in 
additional samples is necessary to confirm these associations, because the results 
presented are often conflicting [10-12], and a more comprehensive screening of genetic 
variants involved in drug metabolism and transport is warranted.
Pharmacogenetics of progressive osteosarcoma
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 Therefore, we have performed a large scale screening of 1,936 genetic variants in 231 
drug metabolism and transporter genes in a large group of osteosarcoma patients aimed 
at discovering a relation to an inadequate drug response during first treatment, followed 
by validation in independent cohorts of patients.
Materials and methods
Patient cohorts
A discovery cohort of 287 osteosarcoma patients was retrospectively collected at 
the Radboud university medical center (Nijmegen), the University Medical Center 
of Groningen (Groningen), Leiden University Medical Center (Leiden) and the Emma 
Children’s Hospital/Academic Medical Center (Amsterdam), The Netherlands. All patients 
were treated between 1978 and 2013 and the clinical data was retrospectively collected 
from medical records. Eligibility criteria were: histological diagnosis of primary high-
grade osteosarcoma with or without metastatic disease, age ≤45 years, treatment with 
cisplatin and doxorubicin-based chemotherapy (also neoadjuvant), and self-reported 
Caucasian ethnicity. Patients were treated either according to institutional standard 
therapy consisting of cisplatin (maximum cumulative dose 600 mg/m2) and doxorubicin 
(maximum cumulative dose 450 mg/m2), or according to the standard schedule as given 
in the EURAMOS-1 trial, which consisted of cisplatin (480 mg/m2)/ doxorubicin (450 mg/
m2) and additionally high-dose methotrexate (MTX; 144 g/m2), with or without additional 
ifosfamide/etoposide or interferon-α [13]. The study was approved by the Institutional 
review board of the Radboud university medical center, and approval for inclusion 
of patients in other institutions was obtained from institutional ethics committees. All 
patients and/or parents provided written informed consent.
 A combined cohort of 146 high-grade osteosarcoma patients treated with cisplatin and 
doxorubicin-based chemotherapy from Spain (N=95) and England (N=51) was used for 
independent validation of the positive findings in the discovery cohort [14,15]. Information 
on treatment has been reported previously [14,15]. In a second validation phase, a cohort 
of 28 high-grade osteosarcoma patients, treated with cisplatin and doxorubicin-based 
chemotherapy from Australia (Sydney Children’s Tumour Bank Network), was included. 
Patients were treated with a cisplatin cumulative dose of 480 mg/m2 or 600 mg/m2 and 
doxorubicin cumulative dose of 450 mg/m2. The same inclusion criteria as used in the 
discovery cohort were applied, with the exception of ethnicity. The study was approved 
by the local ethics committees of these validation cohorts and written informed consent 
was obtained from parents and/or patients. 
Response definition
The clinical (radiological) response to the treatment was based on imaging results (CT/
MRI/X-ray) reviewed by local expert radiologists. An initial inadequate drug response 
was operationalized as progressive disease. This was defined as: (1) growth of the 
primary tumor (>20%) and/or metastases (>20%), or development of new lesions, in the 
time from start of primary treatment until 3 months after end of adjuvant chemotherapy 
or end of first-line treatment in case of primary metastatic disease, and/or (2) inadequacy 
to reach complete remission at the end of (surgical and chemotherapeutic) therapy for 
primary localized or primary metastatic osteosarcoma. The opposite extremes, patients 
showing an adequate drug response with no signs of relapse were considered controls. 
Thus patients with recurrent disease, defined as local or distant relapse from 3 months 
after end of primary treatment to end of follow-up, were excluded from the analysis.
Genotyping methods
For the discovery cohort, germline DNA was isolated from blood using the QIAamp DNA 
Blood Midi kit (Qiagen, Venlo, The Netherlands), or from saliva using the Oragene saliva 
collection kit (DNA Genotek, Kanata, Ontario, Canada) according to the manufacturer’s 
protocols. From patients who had died before inclusion in this pharmacogenetic study, DNA 
was isolated from normal formalin-fixed, paraffin-embedded (FFPE) tissue as described 
previously [16,17]. The DNA samples were genotyped for 1,936 genetic variants using 
the Affymetrix DMET Plus array according to the manufacturer’s instructions (Affymetrix 
UK Ltd, High Wycombe, UK). All samples were normalized to 60 ng/μL based on 
NanoDrop measurements (NanoDrop 2000; Thermo Scientific, Breda, The Netherlands). 
Genotypes were calculated with DMET console software 1.3 using the Dynamic Genotype 
Boundaries version 2 algorithm. Variants were excluded from analysis if the genotype 
cluster plots were considered unreliable, being plots with genotype calling showing 
merged clusters without distinct cluster boundaries. Additional stringent evaluation of the 
genotype clustering in combination with expected genotype frequencies was carried out 
for variants significant in association analysis. Quality control was carried out on the total 
cohort of 316 genotyped patients. Samples and variants were excluded if call rates <0.9, 
minor allele frequency (MAF) <0.01 and/or deviating from Hardy-Weinberg equilibrium 
(HWE) (P-value <0.0001). The five copy number variants, 46 X-chromosomal variants 
and one tri-allelic variant present on the array were not included in the analyses. 
 Isolation of germline DNA in the validation cohort has been previously reported 
[14,15]; from the Australian validation cohort germline DNA was isolated from blood using 
the QIAamp DNA Blood Mini kit (Qiagen) according to the manufacturer’s instructions. 
Genotyping of the validation cohort was performed for six of the ten variants that 
showed significance in the discovery cohort, excluding four variants that were in linkage 
disequilibrium (based on r2≥0.8) with any of the six variants and that had higher P-values 
Pharmacogenetics of progressive osteosarcoma
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than their linked variants. Genotyping of the second validation cohort was subsequently 
performed for the four variants that were significant in the first validation stage and that 
showed the same direction of effect in the discovery and validation cohorts. KASP-On-
Demand (KOD) assays were used for CYP4F12 rs688755, SLC22A5 rs274548, and 
FMO6 rs7886938; KASP-By-Design (KBD) assays were used for CYP8B1 rs6771233, 
SLC22A2 rs316003, and SLC7A8 rs1884545, all according to the manufacturer’s 
protocol (LGC Genomics, Hoddesdon, UK). Fluorescence was measured with a 
7500FAST Real-Time PCR System (ThermoFisher, Nieuwegein, The Netherlands). 
Genotypes were scored using the algorithm and software (v2.0.6) supplied by 
ThermoFisher. Blanks (3%) as well as duplicates between plates were included as quality 
controls for genotyping.
Statistical analysis
Statistical differences in demographic data between patients with progressive disease 
and control patients were assessed by the Fisher exact, Pearson chi-square or Mann-
Whitney U tests as appropriate using SPSS v22 (SPSS Inc., Chicago, Ill, USA). To 
assess the effect of a genetic variant on occurrence of progressive disease, the data was 
dichotomized to progression yes/no (yes: patients with progressive disease; no: control 
patients). Associations between genetic variants and the occurrence of progressive 
disease were assessed by multivariable logistic regression analysis in PLINK using the 
command --logistic (additive model) (PLINK v1.07) [18]. For the genetic variants that 
were significantly associated with progressive disease in the discovery cohort, we also 
assessed potential associations with two other clinical endpoints: recurrent disease 
(using PLINK), and 5-year disease free survival (DFS) (time interval from diagnosis 
to either progression or recurrence) using Cox proportional hazards models in SPSS. 
These variants were excluded from subsequent analysis, to filter out those variants that 
were not specific for the inadequate drug response observed in progressive patients. 
Reported P-values are two-sided and are considered statistically significant if <0.05 in 
the genetic analyses (<0.1 for selection of clinical covariables). No correction for multiple 
testing was performed because of the exploratory nature of the study. Meta-analysis of 
the association analysis results of the discovery and validation cohorts, and of all three 
cohorts including the second validation cohort, was performed using a fixed effects or 
random effects (in case of large heterogeneity: I2>50) model in PLINK.
 To investigate whether the variants associated with progressive disease are also 
related to 5-year overall survival (OS) (as patients with progressive disease are generally 
expected to die), we assessed the effect of a combination of genetic variants on the 
5-year OS, by calculation of a genetic risk score as previously described [19]. The score 
is the sum of the number of unfavorable alleles (i.e. alleles inducing risk of progressive 
disease) carried by each patient for each of the variants significantly associated with 
progressive disease in the meta-analyses. The influence of the risk score on 5-year OS 
was visualized using Kaplan-Meier survival curves.
Results
Patient population
The study was carried out following a three-stage design, including a discovery cohort, 
an independent validation cohort and an independent second validation cohort. Of the 
287 eligible patients in the discovery cohort, four patients were excluded based on a 
genotype call rate lower than 0.9, leaving 283 patients for analysis. From the validation 
cohort, all 146 patients were successfully genotyped; from the second validation cohort, 
one of the 28 patients was excluded based on genotyping failure for all variants, leaving 
27 patients for analysis. The patient characteristics of the three cohorts are provided in 
Table 1. Progressive disease was observed in 13.8%, 12.3% and 18.5% of patients in the 
discovery cohort, validation cohort, and second validation cohort, respectively.
 In the discovery cohort, of all clinical variables included in Table 1, higher age at 
diagnosis (P=0.058), male gender (P=0.003), the presence of primary metastases 
(P<0.001), and poor histologic response (P<0.001) were significantly associated with the 
occurrence of progressive disease and were therefore included as clinical covariables 
in the genetic analyses, with the exception of the histologic response. As the histologic 
response and progression are both a reflection of the response to chemotherapy, 
inclusion of the histologic response as covariable would unintentionally remove variation 
between progressive and control patients and would therefore result in overcorrection. 
 In the discovery cohort, 11 (28.2%) of 39 patients with progressive disease survived 
despite progression; nine of these patients had a follow-up of >5 years. Seven of these 
patients were classified as progressive because of progression of the primary tumor, 
which was in all cases followed by interruption of chemotherapy and early invasive 
surgery. The other four patients showed progression of metastases (N=3), or progression 
of both of the primary tumor and metastases (N=1); in three of these cases surgical 
removal of the metastatic lesions has been reported. In the validation cohort, six (all with 
follow-up of >5 years) of 18 patients survived progression of the primary tumor (N=1), 
metastases (N=3), local recurrence (N=1) or unknown (N=1). In the second validation 
cohort, two of five patients survived progression either in the form of local recurrence 
(follow-up <1 year) or metastases. 
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Table 1. Clinical characteristics of osteosarcoma patients of the discovery and validation cohorts.
Discovery cohort Validation cohort Second validation cohort
Progression 
(N=39)
Controls 
(N=168)
Progression 
(N=18)
Controls 
(N=93)
Progression 
(N=5)
Controls 
(N=19)
Age at diagnosis, median (range) 17.2 (6.8-44.7) 15.2 (3.4-45.8) 15.4 (1.9-37.0) 15.0 (6.1-39.0) 15.3 (8.7-16.8) 14.2 (1.1-16.3)
Male gender, n (%) 29 (74.4%) 81 (48.2%) 11 (61.1%) 47 (50.5%) 4 (80.0%) 7 (36.8%)
Axial tumor, n (%) 4 (10.3%) 5 (2.98%) 1 (5.6%) 2 (2.2%) 1 (20.0%) 0 (0%)
Primary metastases, n (%) 16 (41.0%) 16 (9.52%) 9 (50.0%) 8 (8.6%) 3 (60.0%) 1 (5.3%)
Cumulative dose (mg/m2)
Cisplatin, median (range)
Doxorubicin, median (range)
400 (100-600)
375 (75-450)
480 (0-720)
450 (150-455)
354 (175-1,064)
242 (143-950)
474 (0-1,038)
385 (90-623)
480 (480-600)
450 (450-450)
480 (480-600)
450 (450-450)
MTX treatmenta, n (%) 27 (69.2%) 90 (53.6%) 16 (100%) 86 (96.6%) 5 (100%) 15 (78.9%)
Poor histologic responseb, n (%) 28 (82.4%) 79 (49.4%) 10 (62.5%) 37 (41.6%) 4 (100%) 4 (44.4%)
5-year overall survival 26.8% 100% 33.3% 98.9% 30.0% 100%
MTX, methotrexate.
Patients with recurrent disease are not included in the table: discovery cohort N=76, validation cohort 
N=35, second validation cohort N=3.
a  Number of patients with MTX treatment data available; discovery cohort: all patients; validation cohort: 
progression N=16, controls N= 89; second validation cohort: progression N=5, controls N=19.
b  Number of patients with histologic response data available; discovery cohort: progression N=34, 
controls N=160; validation cohort: progression N=16, controls N=89; second validation cohort: 
progression N=4, recurrence N=2, controls N= 9.
Association analyses in the discovery cohort
Of the 1,884 variants included in the quality control, 90 variants were excluded based 
on unreliable clusterplots, 28 variants were excluded because of genotype call rates of 
<0.9 and 1,056 variants because of a MAF of <0.01. All remaining variants were in HWE. 
After quality control, 710 variants were included in the analysis of the discovery cohort. In 
multivariable logistic regression analysis comparing patients with progressive disease to 
control patients including sex, age at diagnosis, and the presence of primary metastases 
as covariables, 11 genetic variants were significantly associated with progressive 
disease, after filtering of variants also associated with recurrent disease or 5-year DFS. 
The genotype clusterplot of one of these variants, CYP2B6 rs2279341, was considered 
unreliable after additional stringent evaluation of the clustering combined with expected 
genotype frequencies, leading to 10 remaining variants in 6 genes (Table 2). 
Table 2. Association analysis results for the discovery cohort.
SNP Gene Chromosome Minor allele MAF OR 95% CI P-value
rs1884545 SLC7A8 14 T 0.127 0.22 0.06-0.78 0.019
rs8013529 SLC7A8 14 C 0.128 0.23 0.06-0.81 0.023
rs6771233 CYP8B1 3 A 0.332 1.95 1.08-3.54 0.027
rs6774801 CYP8B1 3 A 0.330 1.95 1.08-3.54 0.027
rs688755 CYP4F12 19 C 0.228 2.06 1.07-3.98 0.031
rs593421 CYP4F12 19 C 0.221 2.02 1.06-3.84 0.033
rs7886938 FMO6 1 A 0.170 2.14 1.06-4.32 0.033
rs7889839 FMO6 1 G 0.170 2.14 1.06-4.32 0.033
rs316003 SLC22A2 6 G 0.205 0.44 0.20-0.97 0.042
rs274548 SLC22A5 5 T 0.146 2.13 1.01-4.48 0.048
MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confidence interval.
OR and 95% CI are reported for the minor allele, an OR<1 indicates a protective effect of the minor 
allele and risk of progression for the major allele.
Variants within CYP4F12, CYP8B1, FMO6, and SLC7A8 are in linkage disequilibrium with r2>0.8.
Validation results
In the validation cohort, six variants were investigated based on the results of the 
discovery cohort. All variants were in HWE (P>0.05) and showed an average call rate 
of 0.98. Upon multivariable logistic regression analysis of the validation cohort similar 
to the discovery cohort, one of the six genetic variants showed a significant association 
with progressive disease (Table 3). For this variant, rs1884545 located in the Solute 
Carrier Family 7 (Amino Acid Transporter Light Chain, L System) Member 8 (SLC7A8) 
gene, a protective effect was observed for patients carrying the T allele (P=0.020). The 
effect remained significant with addition of inclusion site (Spain or England) as covariable 
(P=0.018). 
Meta-analysis
In a meta-analysis of the association analysis results of the six variants genotyped in 
both the discovery and validation cohort, the independently validated SLC7A8 rs1884545 
variant showed a significant protective effect in patients with progressive disease with 
an odds ratio (OR) of 0.16 (95% confidence interval 0.05-0.50) (Table 3). In both the 
discovery and validation cohorts, none of the patients with progressive disease were 
homozygous for the T allele, whereas in the control groups of the discovery and 
validation cohort, 1.2% and 2.2% of patients were homozygous, respectively. In addition, 
a substantially lower percentage of patients were heterozygous in the progressive group 
141140
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(7.7% in discovery and 5.6% in validation) compared to the control patients (25.0% and 
24.2%). In addition to the SLC7A8 variant, three other variants (CYP8B1 rs6771233, 
SLC22A2 rs316003, SLC22A5 rs274548) were significantly associated with progressive 
disease in the meta-analysis, showing a stronger association compared to the results of 
the discovery or validation cohort alone. 
 On the basis of the meta-analysis results of the discovery and validation cohort, 
four variants were investigated in a second validation cohort, including 27 additional 
patients. In a meta-analysis including all samples investigated, a significant association 
of SLC7A8 rs1884545 with an OR of 0.22 (0.07-0.63) was observed, corresponding to an 
approximately four to five-fold protective effect, although the association did not become 
stronger compared to the meta-analysis without these additional 27 patients (Table 
3). The other three variants, SLC22A5 rs274548, CYP8B1 rs6771233, and SLC22A2 
rs316003, remained significantly associated with progressive disease, with the latter two 
showing a stronger association. 
 After calculation of a genetic risk score based on the four variants associated with 
progressive disease, a decreasing 5-year OS was observed with an increasing genetic 
risk score (Figure 1). The 5-year OS curves for each individual variant associated 
with progressive disease did not reflect a difference in OS between the genotypes 
(Supplementary Figure S1). However, based on the observation of a combined effect of 
the four variants, we constructed the genetic risk scores starting with the two variants 
(rs274547 and rs316003) showing some divergence of the survival curves. The group 
with the highest genetic risk score combining the effect of the three variants rs274548, 
rs316003 and rs6771233, revealed the lowest OS, comparable to the highest genetic risk 
score group combining all four variants, indicating that these three are the variants that 
contribute to OS.
Table 3. Association analysis results validation cohort and meta-analyses.
Validation Second validation
Validation cohort Meta-analysis Meta-analysis overall
SNP Gene Chromosome Minor 
allele
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
rs1884545 SLC7A8 14 T 0.05 0.005-0.63 0.020 0.16 0.05-0.50 0.002 0.22 0.07-0.63 0.005
rs6771233 CYP8B1 3 A 1.70 0.78-3.72 0.184 1.86 1.16-2.98 0.010 1.91 1.20-3.05 0.006
rs316003 SLC22A2 6 G 0.58 0.20-1.69 0.318 0.48 0.25-0.92 0.026 0.49 0.26-0.91 0.023
rs274548 SLC22A5 5 T 1.75 0.59-5.18 0.311 2.00 1.08-3.69 0.027 1.94 1.08-3.52 0.028
rs7886938 FMO6 1 A 0.83 0.22-3.17 0.788 1.75 0.94-3.25 0.078 NA NA NA
rs688755* CYP4F12 19 C 0.73 0.29-1.83 0.499 1.29 0.47-3.57 0.623 NA NA NA
OR, odds ratio; 95% CI, 95% confidence interval; NA, not analyzed.
OR and 95% CI are reported for the minor allele, i.e. an OR<1 indicates risk of progression for the major 
allele.
*I2>50.
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Figure 1. Kaplan-Meier survival curves based on the genetic risk score of the genetic variants associated 
with progressive disease. Curves of the 5-year overall survival are depicted, based on the genetic risk 
score of (A) all four genetic variants significant in the meta-analysis, (B) two of four variants, rs274548 
and rs316003, (C) three of four variants, rs274548, rs316003, and rs6771233, (D) three of four variants, 
rs274548, rs316003, and the independently validated variant rs1884545.
A
C
B
D
Discussion
Progressive disease occurs in osteosarcoma when there is failure of response to 
standard chemotherapy. The background of this lack of response is poorly understood. 
As non-response to chemotherapeutic treatment might be explained by genetic variations 
in genes encoding metabolizing enzymes and drug transporters, a pharmacogenetic 
approach could provide important insight in the underlying molecular mechanisms. 
Therefore, we performed an exploratory study and provide evidence that specific genetic 
variants involved in drug metabolism and transport are specifically and only associated 
with progressive disease. We identified four genetic variants associated with progressive 
disease, of which one variant in SLC7A8 was confirmed in an independent validation 
cohort. In addition, three variants in other genes showed the same direction of effect in 
the discovery and validation cohorts and were significantly associated in meta-analyses. 
 Until now, a few studies have examined a small number of candidate genes involved 
in cisplatin pharmacology for association with poor response (defined as stable or 
progressive disease) in small osteosarcoma cohorts [8-12]. The approach of the present 
study is slightly different with respect to the grouping of patients, as we focus on the 
subgroup of patients that do not show an adequate response to standard treatment for 
osteosarcoma. This subgroup, referred to as patients with progressive disease, includes 
patients with disease progression under treatment or the lack of complete remission 
(including partial response or stable disease). This is a slightly broader subgroup than 
progressive patients according to the RECIST criteria, to include all patients showing an 
inadequate drug response [20]. To ensure identification of genetic variants specific for 
this subgroup of patients, we analyzed whether the variants associated with progressive 
disease could also be linked to the patient group that was initially disease free after 
treatment, but experienced recurrent disease later on. One can imagine that the same 
genes or mechanisms, to varying extents, could play a role in both progressive and 
recurrent disease. For the same reason, we excluded variants significantly associated 
with 5-year DFS. 
 The present study is the first large scale study investigating a wide range of genes 
involved in drug metabolism and transport in relation to progressive disease. The top 
associated variant is located in the SLC7A8 gene that encodes an amino acid transporter 
present in the basolateral membrane of the proximal tubule in the kidney, as well as in 
the colon and intestine [21]. Ovarian cancer cells resistant to treatment including cisplatin 
and doxorubicin showed reduced expression of SLC7A8 [22]. In addition, two other 
genetic variants in this gene that are not in LD with the rs1884545 variant have been 
linked to outcome after platinum-based therapy in esophageal cancer [23]. For both the 
synonymous rs1884545 variant and the linked rs8013529 variant, the functional effect is 
unknown; it is possible that another linked variant in close proximity is the causal variant.
145144
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Notably, two other genes (SLC22A2, Solute carrier family 22 member 2 and SLC22A5, 
Solute carrier family 22 member 5) of the four identified genes also encode transporters 
that function in the kidneys. SLC22A2 is implicated in the transport of cisplatin in tubular 
cells. A genetic variant in the gene (rs316019, not in LD with rs316003) has been linked 
to cisplatin induced nephrotoxicity [24-26]. SLC22A5 is involved in the reabsorption 
of carnitine by the proximal tubular cells. Studies have indicated that cisplatin inhibits 
SLC22A5 functioning also leading to nephrotoxicity [27,28]. Unfortunately, we could not 
further investigate the relation between the identified variants in SCL22A2 and SLC22A5 
and nephrotoxicity, as the availability of information on the adverse drug event in our study 
cohort was only limited. The fourth identified gene (CYP8B1, Cytochrome P450 8B1) is 
expressed in hepatocytes and is involved in bile acid production and glucose homeostasis 
[29]. Thus far, no clear connection between this gene and chemotherapy treatment has 
been reported. The SLC22A5 rs274548 variant was significantly associated with 5-year 
progression-free survival in a previous DMET analysis of our group [30]; however, the 
association was not significant in the present study involving similar analysis (of DFS), 
probably due to differences including analysis in the combined Dutch cohort rather than 
meta-analysis of two individual cohorts, and inclusion of multiple clinical covariables in 
addition to metastases at diagnosis in the present study.
 Our data indicate that the link between progressive disease and overall survival is not 
complete. Although we acknowledge that overall survival is not a pure pharmacogenetic 
endpoint, especially the top hit SLC7A8 rs1884545 did not contribute to prediction of 
overall survival, suggesting that progressive disease and overall survival are different 
disease outcome entities. This is reflected by the observation that not all patients with 
progressive disease died. However, the survival curves of the genetic risk score of the 
other three variants suggested a cumulative contribution to overall survival which is not 
reflected in the survival curves of the individual variants.  
 We have studied the largest osteosarcoma cohort for pharmacogenetic research 
regarding progressive disease to date and are the first to include independent validation 
cohorts. Nevertheless, the patient numbers are still relatively low for genetic association 
studies and the number of patients with progressive disease is rather low, which is 
in line with the low incidence of the disease and of disease progression. Therefore, 
we consider the current study as an important but first step into the pharmacogenetic 
background of an inadequate drug response in patients with osteosarcoma. As we have 
retrospectively included patients diagnosed over the past decades, during which imaging 
techniques have improved, it is possible that we have missed some cases of progressive 
disease in patients diagnosed in the early years. In addition, the discovery cohort was 
heterogeneous regarding treatment protocols. A proportion of the patients received two 
drugs (doxorubicin and cisplatin), whereas other patients also received other drugs 
in addition to cisplatin and doxorubicin (mostly only MTX), which could give a more 
favorable outcome. However, there was no significant effect of the presence of MTX in 
the treatment regimen on progressive disease in our cohort, which makes it likely that the 
influence of the differences in treatment regimens on the results is limited. Furthermore, 
because we studied germline variants, we could have missed tumor-specific mutations in 
genes involved in the uptake of the chemotherapeutic drugs, although studies on genetic 
variants in genes involved in drug metabolism and transport showed high concordance 
between DNA derived from tumor and blood or saliva [31]. In addition, the tumor genetic 
background is also likely to define the intrinsic response to chemotherapy [32].
 The goal of identifying pharmacogenetic variants involved in progressive disease 
is to enable upfront identification of the subgroup of patients showing a very poor 
response to treatment with conventional chemotherapy. The variants identified in the 
present study are as single variants not yet discriminative for implementation in the 
clinical setting, but in the future a combination of these germline variants with tumor 
intrinsic (genetic) factors could be used to draw a predictive profile for each patient. 
After upfront identification of patients, other treatment options could be considered which 
have shown beneficial effects in clinical trials including mostly progressive patients, e.g. 
45% 6-months progression free survival with sorafenib and mTOR inhibitor everolimus 
[7]. Other second-line treatments could also be considered as first-line treatment for this 
subgroup of patients [2-6]. In addition to such a clinical implementation, these genetic 
association studies are important to gain more insight into the mechanisms of action of 
the drugs investigated. This is illustrated by the outcome of the present study in which 
three of the four genes are implicated in the transport of cisplatin. In addition, these 
results may provide new leads for development of agents to modulate the response to 
chemotherapy.
 From the patient’s perspective, it will be important to identify the patients at risk of 
a poor response to chemotherapy. This study illustrates that it is indeed possible to 
distinguish this patient group from good responders, as we identified pharmacogenetic 
variants specifically associated with progressive disease in patients with osteosarcoma. 
Ultimately, clinical implementation of a validated (genetic) risk profile may enable 
treatment strategies specifically targeting this subgroup of patients.
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Chapter 8
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8Scope and aim of thesis
The treatment of osteosarcoma poses a major burden to patients because of the 
combination of often disabling surgery and toxic chemotherapy with the risk of serious 
long-term side effects. At diagnosis, the patient’s response to chemotherapy with regard 
to efficacy and toxicity, is largely unknown and is predominantly a matter of close 
monitoring during and after therapy, as large variation exists between patients’ drug 
responses. Drug response is a complex trait and the increasing knowledge of genetics 
has led to the understanding that genetic factors also contribute to variation in drug 
response. In cancer, both the somatic and germline genome are relevant for treatment 
outcome [1]. Whereas the somatic genome has been a major focus area in research to 
understand therapy resistance and efficacy, the germline genome can also be highly 
relevant for treatment efficacy and toxicity through involvement in drug exposure and 
drug effects. The science of pharmacogenetics aims to facilitate personalized medicine 
by concentrating on the influence of heritable genetic variation on drug response, with 
the purpose to predict drug efficacy or toxicity at diagnosis using genetic biomarkers. 
In addition, it can increase the understanding of the interindividual variation in drug 
response, and provide new therapeutic targets. The aim of this thesis was to gain 
insight into the germline genetic factors underlying chemotherapy efficacy and toxicity in 
patients with osteosarcoma. This could ultimately contribute to more effective treatment 
and prevention of undesired side effects. We have focused on validation of genetic 
associations reported in literature by ourselves and others as well as on discovery of 
novel associations. In this final chapter, the findings of the research presented in this 
thesis are discussed, followed by a discussion of the studies’ strengths and limitations, 
and a future perspective on further research and the clinical setting.
Main findings
For pharmacogenetic analysis of Dutch osteosarcoma patients as presented in this 
thesis, we retrospectively recruited patients diagnosed from as early as 1975 up to 
2013. As a proportion of these patients was not alive at the time of inclusion, from these 
patients the only available source of germline DNA was normal formalin-fixed, paraffin-
embedded (FFPE) tissue that had been archived for many years. In chapter 2, we have 
validated the use of germline DNA isolated from normal FFPE tissue for genotyping 
with the Drug Metabolizing Enzymes and Transporters (DMET) Plus array, by comparing 
genotypes obtained with blood or saliva-derived DNA with those of normal FFPE tissue-
derived DNA from sixteen alive osteosarcoma patients. We have been the first to report 
that DNA isolated from archived normal FFPE tissue samples can be reliably used as 
152
a template for the DMET Plus array. This finding was an essential technical validation 
step for our subsequent pharmacogenetic studies using this platform. Moreover, it adds 
to the existing literature on the suitability for the use of DNA from FFPE tissue samples 
with a variety of genotyping technologies [2-5], which unlocks the opportunity to access 
genetic information of large retrospective series of samples for use in pharmacogenetic 
studies. This is especially valuable for establishing unbiased and well-powered cohorts in 
retrospective studies of cancers with low incidence and survival, as prospective sample 
collection within clinical trials, which has become more routine, will take years to establish 
large cohorts of rare diseases such as osteosarcoma. 
 In the study reported in chapter 3, we have investigated a variant in the ACYP2 
gene, which was identified as a pharmacogenetic marker of cisplatin-induced ototoxicity 
in patients with brain tumors in a recent genome-wide association study (GWAS) by Xu 
et al. Cisplatin-induced ototoxicity is a serious clinical problem with large interpatient 
variability, which cannot be fully explained by clinical or genetic risk factors identified thus 
far. We have been the first to replicate the finding of Xu et al. in an independent cohort 
of 156 cisplatin-treated patients with osteosarcoma. In line with the previous publication, 
all patients carrying the A allele of the genetic variant in the ACYP2 gene presented with 
ototoxicity. We have not only confirmed the association itself but we have also shown 
that it is generalizable among other cancers. Therefore, the genetic variant is of clinical 
relevance and provides essential evidence for the genetic basis of cisplatin-induced 
ototoxicity, which has proven to be difficult to pinpoint in previous pharmacogenetic 
studies. Although the ACYP2 variant should be considered a useful marker for upfront 
identification of patients susceptible to ototoxicity based on our results, the frequency 
of the variant is low. Hence, there is a proportion of patients presenting with ototoxicity 
without having the ACYP2 variant, and thus the variant covers only a part of the variation 
observed in the susceptibility to ototoxicity. 
 Following a previous candidate gene analysis of our group investigating methotrexate 
(MTX) plasma levels and toxicity in a small cohort of osteosarcoma and acute lymphoblastic 
leukemia patients (thesis Melanie Hagleitner [6]), we have further explored the role of 
absorption, distribution, metabolism, and excretion (ADME) genes in MTX-induced 
toxicity using the DMET Plus array in exclusively osteosarcoma patients, as presented in 
chapter 4. We have focused specifically on hepatotoxicity because this can be related 
to MTX but not to the other agents of the osteosarcoma treatment regimen. None of the 
32 genetic variants that were associated with high 48 hour MTX plasma levels, were also 
associated with MTX-induced hepatotoxicity. However, when we focused on the extreme 
cases, i.e. patients with frequent hepatotoxicity (elevated liver enzymes after ≥4 of 12 
MTX courses), we found a protective effect of the GSTM3 rs1799735 (delAGG) variant 
(GSTM3*B) for frequent hepatotoxicity. GSTM3 codes for a glutathione S-transferase, 
an enzyme involved in detoxifying electrophilic xenobiotics, including antitumor agents, 
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by conjugation with glutathione [7]. The GSTM3*B allele, which is suggested to lead to 
increased levels of the GSTM3 enzyme, has not been investigated in previous studies 
into the pharmacogenetics of MTX plasma levels and hepatotoxicity in osteosarcoma 
[8-14]. Interestingly, the same variant has also been reported to protect from cisplatin-
induced ototoxicity in osteosarcoma [15], indicating that the effect of the variant may be 
favorable in the context of toxicities of different drugs included in the treatment protocols 
for osteosarcoma. 
 In chapter 5, we have reported on the confirmation of the role of a genetic risk 
score that we have previously reported, consisting of several pharmacogenetic 
markers associated with the treatment efficacy in osteosarcoma patients [16]. Even in 
the absence of reliable genotypes for the CYP3A4 variant, which was one of the five 
previously identified markers, we were able to reproduce the association of a genetic 
risk score based on genetic markers in FasL, MSH2, CASP3, and ABCC5 with 5-year 
progression-free survival (PFS) in independent osteosarcoma cohorts. Additionally, in 
a meta-analysis also including the two cohorts of the original study, we confirmed the 
association of two of the individual variants (in MSH2 and ABCC5) with 5-year PFS. 
Although the validation was not complete, in the sense that the association of the genetic 
risk score with outcome was not statistically significant in the individual cohorts but only 
after combining cohorts, and that not all individual variants were significant in the meta-
analysis, the findings highlight that even in relatively small patient cohorts it is possible 
to identify clinically relevant markers. When compared to other pharmacogenetic studies 
into drug efficacy in osteosarcoma, this is a unique finding, even though further validation 
in larger datasets is needed.
 The DMET analysis reported in chapter 6 represented a next step in the search for 
the pharmacogenetic basis of drug efficacy in osteosarcoma. Eight genetic variants 
were identified in relation to 5-year PFS, from which a variant in the ABCB1 gene was 
independently validated in one of the validation cohorts. Seven other variants were 
significantly associated with 5-year PFS in a combined meta-analysis of discovery 
and validation cohorts. Our findings are an addition to other reports indicating that 
polymorphisms in ABCB1 contribute to differential drug efficacy in osteosarcoma patients 
[17-21]. It is also the first indication that variation in genes of the solute-linked carrier 
family are involved in drug efficacy in osteosarcoma. Furthermore, none of the variants 
that were associated with histologic response (HR) in our two Dutch cohorts, could be 
validated in independent cohorts. Also in the previous pathway-based study of our group, 
no variants relevant to the HR could be identified. There could be several explanations 
for this. One potential explanation is that it may be possible that the genetic basis of 
HR should be searched for mainly in the somatic genome, which largely dictates the 
tumor behavior and response. It could also be possible that pharmacodynamic genes 
(at germline level) rather than pharmacokinetic genes as studied in the DMET analysis 
and other than the pharmacodynamics genes studied in the previous pathway-based 
approach are involved in the variability in histologic response. In addition, the HR may not 
be a suitable endpoint for (retrospective) analysis for example because of heterogeneity 
due to sensitivity to interobserver differences. 
 In chapter 7, we have reported on the results of a DMET analysis as the first step to 
identify patients for whom standard chemotherapeutic treatment is ineffective, of which the 
background is poorly understood. We have focused on the subgroup of patients showing 
progressive disease during or shortly after treatment and identified genetic variants 
involved in drug metabolism and transport that were specifically and only associated 
with progressive disease. Of four genetic variants associated with progressive disease, 
an SLC7A8 variant with a protective effect was confirmed in an independent validation 
cohort. In addition, three variants in other genes (CYP8B1, SLC22A2, SLC22A5) were 
significantly associated in a meta-analysis. The SLC7A8 transporter has been linked to 
cisplatin and doxorubicin resistance and outcome after platinum-based therapy in other 
cancers, and it is therefore considered a plausible outcome of this exploratory study 
deserving further follow-up [22,23]. 
 In the present thesis, we have described studies using the DMET array focusing 
on either toxicity or efficacy endpoints. Of note, there is some overlap regarding the 
involvement of genes in MTX plasma levels (chapter 4) and in the meta-analysis results 
of 5-year PFS analysis (chapter 6), namely ABCC4 and SLC22A14. In the MTX-treated 
patient population studied in chapter 4, both genes were associated with MTX plasma 
levels (though not with hepatotoxicity). However, there was no association of MTX 
plasma levels (which is influenced by pharmacokinetics) with 5-year PFS (which might 
be influenced by pharmacokinetics, pharmacodynamics, or both), making it difficult to 
interpret the relevance of these genes in the context of MTX treatment. The association 
of these genes with 5-year PFS might be related to transport of other chemotherapeutics 
used in the treatment of osteosarcoma, especially for ABCC4 for which a link to cisplatin-
resistance has been reported in other forms of cancer [24].
Strengths and limitations
Some of the most important determinants of an informative outcome of observational 
research in the medical sciences are sufficient sample size and representative sampling 
of the patient population under study. Genetic association studies integrate clinical data 
from medical files and genetic information of each patient; of which the latter is the 
most critical and challenging factor for establishing an informative patient cohort. In the 
context of osteosarcoma research, this is even more challenging because total patient 
numbers are limited by the rarity of the malignancy. In addition, a proportion of patients 
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is unavailable for sampling in a retrospective setting because of the high mortality of the 
disease. From this perspective, large numbers of osteosarcoma patients were included 
in the studies presented in this thesis, with up to 310 Dutch patients the largest cohort 
used in pharmacogenetic research in osteosarcoma in the world, and inclusion of study 
cohorts of also exclusively osteosarcoma patients from collaborative research groups. 
Moreover, to maximally prevent bias, every effort was made to include the (Dutch) 
patients who had died before start of the studies, by collecting samples from the pathology 
archives. Nonetheless, patient numbers were still relatively low for genetic association 
analysis, which could result in false-negative outcomes by missing true associations, 
or underestimation of the strength of associations, for example of the genetic variants 
that were significantly associated with PFS or progression in meta-analysis of multiple 
cohorts, but could not be reproduced in individual validation cohorts. On the other hand, 
the findings of mainly the ACYP2 study (chapter 3) and DMET analysis of PFS with 
ABCB1 as outcome (chapter 6), nicely illustrate that the investigated cohorts were of 
sufficient sample size to detect associations of genetic variants with low frequency or 
small effect size. The limited number of patients, in combination with the low frequency 
of the phenotype under study, as was the case for patients progressive disease (chapter 
7), has determined the design of that particular study, which included combining multiple 
cohorts into a single cohort for statistical analysis, making this an exploratory study.
 A rational choice of genes to study, which may include selection of meaningful 
biological pathways or instead taking a genome-wide approach, depending on the 
existing knowledge, patient numbers, and resources, is another determinant of the 
value of a genetic association study. The main research described in this thesis included 
analysis with the DMET Plus array. The DMET gene selection was based on a core list of 
ADME genes defined by academic, industry, and genomic experts in the PharmaADME 
consortium, with addition of genes regulating intracellular processes that facilitate ADME 
[25]. The variants within these genes were ranked according to clinical research utility. 
Following small candidate gene studies reported in literature and a candidate pathway-
gene based approach previously performed by our group, with all of these studies 
selecting genes for their known function in the processing of the chemotherapeutics used 
in osteosarcoma treatment, the studies presented in this thesis involving DMET analysis 
are the first to include such a substantial number of genes. Although this is still a form of 
a candidate gene selection since all genes are related to drug absorption, metabolism, 
excretion and transport, the array also includes metabolic or transporter genes without 
a direct link with the chemotherapeutics involved, which enables discovery of novel 
associations. Related to that is the fact that several of the genetic variants previously 
described in osteosarcoma pharmacogenetics literature (such as several ABCB1 and 
GSTP1 variants related to drug efficacy) were analyzed in our cohorts because they are 
present on the DMET Plus array. Hence, although our DMET analyses were designed 
to discover novel associations, it has also given the opportunity to assess previously 
described associations, especially as the size of our Dutch cohort(s) was suitable for 
validation of markers described in literature, which is illustrated by the ACYP2 study. The 
downside of this platform is that it includes a large number of rare variants, which are 
included because they are presumably more likely to be causal than common variants. 
However, they were monomorphic or had a frequency too low to include in association 
analysis, because extremely low minor allele frequencies would require substantially 
larger patient cohorts to have sufficiently powered analyses. This was not only the 
case in our studies but also in other association studies using this platform [23,26-
28]. This substantially decreased the number of genetic variants eligible for analysis. 
Furthermore, the selection of genes included in the array is based on the gene function 
in pharmacokinetics and is therefore not completely hypothesis-free [25]. Therefore, we 
might still have missed associations of pharmacodynamic-related genes or of genes 
affecting drug response through other mechanisms. 
 When interpreting the results of genetic association studies, investigators must always 
be aware of the risk of false-positive findings, especially when large numbers of genetic 
variants are tested. Validation in independent cohorts is therefore an essential component 
to overcome the winner’s curse and be able to appreciate the results and strengthen the 
evidence. In the studies related to drug efficacy presented in this thesis, we have included 
a validation phase with patient cohorts of collaborating research groups from outside of 
The Netherlands. We acknowledge that the cohorts were not ideal validation cohorts 
with respect to size, sampling, and differences in treatment regimen (i.e. different agents 
in addition to the standard regimen of cisplatin and doxorubicin). However, the papers 
presented in this thesis are the only studies within the osteosarcoma pharmacogenetics 
field reported so far that include (multiple) validation sets at all. Moreover, as any 
osteosarcoma cohort is small because of the rarity of the disease, the validation steps 
as presented here were the best available options to date. Small validation cohorts 
carry the danger of false-negative findings leading to incorrect conclusions by missing 
true associations. It is therefore far from obvious that we were able to confirm genetic 
associations in these cohorts, although it is still possible that other true associations 
have been missed. Another main issue encountered in the validation analyses was the 
difference between cohorts with respect to the phenotype under study, with the English 
cohort showing a remarkably high PFS, which was most likely predominantly reflecting 
a selection bias towards survivors. With hindsight, we realized that this cohort might not 
have been a suitable choice for validation of markers associated with PFS. Unfortunately, 
the validation cohorts used in the drug efficacy studies could not be used for our study 
into MTX-induced hepatotoxicity, as no information was available on the liver enzymes of 
these patients.
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 The genetic association studies presented in this thesis were all case-control studies, 
a widespread used study design in the field of genetic epidemiology, in which patients 
are classified based on their clinical drug response (i.e. efficacy or toxicity), and in which 
cases and controls are expected to differ in their prevalence of genetic variants related 
to drug effects. As cases and controls might also differ in other (clinical) factors, such as 
the presence of metastases at diagnosis which is also related to PFS, the endpoint used 
to analyze drug efficacy, we have adjusted for these factors where needed, to remove 
variation between cases and controls that is not directly related to the genetic makeup. 
Nevertheless, a potential difficulty is the possibility that other yet unrecognized clinical or 
biological factors represent subgroups of patients or tumors, that were not accounted for 
in the analyses, and which could dilute or obscure true associations. In addition, we have 
focused on the germline genome, not taking into account the tumor genetics, which could 
be of influence on the efficacy endpoints (histologic response, PFS) by determining drug 
resistance or natural tumor behavior. However, it is clear from the current literature that 
the complex genomic profile and genomic instability of the tumor are highly challenging 
in research aiming to define correlations of genetic tumor profiles and survival. To date, 
there is no distinct, reproducible genetic profile reported of osteosarcoma which could 
be screened for and included in our studies. Moreover, it is exactly because of the large 
heterogeneity within and between tumors, that it is unlikely that a substantial proportion 
of patients in our cohorts would harbor the same yet undefined poor prognostic genetic 
tumor profile. Hence, the influence of the tumor genetics is not expected to have largely 
influenced our results. Furthermore, although concordance between germline and tumor 
DNA has been described for other tumors [29], it could be a relevant step to validate 
the findings from germline studies into the treatment efficacy in osteosarcoma patients 
using tumor DNA, depending on the gene function, which has not been carried out in the 
described studies. 
 An intrinsic limitation of genetic association studies is the fact that the results do 
not provide an answer to the question as to whether an associated variant itself is of 
causal influence on the phenotype under study, or whether another variant in linkage 
disequilibrium with the associated variant is so, although in case of associated variants 
with a known functional effect, the former becomes more likely. Additionally, in the context 
of multidrug treatment, it also remains a question as to which drug the genetic effect is 
related, or whether it is related to multiple drugs, which generally remains speculation until 
mechanistic evidence supporting the findings is provided. Furthermore, with the potential 
future use of pharmacogenetic variants as screening tool in mind as an ultimate aim of 
pharmacogenetic analyses, the causality of a specific drug in adverse drug reactions is 
also a point of interest. It is for this reason that specifically hepatotoxicity induced by MTX 
was studied (chapter 4), and other toxicities such as bone marrow depression, which is 
also a common side effect of the other agents in the MAP (MTX, doxorubicin, cisplatin) 
treatment regimen, were not studied. Furthermore, based on the indications that MTX 
plasma levels are related to MTX-induced toxicities, and also to narrow down the range 
of genetic variants included in genetic association analysis with hepatotoxicity, we first 
analyzed the association of genetic variants with high MTX plasma levels (chapter 4). 
As it became clear from our cohort that MTX-induced hepatotoxicity not necessarily 
presents in patients with high MTX plasma levels, the downside of the approach is 
that we might have missed genetic variants related to MTX-induced hepatotoxicity that 
is not a consequence of high exposure. In fact, this brings up new questions from a 
pharmacological point of view about the mechanisms of MTX-induced hepatotoxicity, as 
it seems surprising that it is not (necessarily) a result of high MTX plasma levels. With 
passive diffusion being dependent on the extracellular MTX concentration [30,31], could 
it be that in patients with rapid clearance, hence with relatively low MTX plasma levels, 
there is relatively higher active MTX uptake in the liver, contributing to hepatotoxicity? 
Furthermore, as MTX is subject to intracellular polyglutamation in liver cells, which 
prevents it from moving out of the cell, the extent of polyglutamation of MTX might also 
be of influence [32].
 Last of all, we analyzed only those patients with available clinical data, ignoring 
missing data. Although survival data were available for virtually all included patients, 
data on adverse events (ototoxicity and hepatotoxicity) was lacking for a proportion of 
patients, even though the large majority of patients had been treated within a clinical 
trial with close monitoring. In general, the availability of toxicity data might be biased 
towards patients experiencing toxicity leading to increased monitoring, although in our 
study cohort we did not observe an extremely high frequency of ototoxicity in the included 
patients. Furthermore, pharmacogenetic analysis of doxorubicin-induced cardiotoxicity 
was not carried out because of the absence of uniform measurements of a substantial 
number of patients.
Future perspective
Research perspective
The pharmacogenetic studies in osteosarcoma reported in literature so far give some clues 
on the genetic component of variability in response to chemotherapy in the treatment of 
osteosarcoma, but also illustrate the complexity of pinpointing the most relevant genes, 
especially in the context of a complex phenotype as drug response and in a rare disease. 
The research presented in this thesis has provided several validated genetic markers 
of chemotherapy efficacy or toxicity, indicating that a pharmacogenetic approach is 
able to yield reproducible insights in osteosarcoma therapy response. Nevertheless, to 
some extent the DMET analyses did not yield truly unexpected findings with respect to 
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the validated markers, for example ABCB1 variants in relation to therapy outcome have 
been studied before as a candidate gene. This raises the question as to whether the 
genetic effects that have been identified until now, in fact represent all the genetics underlying 
the variability in drug response, or alternatively, whether pharmacokinetics, which was 
the focus of the DMET studies, is just not the mechanism in which to search further. 
In addition, any further explanation of variability in drug response might also need to 
be searched for in non-genetic factors, for example environmental factors such as nutrition, 
tobacco smoking, alcohol use, co-administered drugs, and environmental chemicals. 
In case the current findings represent all pharmacokinetics related genetic effects 
in osteosarcoma treatment, it would be worthwhile to more extensively study 
pharmacodynamic genes or to go beyond typical pharmacokinetic and pharmacodynamic 
pathways and more forward to scanning the whole genome by a GWAS or next generation 
sequencing. Such truly hypothesis-free methods have the potential to discover novel 
associations of unexpected genes with drug response. Whereas genome-wide approaches 
have been exhaustively carried out in many other diseases, often without clinically 
relevant and applicable results, this type of analysis is yet to start in osteosarcoma 
pharmacogenetics. Although a GWAS has been carried out in osteosarcoma to detect 
disease or metastasis susceptibility genes, no pharmacogenetic endpoints were included, 
presumably because of lacking clinical drug response datasets [33,34]. As the first GWAS 
into cisplatin-induced ototoxicity in a relatively small population of pediatric patients has 
resulted in the identification of a genetic variant (in ACYP2) that could be confirmed in 
osteosarcoma as described in this thesis, it seems worthwhile to explore this approach 
further in osteosarcoma. Moreover, pharmacogenetic findings could not only lead to a 
genetic profile for prediction of drug response, but also holds the opportunity to increase 
our understanding of drug response in patients with osteosarcoma, and to provide new 
druggable targets for developing novel agents for patients prone to have a poor response 
to conventional treatment. 
 Real progress in the osteosarcoma pharmacogenetics field will require large studies 
with respect to patient numbers. Mixed cancer populations could provide a good option 
for large scale studies to detect associations that are not tumor-specific. This is primarily 
feasible for toxicity studies because drug toxicity is similar among different cancers 
treated with the same chemotherapeutics, and the effect sizes are expected to be larger 
than observed in efficacy studies. Mixed cancer cohorts are less suitable for efficacy 
studies, because efficacy endpoints are difficult to compare between different tumors. 
Other than combining cancers, the patient population of the recent EURAMOS-1 trial with 
over 2,200 similarly treated osteosarcoma patients provides an excellent opportunity for 
large scale pharmacogenetic investigations, as well as for further validation of genetic 
markers reported in literature and identified in the research described in this thesis [35]. 
Aside from validation in osteosarcoma cohorts, it could also be worthwhile to translate the 
findings of variants such as the ACYP2 variant to other cancers with the same treatment, 
for example adult cisplatin-treated patients with head and neck cancer.
 Functional characterization of the effect of genetic variants found in genetic 
association studies in osteosarcoma, including the research presented in this thesis, is 
(mostly) lacking. Understanding of the biological mechanism underlying the findings and 
proving causality will be valuable to provide additional evidence of the genetic findings, 
especially in the context of the limited sample sizes of osteosarcoma studies. Moreover, 
it could also shed light on the specific chemotherapeutic agent to which the genetic 
variant is linked, which may not always be clear in the context of multidrug treatment. In 
functional studies, a distinction should be made between the effect of genetic variants 
in the germline or specifically in the tumor. Whereas for liver enzymes the effect of a 
germline genetic variant can be expected to be restricted to its function in the liver, for 
drug transporters present in typical drug processing organs such as liver and kidneys but 
also in the tumor, prediction of the effect of a variant also involves studying the effect at 
the tumor level using osteosarcoma cell models. 
 The interpretation of pharmacogenetic data is still a challenge for translation to the 
clinic. Until now, the efforts in pharmacogenetic studies in osteosarcoma in the recent 
years have not led to a change in clinical practice. All discovered variants are still in the 
research phase and warrant further validation. Hence, future studies should be focused 
not only on independent validation of current findings and discovery of yet unknown 
associations, but also on the pathway towards clinical implementation, which includes 
testing of clinical validity and translation through prospective studies demonstrating 
improvement of outcome [36].
Clinical perspective
As survival of osteosarcoma patients treated with conventional chemotherapy has 
stagnated over the past decades, many efforts are made to identify and develop alternative 
treatment options. Apart from a variety of ongoing trials [37], there have been a few 
publications of clinical investigations of new drugs for the treatment of osteosarcoma 
during the past four years while the research presented in this thesis was conducted. 
The bisphosphonate zoledronic acid, which targets the bone microenvironment, is in an 
early trial phase [38], but a first report on clinical experience with zoledronic acid only has 
shown encouraging results with respect to PFS in metastatic patients [39]. Another type 
of investigational agent is muramyl tripeptide-phosphatidyl ethanolamine encapsulated 
in liposomes (L-MTP-PE), which is an immunomodulating agent that has shown positive 
results with improvement in overall survival in localized and metastatic osteosarcoma 
[40]. The EURAMOS-1 trial has investigated the immunomodulator interferon alpha 2b 
as maintenance therapy for good responders to neoadjuvant chemotherapy. The first 
results do not support routine use of interferon alpha 2b as event-free survival was not 
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improved in the experimental arm [41]. Furthermore, the use of monoclonal antibodies, 
which receive much attention in other cancers, is also being tested in the treatment of 
osteosarcoma. The HER2 targeting monoclonal antibody trastuzumab has not resulted 
in improved outcome of patients with a HER2 overexpressing tumor in a phase II trial 
[42]. Another phase II trial has shown positive results of the combination of mTor inhibitor 
everolimus and angiogenesis inhibitor sorafenib [43]. It is clear that there are only a 
few promising new agents for osteosarcoma treatment, and it will take time to bring 
these to clinical practice. Therefore, another parallel approach for clinical research in 
osteosarcoma is the personalization of treatment with chemotherapy by optimizing the 
use of the drugs currently available.
 How could pharmacogenetic variants be used to guide therapy for osteosarcoma 
patients? Generally speaking, for patients harboring a genetic risk profile for developing 
toxicities, increased surveillance and use of protective agents without hampering the 
antitumor efficiency of the chemotherapeutic drug might be future clinical applications. 
Dose reductions could be considered, as often variants increasing susceptibility to toxicity 
might also increase efficacy; however, this requires large confidence of the genetic effect. 
Specifically, considerations for preventing cisplatin-ototoxicity include using alternative 
chemotherapeutics such as carboplatin, decreasing cisplatin dose [44], increasing 
monitoring, or using otoprotective agents such as sodium thiosulfate [45]. The ACYP2 
variant reported in chapter 3 as predictor of cisplatin-induced ototoxicity represents a 
good candidate to be considered for investigation in the setting of future international 
osteosarcoma trials. As the frequency of the variant is rather low, a suitable approach 
could be to focus on the subset of patients carrying the genetic variant and extrapolate 
the results to the patient population as a whole. It is also questionable whether genotyping 
for this variant could be cost-effective; however, this might be considered incidental in the 
vulnerable pediatric oncology patient population. In addition, despite the low frequency 
of the ACYP2 variant, cost-effectiveness might be reachable when considering the high 
health care costs and high impact on quality of life for patients experiencing (severe) 
ototoxicity. Clinical application of genetic markers of MTX-induced hepatotoxicity could 
involve dose reduction to prevent hepatotoxicity; however, this is not without the concern 
of reducing efficacy as well. In the oncological setting, quite a level of toxicity is accepted 
in favor of maximizing efficacy. Hence, if MTX dose reductions compromise its efficacy, 
such a trade-off is certainly undesired and unlikely to be accepted for clinical practice. 
Moreover, although the genetic variant identified in our study was related to both MTX 
plasma levels and hepatotoxicity, there was also a major proportion of patients presenting 
with hepatotoxicity in the absence of high MTX plasma levels, which in fact makes it 
questionable whether dose reduction would diminish the risk of hepatotoxicity. At the 
same time, for patients with genetic variants predicting poor efficiency of the treatment, 
the option of intensification of therapy is a difficult one because of the risk of toxicities. 
Moreover, to date the intensification by adding alternative agents such as in the MAPIE 
regimen of EURAMOS-1 has not shown the desired improvement of survival [46]. Instead, 
a poor predictive profile might help to identify those patients for whom alternative treatment, 
once it is available, should be favored over the standard (chemotherapy) treatment. In 
addition, pharmacogenetic profiling might enable the identification of those patients 
who are now in fact undertreated and could be subjected to more intense treatment. 
Furthermore, for patients not responding to standard chemotherapy, such as focused 
on in chapter 7, the question arises as to whether chemotherapeutic treatment should 
be started at all, or whether prevention of treatment that is ineffective and unnecessarily 
harmful with respect to side effects should be favored for the patient’s quality of life. 
For this group of patients, the use of experimental drugs could also be considered. For 
the small group of patients that survived despite their inadequate drug response in our 
study cohort, who probably belong to the small proportion of patients that is known to 
survive due to successful surgery, the choice to restrain from chemotherapy might even 
be a favorable option with positive outcome. Obviously, this could only be considered in 
light of large confidence of the predictive capacity of the (genetic) profile, which is truly a 
future perspective.
 
Concluding remarks
The studies presented in this thesis have provided interesting results further supporting 
a pharmacogenetic approach in osteosarcoma research. Only through joint efforts with 
intensive international collaboration and integration of results from pharmacogenetic 
research with potential future insights at the somatic level, it might eventually be 
possible to implement a priori genetic screening for guidance of therapy for the benefit 
of osteosarcoma patients. 
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Summary
Osteosarcoma is the most common bone tumor in children and adolescents. Since 
the seventies in the last century, patients with this malignant tumor are treated with 
a combination of surgery and chemotherapy, the latter consisting of at least cisplatin 
and doxorubicin. Although the addition of chemotherapy to the treatment regimen 
has had a strong impact on survival, for still around 40% of patients this treatment is 
inadequate and they do not survive. In addition, survivors frequently experience long-
term side effects as a result of the toxic chemotherapeutic treatment. More insight into 
the genetic factors underlying therapy resistance and/or sensitivity to toxicities could 
be helpful for upfront risk stratification, optimization of the treatment, and development 
of new therapeutic approaches. In general, many genes are known to play a role in 
the interaction of drugs and the body (‘pharmacogenetics’). Subtle variations in these 
genes can have an influence on this interaction. In the studies presented in this thesis, 
a potential link between variations in genes related to drug absorption, distribution, 
metabolism, and excretion (ADME) and the effect of chemotherapy in osteosarcoma 
patients was investigated with regard to efficacy and toxicity.
Chapter 1 provides a general introduction including a comprehensive overview of 
published pharmacogenetic research involving patients with osteosarcoma.
Chapter 2 describes a technical validation of the use of DNA isolated from long-term 
stored tissue from the pathology archives on a specific genotyping technology, the Drug 
Metabolizing Enzymes and Transporters (DMET) Plus array, which is used in the majority 
of pharmacogenetic studies presented in this thesis. A proportion of osteosarcoma 
patients included in our studies was not alive at the time of retrospective sample 
collection, and therefore the only available source for germline DNA of these patients was 
normal formalin-fixed, paraffin-embedded (FFPE) tissue. As the long-term storage and 
tissue fixation procedures can negatively influence the quality of FFPE-derived DNA, we 
compared the DMET array genotyping results of DNA isolated from archived normal FFPE 
tissue with DNA from matched blood or saliva from sixteen patients with osteosarcoma. 
We observed high call rates for the FFPE-derived DNA samples (98.9%) as well as high 
concordance among the blood/saliva-FFPE DNA pairs (97.4%). We therefore concluded 
that DNA isolated from archived normal FFPE tissue samples can be reliably used as a 
template for the DMET Plus array. 
The next two chapters describe studies into the pharmacogenetics of chemotherapy-
induced toxicities in patients with osteosarcoma. In chapter 3 we focused on cisplatin-
induced hearing loss (ototoxicity), which is an irreversible side effect with large, partly 
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unexplained interpatient variability. In a recent genome-wide association study, a genetic 
variant (rs1872328) in the ACYP2 gene was identified as pharmacogenetic marker of 
cisplatin-induced ototoxicity in patients with brain tumors. We confirmed this finding in 
an independent cohort of 156 osteosarcoma patients by demonstrating a significant 
association between carriership of the A allele of the genetic variant in the ACYP2 gene 
and cisplatin-induced ototoxicity. This also shows that the association applies to different 
types of cancer with different treatment protocols. We concluded that the ACYP2 variant 
should be considered a predictive pharmacogenetic marker for hearing loss, which may 
be used to guide therapies for cisplatin-treated patients.
Chapter 4 describes an exploratory pharmacogenetic study focused on high-dose 
methotrexate (HD-MTX)-induced hepatotoxicity. MTX is a chemotherapeutic frequently 
used in the treatment of pediatric osteosarcoma, and was one of the standard agents 
used in the recent EURAMOS-1 trial in osteosarcoma. Delayed clearance of MTX may 
increase the risk of MTX-induced side effects such as hepatotoxicity. We explored the 
influence of 1936 genetic variants in 231 ADME genes on interindividual variation in MTX 
plasma levels and hepatotoxicity in 144 HD-MTX-treated osteosarcoma patients using 
the DMET Plus array. When we analyzed a total of 1250 HD-MTX courses, we detected 
associations of 32 genetic variants with 48 hour MTX plasma levels. This included a 
variety of genes unknown to play a role in MTX pharmacokinetics. Of the genetic variants 
associated with MTX plasma levels, we identified a protective effect of GSTM3 rs1799735 
(delAGG) (GSTM3*B) in relation to frequent hepatotoxicity. These findings indicate a 
role of pharmacogenetic variants in the interindividual variation in MTX plasma levels 
and HD-MTX-induced hepatotoxicity and contribute to pinpointing the specific genes 
involved. Upon validation of the results, the identified GSTM3 marker might eventually 
be useful for optimization of MTX treatment.
The next chapters concentrate on the pharmacogenetics of chemotherapy efficacy. In 
chapter 5 we report on a study assessing the reproducibility of our previously identified 
association of a genetic risk score, based on several pharmacogenetic markers, with 
5-year progression-free survival (PFS) using independent Dutch, Spanish, and English 
osteosarcoma cohorts. Although one of the variants, located in CYP3A4, could not be 
reliably determined, we could still reproduce the association of the genetic risk score with 
5-year PFS based on markers in FasL, MSH2, CASP3, and ABCC5. Patients carrying no 
or one risk allele showed a 5-year PFS of 78.5%, compared to a 5-year PFS of 59.5% in 
patients carrying 2-3 risk alleles, 48.0% with 4–5 alleles, and 57.1% with more than 5 risk 
alleles (P=0.040). In addition, we also confirmed the association of two of the individual 
variants (in MSH2 and ABCC5) with 5-year PFS in a meta-analysis also including the two 
cohorts of the original study. These pharmacogenetic findings are potentially very useful 
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for risk stratification at diagnosis and provide a basis for pharmacogenetic profiling in the 
future. 
As a next step, we performed a DMET analysis to identify (additional) associations 
of variants in ADME genes with 5-year PFS, described in chapter 6. Upon discovery 
in 283 Dutch osteosarcoma patients and validation in Spanish and English cohorts, 
we identified eight genetic variants in relation with 5-year PFS. Of these, the variant 
rs17064 in the ABCB1 gene was independently validated. Seven other variants of five 
drug transporter genes (ABCC4, ABCC5, ABCG1, SLC22A5, and SLC22A14) were 
significantly associated with 5-year PFS in a combined meta-analysis of discovery and 
validation cohorts. These findings contribute to the indications of other studies reporting 
the influence of polymorphisms in ABCB1 on outcome after chemotherapy-based 
treatment in osteosarcoma, and for the first time indicate a role of solute-linked carriers. 
These markers are of potential interest for the development of new treatment strategies 
and optimizing current therapy.
In chapter 7 we describe another DMET analysis in which we focused on the subgroup 
of patients showing an inadequate drug response, defined as progressive disease during 
or shortly after treatment. Upon discovery in our Dutch cohort of 283 osteosarcoma 
patients and validation in Spanish, English, and Australian patients, we identified an 
independently validated SLC7A8 variant (rs1884545) specifically and only associated 
with progressive disease, showing a protective effect. Additionally, three variants in 
other genes (CYP8B1, SLC22A2, SLC22A5) were significantly associated in a meta-
analysis. This exploratory analysis represents the first step to identify patients for whom 
chemotherapeutic treatment is ineffective and should be further explored in additional 
cohorts.
Chapter 8 provides a summarizing discussion of the research described in this thesis, 
including a future perspective on further (pharmacogenetic) research in osteosarcoma as 
well as on the clinical aspects of osteosarcoma treatment.
Samenvatting
Osteosarcomen zijn de meest voorkomende bottumoren bij kinderen en adolescenten. 
Sinds de jaren zeventig van de vorige eeuw worden patiënten met deze kwaadaardige 
tumoren behandeld door middel van een operatie en chemotherapie, bestaande uit een 
combinatie gebaseerd op cisplatin en doxorubicine. Hoewel de kans om de ziekte te 
overleven sterk is verbeterd sinds de introductie van chemotherapie in de behandeling, 
schiet de behandeling voor een deel van de patiënten tekort waardoor nog ongeveer 
40% overlijdt. Daarnaast hebben patiënten die de ziekte wel overleven ook op lange 
termijn vaak te maken met schadelijke bijwerkingen van de chemotherapie, zoals 
hartschade, nierschade en gehoorschade. Meer inzicht in de genetische factoren die een 
rol spelen bij (on)gevoeligheid voor het antitumor effect van de chemotherapie of juist 
gevoeligheid voor de bijwerkingen, zou kunnen leiden tot een effectievere en veiligere 
behandeling. In algemene zin is van allerlei genen al bekend dat ze een rol spelen bij 
de werking van medicijnen (‘farmacogenetica’). Kleine variaties in deze genen kunnen 
een effect hebben op deze werking. In het in dit proefschrift beschreven onderzoek 
is in osteosarcoompatiënten gekeken naar genen betrokken bij absorptie, distributie, 
metabolisme en excretie (ADME) van medicijnen en of bepaalde variaties hierin een 
verband hebben met het effect van de chemotherapie, zowel met betrekking tot de 
effectiviteit als de toxiciteit.
Hoofdstuk 1 is een algemene introductie waarin een uitgebreid overzicht wordt 
gegeven van de bestaande literatuur met betrekking tot farmacogenetisch onderzoek in 
osteosarcoompatiënten.
In hoofdstuk 2 wordt een technische validatie beschreven voor het gebruik van DNA, 
geïsoleerd uit opgeslagen weefsel uit het pathologie archief, voor een specifieke 
genetische analysetechniek, namelijk de Drug Metabolizing Enzymes and Transporters 
(DMET) Plus array. Deze array is gebruikt voor verschillende farmacogenetische studies 
in dit proefschrift. Aangezien een deel van de geïncludeerde osteosarcoompatiënten niet 
meer in leven was op het moment van inclusie, was van deze patiënten geen bloed of 
speeksel beschikbaar voor DNA isolatie, maar opgeslagen weefsel (formaline gefixeerd 
en ingebed in paraffine) bestaande uit tumor met omringend normaal weefsel. In het 
algemeen is het DNA verkregen uit dergelijk materiaal van mindere kwaliteit, wat invloed 
kan hebben op de resultaten bij genetische analyses. We hebben daarom de genetische 
resultaten vergeleken tussen kiembaan DNA geïsoleerd uit normaal opgeslagen weefsel 
en bijbehorende bloed- of speekselmonsters van zestien osteosarcoompatiënten. We 
hebben daarbij een hoge overeenstemming (97.4%) gevonden tussen de resultaten 
verkregen uit opgeslagen weefsel en bloed of speeksel. Dit resultaat geeft aan dat DNA 
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geïsoleerd uit opgeslagen, normaal weefsel betrouwbare resultaten geeft met de DMET 
Plus array en daarmee geschikt is voor gebruik voor dit platform.
De twee hierop volgende hoofdstukken beschrijven onderzoek naar de farmacogenetica 
van bijwerkingen van chemotherapie bij osteosarcoompatiënten. In hoofdstuk 3 ligt 
de focus op cisplatin-geïnduceerde gehoorschade (ototoxiciteit), wat een irreversibele 
bijwerking is met een grote, deels niet-verklaarde variatie tussen patiënten. In een 
recente genoomwijde associatiestudie in patiënten met hersentumoren is een genetische 
variant (rs1872328) in het ACYP2 gen geïdentificeerd als farmacogenetische marker 
voor cisplatin-geïnduceerde ototoxiciteit. We hebben deze bevinding bevestigd in een 
onafhankelijk cohort van 156 osteosarcoompatiënten, waarbij we een significante 
associatie aantoonden tussen het dragen van het A allel van de genetische variant in 
het ACYP2 gen en cisplatin-geïnduceerde ototoxiciteit. Dit resultaat geeft tevens aan dat 
de associatie van toepassing is op verschillende vormen van kanker met verschillende 
behandelprotocollen. We concludeerden dat de ACYP2 variant beschouwd kan worden 
als een voorspellende farmacogenetische marker voor gehoorschade welke mogelijk 
gebruikt kan worden voor optimalisatie bij patiënten die behandeld worden met cisplatin 
en daarom van meerwaarde is voor de klinische praktijk.
Hoofdstuk 4 beschrijft een exploratieve farmacogenetische studie op het gebied van 
leverschade (hepatotoxiciteit) als gevolg van behandeling met hoge dosis methotrexaat (HD-
MTX). MTX is een chemotherapeutisch middel dat vaak gebruikt wordt bij de behandeling 
van kinderen met een osteosarcoom en was een van de standaard chemotherapeutica in 
de recente EURAMOS-1 trial in osteosarcoompatiënten. Vertraagde klaring van MTX kan 
mogelijk het risico op MTX-geïnduceerde bijwerkingen zoals hepatotoxiciteit verhogen. 
We hebben de rol van 1936 genetische varianten in 231 ADME genen onderzocht in 
relatie tot inter-individuele variatie in MTX plasmaspiegels en hepatotoxiciteit in 144 
osteosarcoompatiënten die behandeld zijn met HD-MTX, daarbij gebruik makend van de 
DMET Plus array. Bij analyse van 1250 HD-MTX kuren, hebben we associaties gevonden 
van 32 genetische varianten met 48-uurs MTX plasmaspiegels. Dit betrof ook genen 
waarvan niet eerder een relatie is beschreven met de farmacokinetiek van MTX. Van de 
genetische varianten die geassocieerd waren met MTX plasmaspiegels, vonden we een 
beschermend effect van  de variant GSTM3 rs1799735 (delAGG) (GSTM3*B) in relatie 
tot frequente hepatotoxiciteit. Deze bevindingen wijzen erop dat farmacogenetische 
varianten een rol spelen in de inter-individuele variatie in MTX plasmaspiegels en HD-
MTX geïnduceerde hepatotoxiciteit en dragen daarmee bij aan de identificatie van de 
specifieke genen die hierbij betrokken zijn. Indien de resultaten gevalideerd kunnen 
worden in vervolgonderzoek, zou de GSMT3 marker mogelijk toekomstig gebruikt kunnen 
worden voor optimalisatie van de behandeling van patiënten met MTX.
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De hoofdstukken 5-7 beslaan onderzoek dat gericht is op de farmacogenetica van de 
effectiviteit van chemotherapie bij osteosarcoompatiënten. In hoofdstuk 5 beschrijven 
we een studie waarin we de reproduceerbaarheid hebben onderzocht van een door 
onze groep eerder gevonden associatie van een genetische risico score, gebaseerd op 
enkele farmacogenetische markers, met 5-jaars progressievrije overleving (PFS). De 
genetische risicoscore is het aantal ongunstige genetische varianten (risico allelen) van 
een patiënt. Hierbij maakten we gebruik van zowel een Nederlands, Spaans als Engelse 
cohort. Hoewel een van de varianten (in CYP3A4) niet betrouwbaar bepaald kon worden, 
konden we de associatie van de genetische risicoscore op basis van markers in FasL, 
MSH2, CASP3 en ABCC5 bevestigen. Patiënten zonder of met één risico allel hadden 
een 5-jaars PFS van 78.5%, vergeleken met een 5-jaars PFS van 59.5% in patiënten met 
2-3 risico allelen, 48.0% met 4 of 5 risico allelen en 57.1% met meer dan 5 risico allelen 
(P=0.040). Daarnaast konden we de associatie van twee individuele genetische varianten 
(in MSH2 en ABCC5) met 5-jaars PFS bevestigen in een meta-analyse waarin ook de 
cohorten van de oorspronkelijke studie werden meegenomen. Deze farmacogenetische 
bevindingen zijn mogelijk van nut voor stratificatie van patiënten bij diagnose en kunnen 
een basis vormen voor farmacogenetische screening in de toekomst.
Hoofdstuk 6 beschrijft een volgende stap in het onderzoek naar farmacogenetische 
markers voor de effectiviteit van chemotherapie, om (additionele) associaties te vinden 
van varianten in 231 ADME genen met 5-jaars PFS middels een DMET analyse. Na 
analyse in een discovery fase met twee Nederlandse osteosarcoomcohorten (totaal 
283 patiënten) en validatie in Spaanse en Engelse cohorten, identificeerden we acht 
genetische variaties in relatie tot 5-jaars PFS. Van deze varianten was rs17064 in het 
ABCB1 gen onafhankelijk gevalideerd. Zeven andere varianten in vijf genen coderend 
voor transporters (ABCC4, ABCC5, ABCG1, SLC22A5, SLC22A14) waren significant 
geassocieerd met 5-jaars PFS in een gecombineerde meta-analyse van discovery- en 
validatiecohorten. Deze bevindingen dragen bij aan de aanwijzingen uit andere studies 
dat varianten in ABCB1 van invloed zijn op de uitkomst na behandeling van osteosarcomen 
met chemotherapie. Daarnaast geeft het voor het eerst aan dat ook varianten in genen 
coderend voor solute-linked carriers betrokken zijn bij de respons op chemotherapie in 
osteosarcoompatiënten. Deze markers zijn mogelijk van belang bij het ontwikkelen van 
nieuwe behandelstrategieën en optimalisatie van de huidige behandeling van patiënten 
met een osteosarcoom.
Hoofdstuk 7 beschrijft tevens een DMET analyse, waarbij we hebben gefocust op de 
subgroep van patiënten met een inadequate respons op de (chemotherapeutische) 
behandeling, gedefinieerd als progressieve ziekte tijdens of kort na afloop 
van de behandeling. Bij analyse in een Nederlands discoverycohort van 283 
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osteosarcoompatiënten, gevolgd door validatie in een gecombineerd Spaans en Engels 
cohort en tevens Australisch cohort, vonden we een onafhankelijk gevalideerde associatie 
van een variant in het SLC7A8 gen (rs1884545) met progressieve ziekte, waarbij de 
genetische variant een beschermend effect liet zien. Daarnaast waren drie varianten in 
andere genen (CYP8B1, SLC22A2, SLC22A5) significant geassocieerd met progressieve 
ziekte in een meta-analyse van de resultaten van discovery- en validatiecohorten. Deze 
exploratieve analyse is een eerste stap om patiënten te kunnen identificeren voor wie de 
behandeling met chemotherapie niet effectief is.
In hoofdstuk 8 zijn de belangrijkste bevindingen van het onderzoek zoals in dit 
proefschrift beschreven samengevat, met daarbij een discussie van de sterke punten en 
beperkingen van het onderzoek. Daarnaast wordt een mogelijk toekomstig perspectief 
gegeven op de behandeling van osteosarcomen en het (farmacogenetisch) onderzoek in 
en voor deze patiënten.
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